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ABSTRACT 
Metalloproteinases (MPs) include the families of matrix metalloproteinases 
(MMPs) and metalloproteinase-disintegrins (ADAMs). MPs are implicated in 
multiple sclerosis (MS) and experimental auto immune encephalomyelitis (EAE), 
an animal model of MS. Both MS and EAE involve central nervous system (CNS) 
infiltration, microglial activation, and expression of chemokines and cytokines 
including CC chemokine ligand 2 (CCL2) and interferon-y (IFNy). MPs mediate 
cellular infiltration of the CNS parenchyma and regulate activity of chemokines 
and cytokines. This thesis describes studies of MPs in EAE and other animal 
models of neuroinflammation. 
Gene expression of the majority of MPs was upregulated in the CNS of 
mice with EAE. In contrast, four of the six membrane-bound MMPs (MT-MMPs) 
were downregulated. MMP-8, MMP-IO, MMP-12, ADAM-12, TIMP-l, and aIl 
MT-MMPs were selected for further analysis. Macrophages were identified as a 
major source of MMP-12 and the tissue inhibitor of MPs-l (TIMP-I), and 
granulocytes as a major source ofMMP-8. ADAM-12 was expressed primarily by 
T cells. AlI but one of the MT-MMPs were expressed by microglia, and three 
MT-MMPs were downregulated by microglia in EAE. Five of the MT-MMPs 
were downregulated in transgenic mice overexpressing IFNy specifically in the 
CNS. 
MPs were also regulated in non-immune models of CNS infiltration that 
did not involve production of IFNy. After entorhinal cortex stab lesion, which 
results in prominent influx of leukocytes to the injured area, three MT-MMPs 
were significantly downregulated. In transgenic (Tg) mice that overexpress CCL2 
specifically in the CNS, leukocytes spontaneously cross the endothelial basement 
membrane of the blood-brain barrier (BBB) and accumulate in the perivascular 
space surrounding CNS vessels, but the mice do not show clinical symptoms. 
Pertussis toxin (PTx) given intraperitoneally induced encephalopathy and weight 
loss in CCL2 Tg mice. This involved leukocyte migration across the glia limitans 
6 
into the brain parenchyma. PTx induced expression of TlMP-l, ADAM-12 and 
MMPs 8 and 10 in brains of CCL2 Tg mice, whereas there was no significant 
change in expression of MT-MMPs. Weight loss and parenchymal infiltration 
induced by PTx were significantly inhibited by the broad-spectrum MP inhibitor 
BB-94/Batimastat. 
These studies identify cellular sources of MPs in neuroinflammation and 
links stages of cellular CNS infiltration to distinct MP profiles. 
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RESUME 
Parmi les métalloprotéinases (MPs) on retrouve la famille des métalloprotéinases 
matricielles (MMPs) et celle des métalloprotéinase-disintégrines (ADAMs). Les 
MPs sont impliquées dans la sclérose en plaques (SP) et l'encéphalomyélite 
auto immune expérimentale (EAE), un modèle animal de la SP. La SP et l'EAE 
sont caractérisées par l'infiltration du système nerveux central (SNC), l'activation 
des cellules de la microglie et l'expression de chimiokines (e.g. CCL2) et de 
cytokines (e.g. interféron (IFN)-gamma). Les MPs régulent la pénétration du 
parenchyme du SNC par les cellules inflammatoires et l'activité des chimiokines 
et des cytokines. Cette thèse présente des études sur le rôle des MPs dans l'EAE 
et neuroinflammation. 
L'expression de la majorité des gènes MPs est élevée dans le SNC de 
souris atteintes d'EAE. Au contraire, l'expression de quatre des six membrane-
type MMPs (MT-MMPs) est réduite. MMP-8, MMP-IO, MMP-I2, ADAM-I2, 
l'inhibiteur de tissu des MPs (TIMP)-I, et toutes les MT-MMPs ont été choisies 
pour des analyses plus approfondies. Les macrophages ont été identifiés comme 
source importante de MMP-I2 et de TIMP-I et les granulocytes comme source 
importante de MMP-8. ADAM-I2 est principalement exprimé par les cellules T. 
Toutes les MT-MMPs sauf une sont exprimées par les cellules de la microglie et 
l'expression de trois des MT-MMPs est réduite par les cellules de la microglie 
chez les souris atteintes d'EAE. L'expression de cinq des MT-MMPs est réduite 
chez les souris transgéniques (Tg) qui expriment l'IFN-gamma spécifiquement 
dans le SNC. 
L'expression des MPs est également régulée dans les modèles d'infiltration 
non-immunitaires, où les cellules pénètrent le SNC sans produire d'IFN-gamma. 
Après une lésion du cortex entorhinal, qui provoque l'infiltration de leucocytes 
dans le tissu endommagé, l'expression de trois des MT-MMPs est réduite de 
manière significative. Dans les souris Tg qui expriment CCL2 spécifiquement 
dans le SNC, les leucocytes traversent spontanément la membrane basale des 
8 
cellules endothéliales qui forment la barrière hématoméningée (BHM) et 
s'accumulent dans l'espace périvasculaire entourant les vaisseaux sanguins et ce, 
sans induire des symptômes cliniques. L'administration intrapéritonéale de toxine 
de Pertussis (PTx) induit une encéphalopathie et une perte de poids chez les souris 
CCL2 Tg. Ce traitement cause aussi la migration de leucocytes au travers du glia 
limitans, dans le parenchyme du cerveau. La PTx induit l'expression de TIMP-I, 
ADAM-12 et des MMPs 8 et 10 dans le cerveau des souris CCL2 Tg, mais 
n'altère pas les niveaux d'expression des MT-MMPs. La perte de poids et 
l'infiltration du parenchyme induites par la PTx sont inhibées par l'inhibiteur 
général des MPs, BB-94/Batimastat. 
Ces études identifient des sources cellulaires de MPs lors du processus de 
neuroinflammation et associent des étapes d'infiltration cellulaire du SNC à des 
profils distincts d'expression de MPs. 
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CHAPTERI 
General Introduction 
Multiple sclerosis (MS) is a neurological disease involving infiltration of immune 
cells to the central nervous system (CNS) as part of the neuroinflammatory 
pathology. Although the etiology of MSis unknown, the neuroinflammation is 
established as detrimental and is the target for all approved MS therapy. 
Metalloproteinases (MPs) are proteolytic enzymes with extracellular matrix 
prote in substrates, and are implicated in cellular transmigration across the blood-
brain barrier. Experimental auto immune encephalomyelitis (EAE) is an animal 
model of MS well suited to investigate mechanisms of neuroinflammation. 
In this thesis, the expression pattern of MP genes in EAE and other models 
of neuroinflammation will be described. AIso, stages of CNS infiltration are 
defined and related to chemokine, cytokine and MP expression. Finally, the 
involvement of a pathogen-derived factor in neuroinflammation is described and 
related to MP expression. 
1.1. Multiple Sclerosis 
1.1.1. A neurological disease with autoimmune characteristics 
Clinical symptoms of MS were first described in the 1830's by Cruveilhier and 
Carswell, and defined as MS in 1868 By Charcot (1). The initial symptoms can be 
varied, but often include temporary paralysis, blindness or other neurological 
impairment. MS is rarely fatal but leads to progressing disability. Despite 
intensive research, MS is still an enigmatic disease with only limited treatment 
possibilities. MS is the most common neurological disorder among young adults 
with a prevalence of about 120 in 100,000 individuals in high-prevalence 
countries in Northern Europe and North America (2). The disease is characterized 
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by inflammation of the CNS, demyelination of nerve fibers and 
neurodegeneration. The cause of MS is unknown and there is no cure. 
The prevailing hypothesis of the etiology of MS is that an autoimmune 
response is triggered by an environmental insult in genetically susceptible 
individuals and propagated within the CNS (3). The CNS can be considered the 
victim organ, which is invaded by pathogenic immune cells crossing the blood-
brain barrier (BBB). CNS inflammation is a hallmark sign of MS, but it is debated 
where the immunological reaction that leads to neuroinflammation is initiated (4). 
Two main possibilities exist: The periphery, by sorne environmental insult, e.g. 
infection leading to an auto immune reaction through molecular mimi cry; or as a 
consequence of an underlying damage to endogenous cells of the CNS. It is 
generally believed that MS is an auto immune disease, although it has been 
proposed that primary oligodendrocyte dysfunction is the precipitating event in 
MS pathogenesis (5). MS is not a uniform disease; rather it can follow different 
courses, with the majority of patients presenting with relapsing-remitting MS, and 
the remaining with primary progressive MS or a milder form of MS described as 
benign MS (6). Of patients with relapsing-remitting disease, 80% will develop 
secondary progressive MS within 10 years. (7). The pathology of MS is also 
heterogeneous (8), so it is possible that MS has several etiologies, aIl leading to 
related symptoms which are classified as various forms of MS. Given the 
involvement of both an inflammatory and neurodegenerative component in MS 
pathogenesis (9), a logical theory would be that relapsing-remitting MS 
predominantly is a consequence of neuroinflammation, whereas the progressive 
pathology is more a consequence of neurodegeneration (10). 
1.1.2. Genes and environment 
MS is primarily a disease of the temperate areas of the world, with prevalence 
increasing with the distance from equator. The curious geographical distribution 
of MS has not been adequately explained, but might have its reason in 
environmental factors and/or in demographics, with descendants of northem 
European ancestry having the highest risk presumably for genetic reasons (11, 
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12). Perhaps exposure to an environmental agent in childhood is involved in the 
etiology, as children, who move before puberty adopts the prevalence oftheir new 
residence, whereas adults, who move after puberty keep the prevalence of their 
original residence (13). Despite long-standing efforts to identify a causal 
environmental agent of MS, the search has so far been fruitless (14). 
More than 30 years ago, it was demonstrated that there is convmcmg 
genetic linkage of MS to regions within the MHC complex (15). In spite of 
considerable effort, the search for other genetic markers of MS has not yielded 
significant new information, other than that regions within both MHC class 1 and 
class II confer MS risk (16). Thisdoes, however, give credence to the hypothesis 
of an autoimmune etiology of MS, or, at least, a strong immune involvement in 
the MS pathogenesis. The inability to identify a single, or even a few, factors as 
cri tic al in MS etiology has led to the consensus that MS is a multifactorial disease, 
where genes, environment and stochastic factors play a role. Epidemiological 
studies clearIy illustrate the involvement of both genetic and environmental 
parameters in the etiology of MS. The concordance rate for homozygotic twins 
was found to be 24% in Denmark (17), considerably higher than for dizygotic 
twins (3%), showing that genotype is important. However, since genetic risk is 
significantly less than 100%, genotype cannot account fully for the occurrence of 
disease; environmental cues must also be important. Those environmental cues 
must work on a population rather than individual basis, as there is no evidence of 
higher risk of MS in a step-sibling of an MS patient (18). 
1.2. Experimental Autoimmune Encephalomyelitis 
1.2.1. An autoimmune animal disease model of MS 
EAE is an animal model of MS. It is an autoimmune neuroinflammatory disease, 
which is most commonly studied in rodents. EAE can be generated actively by 
immunization of animaIs with myelin antigens in the presence of adjuvant, or 
passively by adoptive transfer of myelin specific T cells from immunized animaIs 
(19, 20). The adjuvants most commonly used are complete Freund's adjuvant 
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(CF A) and PTx. CF A contains heat-inactivated Mycobacterium tuberculosis and 
is used for immunizations in an emulsion given sc. PTx is a toxin derived from 
the bacterium Bordetella pertussis, the causative agent of whooping cough, and is 
administered ip. or iv. The adjuvants are thought to substitute for potential critical 
environmental agents in the disease pathogenesis. These environmental agents are 
likely microbial pathogens, and exacerbations of MS have been associated with 
microbial infections (21, 22). 
An adaptive immune system in recipient mice after adoptive transfer of 
mye lin specific T cells is not needed, since EAE can be transferred to SCID mice 
(23). Secondary lymphoid organs in recipient mice are also not needed, when 
EAE is passively transferred (24). The pathology of EAE resembles MS in many 
aspects, including cellular infiltration of the CNS, loss of BBB integrity, 
demyelination and axonal damage, and neurological symptoms including 
paralysis. However, the value of EAE as a model of MS has been called into 
question, based on the fact that it is a pure auto immune disease, and therefore 
might not represent other aspects of MS pathology (25). Nevertheless, 
neuroinflammation involving autoreactive T cells is an important part of MS 
pathogenesis, and that particular aspect is modeled very well by EAE. The 
fundamental process of leukocyte entry to the CNS is shared by MS and EAE, 
regardless of the underlying reason. 
1.3. Neuroinflammation 
1.3.1. The neurovascular unit 
The BBB was originally defined based on exclusion of macromolecules from the 
CNS (26). This exclusion is based on the existence of a specialized endothelium 
with tight junctions in the CNS, and possibly also on paucity of vesicle transport 
through CNS endothelial cells. The mechanisms behind cell trafficking to the 
CNS are more complicated than transport of macromolecules, and it is not 
meaningful to only apply the diffusion-based definition of the BBB with regards 
to cellular infiltration. Other structures surrounding CNS vessels need to be taken 
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into account, and in recent years, many investigators have broadened the 
definition of the BBB to also include the astrocyte endfeet and associated 
perivascular cells of myeloid origin making up the glia limitans (27-29). The term 
"neurovascular unit" has been coined to include all these components (30). To 
prevent confusion, it seems logical to define the BBB simply as the diffusion 
barrier composed of specialized endothelium, which is meaningful to study in the 
context of accessibility of molecules, e.g. drugs, to the CNS. In the context of 
cellular migration into the CNS, aIl the stl11ctures surrounding CNS vessels, Le. 
the neurovascular unit, should be considered. 
1.3.2. Stages ofCNS infiltration 
Two separate steps can be identified in CNS infiltration. The leukocytes first cross 
the endothelial barrier and then the glia limitans (29). CeIls associated with the 
BBB, particularly astrocytes and perivascular antigen presenting ceIls (APCs), 
might be actively involved in MS pathogenesis by regulating leukocyte migration 
across the BBB. In particular, perivascular APCs might regulate the infiltration of 
T cells across the glia limitans by reactivating them in the perivascular space 
through presentation of myelin antigens. The tight junctions have long been 
thought to constitute the main barrier for migrating cells in CNS infiltration. This 
might not actually be the case since cells crossing CNS venules can do so next to 
tight junctions, rather than between cells (31). Between the endothelial basal 
lamina and the glia limitans is the perivascular space, which is usually not 
distinguishable, but becomes enlarged and filled with infiltrating ceIls during 
neuroinflammation; for example in EAE (29). Entering the perivascular space, 
however, is not equivalent to entering the CNS parenchyma (32, 33). The glia 
limitans, mainly composed of astrocyte endfeet, must also be crossed. This 
distinction is important, as the presence of leukocytes in the perivascular space is 
not associated with clinical symptoms (34-36). An important technical 
consideration is that flow cytometry analysis is unable to distinguish between 
cells in the perivascular space and the parenchyma, since the perivascular space is 
non-perfusable. 
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1.3.3. Regulation ofCNS infiltration 
The endothelial cells, pericytes, perivascular myeloid cells and astrocytes are the 
first cell types an infiltrating cell encounters on its way to the brain parenchyma. 
These cells are situated on the border between the CNS and the periphery and are 
therefore ideally situated to regulate CNS infiltration. Microglia are the resident 
CNS antigen presenting cells (APC) found dispersed throughout the parenchyma. 
They share myeloid lineage with macrophages. Microglial activation involves a 
change in morphology, and upregulation of molecules involved with antigen 
presentation as well chemokines and proinflammatory cytokines, such as TNFa, 
IL-lj3 and IFNy. It has long been discussed whether activation of microglia is 
advantageous or detrimental in the context of neuroinflammation (37, 38), but 
recent results favor a detrimental role, as prevention of microglial activation 
curbed EAE symptoms (39). 
There is currently much focus on APCs other than parenchymal microglia 
of the CNS. These APCs are found in the perivascular space and defined as 
perivascular microglia, macrophages or dendritic cells (DCs) based on surface 
markers. The perivascular APCs have a higher turn-over rate than parenchymal 
microglia, and they can thereby be distinguished in bone marrow chimeras, where 
the perivascular space is repopulated with APCs of donor origin (40). The 
perivascular position of these APCs make them ideally suited for interacting with 
and stimulating infiltrating lymphocytes. Indeed, antigen presentation by APCs in 
the perivascular space may be necessary for parenchymal infiltration (24, 41-43), 
and perivascular APCs were also found to be critical for epitope spreading in EAE 
(44). 
1.3.4. Blocking cellular entry to the CNS 
In vitro models of the BBB have been used experimentally for over 30 years (45). 
Using such models, it has been shown that transmigration is regulated by various 
adhesion molecules, which participate in a reorganization of the endothelial cell 
structure to permit migration (46). Much of the CUITent development in 
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therapeutic management of MS is focused on targeting the transmigration of 
leukocytes by blocking adhesion molecules on either the endothelial cells or the 
leukocytes. One of the most promising new MS drugs (natalizumab) is based on 
blocking such an adhesion molecule, namely VLA-4 (also called a4~ 1 integrin), 
an integrin expressed on lymphocytes, thereby preventing lymphocytes from 
attaching to and migrating across endothelial cells in the CNS. Blocking VLA-4 
efficiently prevented or reversed EAE (47-49), and promoted recovery from 
symptoms (50). Treatment with natalizumab reduced relapses in MS patients (51, 
52), but it was withdrawn from clinical use after three patients developed severe 
side effects in form of progressive multifocal leukoencephalopathy (PML) (53-
55). This could imply that natalizumab had prevented normal immune 
surveillance of the CNS with detrimental consequences (56), and would stress the 
need for developing treatment strategies that will only target harmful elements of 
leukocyte interaction with the BBB. However, alternative explanations of the link 
between VLA-4 blockade and development of PML have been pointed out, e.g. 
that VLA-4 blockade can have adverse effects on the development of immune 
cells in the bone marrow (57). 
Despite problems with unforeseen side effects, the remarkable efficacy of 
natalizumab in reducing MS relapse by 66% is very encouraging (47). It is proof 
of principle, that limiting access of harmful immune cells to the CNS is of 
substantial bene fit to MS patients. The obvious challenge is to achieve this benefit 
therapeutically without disrupting normal and essential physiological mechanisms 
of cellular interaction and traffic. Another strategy to therapeutically manipulate 
access of leukocytes to the CNS is to target the proteinases which mediate 
transmigration across the neurovascular unit. 
1.4. Metalloproteinases 
1.4.1. A superfamily ofproteinases 
The MMPs belong to the group of Metzincin MPs which also include astacins, 
serralysins and ADAM families (58). In total there are eight groups in the 
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superfamily of MPs, giving a total number of more than 200 proteinases in the 
superfamily. There are 29 mammalian ADAMs of which 17 have the consensus 
MP catalytic site. They aIl have adhesion and transmembrane domains and are 
thought to function primarily as membrane-tethered sheddases (59). Sorne 
ADAMs are specificaIly expressed in testis, but many are expressed in the CNS 
(60). Like MMPs, ADAMs can cleave ECM molecules, but are likely to also 
directly modulate cellular interactions. Importantly, broad-spectrum inhibitors of 
MPs, which initially were developed to inhibit MMPs, are just as efficient in 
inhibiting ADAMS with the consensus catalytic site, since the inhibitors are 
peptidomimetics which mimic the characteristic substrate sequence recognized by 
the MP catalytic site. 
Genes for MMPs are not only present in mammals, but are conserved in 
the evolution of a large variety of species. MMP genes are found in flies (61), 
nematodes (62), and plants (63). The first MMP was described in 1962 as a 
collagenolytic enzyme present in tadpole tail and involved with tissue 
morphogenesis (64). Today, 25 vertebrate MMP genes are described and 
numbered from 1-28, excluding number 4 to 6 (65). The original MMPs 4 to 6 
were subsequently found to be identical to MMP-2 or 3. MMP-18 is considered to 
be specific for Xenopus. MMP-26 is absent in mice, and MMP-22 is absent in 
both mi ce and humans. Mice have two forms of MMP-l and humans have two 
forms ofMMP-23. Thus, the total number ofMMP genes is 24 for humans and 23 
for mice. It is considered unlikely that more MMP genes will be discovered in 
mice and humans as both genomes have been extensively searched. 
1.4.2. MMP substrates 
MMPs are classically known to degrade ECM proteins. This is based on in vitro 
studies where substrate specificities were determined under optimal conditions. 
This approach has led researchers to focus on ECM substrates, which MMPs are 
able to cleave in vitro, rather than potential other substrates in vivo. Only recently 
has there been an appreciation of the various other roles of MMPs. It may even be 
that ECM proteolysis is not the main role of MMPs in tissues (66). A very 
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important and interesting area of MMP research is to identify in vivo substrates, 
which will enable a more insightful interpretation of the consequence of changes 
in expression level and activity ofMMPs (67). 
1.4.3. Structure of MMPs 
MMPs can be grouped based on substrate specificity determined in in vitro 
studies, or based on domain structure. The latter distinction seems most 
appropriate, since there is considerable specificity overlap, and substrates may be 
different in vivo (68). MMPs have a common 3-dimensional structure and a 
common gene arrangement which indicate that they evolved by duplication from a 
common ancestor gene (69). 
There are several characteristic domains in MMPs. AlI members share a 
conserved pro-domain and catalytic domain. The catalytic domain contains three 
histidine residues binding zinc at the catalytic site, and a conserved methionine 
that is positioned beneath the catalytic site (70). The prodomain ensures that 
MMPs in general are expressed as inactive zymogens in order to prote ct against 
excessive proteolysis. The prodomain contains a cysteine residue that forms a 
thiol bond with the zinc in the catalytic site of the MMP in a structure calIed the 
cysteine-switch (71, 72). Removal of the prodomain by another protease disrupts 
the cysteine switch and activates the MMP. Removal of the prodomain is not 
strictly necessary for MMP activation. Breaking the thiol bond in the cysteine 
switch by other means will also cause activation, and this can be do ne chemicalIy, 
for example by oxygenation by leukocyte-derived oxidants (73-75). A hinge-
region connects the catalytic domain with the hemopexin-like domain found in 
most MMPs. The hemopexin-like domain is involved in prote in-prote in 
interactions, and is thought to confer substrate specificity to MMPs (76, 77). 
Six MMPs are membrane-bound (MMP-14, 15, 16, 17,24, and 25) and 
named membrane-type MMPs (MT-MMPs). Four MT-MMPs are type-l 
transmembrane proteins with cytoplasmic domains. The remaining two MT-
MMPs (MMP-17 and 25) are anchored to the cell surface by a 
glycosylphosphatidylinositol (GPI) structure. The cytoplasmic domain of 
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transmembrane MT-MMPs has been proposed to be important for the activity of 
MT-MMPs by facilitating dimerization, clustering, and intemalization (78-81). 
Binding to intracellular ligands could also be an important function of the 
cytoplasmic domain ofMT-MMPs (82). 
1.4.4. Regulation of MP activity 
MMP activity is regulated at five points: Gene transcription, activation, 
compartmentalization, enzyme inhibition and intemalization. MMPs are generally 
not expressed at high levels in normal healthy tissue, but are upregulated in tissue 
undergoing repair, remodeling, inflammation, or in a diseased state (66). The 
induction of MMPs is mainly controlIed by chemokines and cytokines; 
chemokines attract MMP-producing cells, and cytokines regulate transcription of 
MMPs from both infiltrating and endogenous cells (83). Once MMPs are present 
in a tissue, they are activated in a complicated interplay with other MMPs, other 
proteinases, or oxidants. In sorne cases, the need for extracellular activation can 
be bypassed by intracellular cleavage of the prodomain. A furin recognition 
domain makes it possible for intracellular proteases like furin to cleave the 
pro do main off in the trans Golgi network (84). AlI six MT-MMPs have a furin 
recognition domain. This is only the case for three other MMPs: MMP-ll, 23 and 
28. Furin cleavage can bring an MMP to the celI surface in the activated state, as 
has been reported for MMP-14 (85). To prevent undirected proteolysis, MMPs 
can be compartmentalized on the cell membrane. This is naturally the case for 
MT-MMPs, but also secreted MMPs are often confined to the pericelIular 
environment (86-88). For example, MMP-2 binds the av~3 integrin, and MMP-9 
binds the hyaluronan receptor CD44 (89). This prevents diffusion of MMPs and 
ensures that substrates are cleaved in the vicinity of the cell surface, where 
receptors might bind the cleaved product. 
Naturally, proteolysis by activated MPs must to be controlled in order to 
prevent excessive tissue damage. The activity of all MMPs in tissue is controlled 
by tissue inhibitors of MPs (TIMPs), of which four are described. Generally, all 
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secreted MMPs are inhibited to various degrees by all four TIMPs, but TIMP-I is 
a poor inhibitor of most MT -MMPs, whereas TIMP-2 and the membrane-
associated TIMP-3 are efficient inhibitors of MT-MMPs (90). All TIMPs are 
expressed in the CNS, where their expression is controlled by cytokines including 
IFNy and IL-I P (91). In serum, the main inhibitor of MPs is u2-macroglobulin 
(u2M), which cause irreversible clearance of a range of proteinases (92). A 
membrane-bound inhibitor reversion-inducing cysteine-rich protein with kazal 
motifs (RECK) can also control MP activity (93, 94). Another way of inactivating 
MMPs is by internalization after binding to scavenger receptors (95). 
1.4.5. MP-based therapy 
Most of the knowledge about MPs cornes from cancer research, where MPs have 
been investigated since their discovery. MPs are thought to promote tumor 
development in a variety of ways involving invasiveness, angiogenesis, 
proliferation and cell survival (96). MT-MMPs may promote tumor growth or 
spreading in other ways than directly cleaving ECM proteins. MMP-14 can for 
example cleave cell surface molecules which bind matrix molecules, as has been 
shown for CD44 (97). This releases cells from attachment to the surrounding 
matrix and increases migratory capacity. Despite success in animal models, 
broad-spectrum inhibitors of MPs were not effective in cancer trials (98). 
Furthermore, they caused significant side-effects, mainly nausea and joint pain. 
There is hope, however, that more specifie MP inhibitors would be beneficial for 
treatment of cancer patients (99, 100). The only drug approved for clinical use 
based on its action as an MP-inhibitor is the tetracycline-derivative periostat. It is 
used to treat periodontitis (101). Other drugs, such as interferon-p (102, 103), 
used in MS, or minocycline (104) (another tetracycline-derivative) used in 
treatment of acne, also inhibit MMPs, but that was not the rationale behind their 
introduction. 
MPs are thought to generally be pro-inflammatory given their ability to 
facilitate migration of inflammatory cells across barriers and within tissues. 
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Contrary to the general picture, there are indications that sorne MMPs have 
divergent actions in arthritis (105, 106). This reinforces the need to define the 
actions of individual MMPs better in order to design rational therapies aimed at 
only inhibiting detrimental actions of MMPs in certain disease states. 
1.4.6. Metalloproteinases in the CNS 
Since 1980, it has been known that proteinase inhibitors can curb EAE (107), and 
MMPs are increasingly being recognized as important in neuroinflammation (65, 
89, 108). The serum and CSF levels of several MMPs are increased in MS 
patients, and can be correlated to attacks (109, 110). SpecificaUy, the MMP-
9/TIMP-l ratio has been proposed to be diagnostic of attacks (111). MPs can 
cleave mye lin and thereby cause demyelination and axonal injury (112, 113), and 
possibly also generate encephalitogenic peptides which are involved in the 
autoimmune response (114, 115). More recently, it has been recognized that 
actions ofMPs in the CNS might also be beneficial (65). Several MPs and TIMPs 
are expressed in the developing CNS (116), and MMPs are involved in 
neurogenesis (117), axonal growth (118), as well as neurogenic migration after 
stroke. Oligodendrocyte process formation also involves MMPs (93, 119), and 
myelination in ontogeny is impaired in MMP-9 and 12 deficient mi ce (120). 
Sprouting following neuronal injury is dependent on MPs (121). In the peripheral 
nervous system, Wallerian degeneration of transected nerves mediated by MPs is 
a prerequisite to repair (122). 
1.5. Cytokines, Growth factors, Chemokines, and the MPs 
1.5.1. C/eaving bioactive mo/ecu/es 
Among the recently described non-ECM substrates of MMPs are bioactive 
molecules, such as cytokines and chemokines, implicating a regulatory role for 
MMPs (123, 124). Growth factors can also be cleaved or released from the matrix 
by MMPs (125), and MMPs can via that mechanism be involved in ceU survival 
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by influencing availability of these factors. MMPs are also able to induce 
apoptosis in an indirect way by a process termed anoikis (homelessness). This 
implies the detachment of cells from their normal ECM supporting structure 
leading to cell death, presumably from lack of integrin signaling (126). Other 
ways for MPs to influence neuronal survival is by cleaving the neurotrophins 
NGF and BDNF (127), or cleaving FasL (CD 178), the ligand for the death 
receptor Fas (CD95). FasL is important in the protection of the CNS from reactive 
T cells in a process of astrocyte-induced apoptosis (128). MMP3 can cleave FasL 
to diminish Fas-FasL interaction on the surface of neurons in culture, thereby 
protecting them from Fas induced apoptosis (129). 
1.5.2. Cytokine substrates 
The proinflammatory cytokine IL-1 p can be activated in a caspase-1 independent 
way by three MMPs (130), and also inactivated by MMP action (131). The anti-
inflammatory cytokine TGFp can likewise be activated by MMPs (87, 132), 
proving the point of there being both pro and anti-inflammatory roles of MMPs. 
The conversion of membrane-bound TNF to soluble TNF is a weIl known 
example of MP activation of a cytokine (133, 134). The conversion is carried out 
by TACE which is also known as ADAM-17. Mice deficient in ADAM-17 are 
non-viable, indicating the importance of this specific MP, ev en though other 
MMPs (MMP-17, 7 and 12) have been shown to be able to shed TNF, albeit with 
lower efficiency than ADAM-17 (135-137). 
1.5.3. Chemokine substrates 
Chemokines are small chemoattractant cytokines with the ability to direct cellular 
migration. There are more than 50 chemokines described, and more than 18 
receptors. The receptors have seven transmembrane domains and are G-protein 
coupled. Chemokines control leukocyte trafficking into the CNS m 
neuroinflammation (138). Activated glial cells upregulate chemokine production, 
and chemokine levels are elevated in both MS and EAE (139). MMPs can control 
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the activity of chemokines by either activating or inactivating them (140-143), or 
by cleaving other substrates that interact with chemokines (144-146), such as 
receptors (147). MMP-9 inhibits activity of several chemokines (143), whereas it 
increases the activity of IL-8 (142). AIl four human forms of monocyte 
chemoattractant protein (MCP): MCP-1 to 4, can be cleaved and inactivated by 
recombinant MMPs in vitro. Of 8 MMPs tested, MMP-1 and 3 could cleave 
MCP-l (CCL2 in modern nomenclature) to pro duce a truncated form with anti-
inflammatory capacity in vivo (141). By cleaving ECM proteins with attached 
chemokines, MMPs can create gradients of chemokines which then direct 
migration of inflammatory cells as has been demonstrated for MMP-7 (145, 148), 
and MMP-2 (144, 149). 
1.5.4. CCL2IMCP-l 
Several studies led to the conclusion that CCL2 (formerly MCP-l) is a cri tic al 
factor in promoting cellular entry to the CNS. Migration of leukocytes to sites of 
axonal degeneration following transection was significantly curbed in mice 
deficient for the CCL2 receptor CCR2 (150). Likewise, CCR2 deficient mice are 
resistant to EAE (151), just as CCL2 deficient mi ce show significantly mil der 
disease symptoms in EAE (152). CCL2-deficient T cells were capable of 
transferring EAE to recipient WT mice whereas WT T cells were unable to 
transfer disease to CCL2 deficient recipients. From another series of adoptive 
transfer EAE experiments, it was concluded that expression of the CCL2 receptor 
CCR2 on recipient mononuclear cells is critical for induction of disease (153). 
Hence, in order to induce EAE, both CCL2 expression in the CNS and expression 
of the receptor CCR2 on mononuclear cells in the periphery are essential. A 
recent study showed that transgenic low-Ievel expression of CCL2 in the CNS of 
mi ce resulted in protection against EAE (154), apparently due to a weak Th1 
autoimmune response. 
Transgenic expression of CCL2 under control of a truncated MBP 
promoter led to perivascular accumulation of leukocytes, without parenchymal 
infiltration and no clinical pathology (34). In contrast, when the neutrophil-
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attracting chemokine CXCLI was expressed under control of the MBP promoter, 
the transgenic expression resulted in parenchymal infiltration as weIl as 
perivascular accumulation with leukocytes (155). Furthermore, the CXCLI Tg 
mi ce show spontaneous neurological syndromes starting about 40 days after birth. 
In mi ce with astrocyte-directed transgenic expression of CXCLI0 there was 
spontaneous accumulation of leukocytes with no evident changes in brain MMP 
expression (156). The leukocyte accumulation in these CXCLI0 Tg mi ce could be 
potentiated by administration of CF A and PTx, but no overt pathology was 
observed. 
The transgenic expression of CCL2 in the CNS was found to increase 
infarction volume as weIl as cellular brain infiltration following ischemic brain 
injury (157). AIso, CCL2 Tg mice were more sensitive than WT mice to effects of 
LPS injections. Administration of the broad-spectrum synthetic MP-inhibitor BB-
94 reduced ischemic lesion volumes (158). Likewise, in a study of hippocampal 
neuronal damage following ischemia, MMP-2 and 9 activity was shown to be 
increased in the hippocampus (159). Treatment of mi ce with BB-94 protected 
against damage of hippocampal neurons. 
1.6. Pertussis Toxin 
1.6.1. Effects of a microbial product on neuroinflammation 
PTx is used as adjuvant to induce EAE as discussed in section 1.2.1., but the 
mechanism behind the adjuvant effect of PTx has not been clearly identified. In a 
study measuring the effect of PTx on BBB permeability in vitro it was shown that 
PTx inhibits T cell migration across brain endothelial cells by blocking G prote in 
signaling (160). The G-protein coupled receptor is likely to be a chemokine 
receptor, as PTx can inhibit chemokine receptors and is routinely used in in vitro 
assays as a chemokine receptor inhibitor (161). Other studies have proposed that 
PTx increases the permeability of the BBB in vivo (162, 163). It could seem that 
PTx has opposing effects on the permeability of the BBB. Depending on the time 
of administration, PTx can have both enhancing and inhibitory effects in the 
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eontext of indueing autoimmune disease (164). PTx eonsists of two subunits, A 
and B, of whieh B will bind to eeU surfaces foUowed by insertion of the A subunit 
into the cell cytoplasm. Su an colleagues found that the A subunit of PTx is 
responsible for the inhibition of G-protein signaling and the B subunit was the 
disease-inducing part of PTx. Administration of the B subunit alone was 
equivalent to whole PTx in inducing auto immune disease in mi ce, most likely by 
promoting a Thl-polarized innate immune response. Possibly, PTx does inhibit 
migration by inhibiting chemokine receptor signaling, but at the same time 
promotes migration by upregulating adhesion molecules on brain endothelial 
ceUs, such as P-selectin, as has been demonstrated in work by Kubes and 
colleagues (165). Likely, PTx could also promote brain infiltration through an 
effect on leukocytes in the blood-stream by causing them to upregulate expression 
of effector molecules sueh as MPs. PotentiaUy, PTx interaets with leukoeytes by 
binding to innate immune receptors, e.g. TLR4 as suggested (165). 
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HYPOTHESIS AND OBJECTIVES 
Sorne members of the large family of MPs promote neuroinflammation, whereas 
other MPs are neutral or have protective roles. Gaining detailed knowledge about 
the expression pattern of individual MPs in neuroinflammation will aid towards 
designing a rational therapy based on targeting specifie MPs at specifie stages of 
CNS infiltration as occurs in both MS and EAE. 
Hypothesis: CNS infiltration can be divided in stages based on location of 
infiltrating cells in relation to different components of the neurovascular unit: the 
endothelial barrier and the glia limitans. Leukocyte crossing of the endothelial 
barrier resulting in perivascular infiltration is associated with a different profile of 
MP expression compared to parenchymal infiltration after crossing of the glia 
limitans. 
The objectives of this thesis are: 
Chapter 2: to study expression profiles of MPs in EAE and identify cellular 
sources of selected MPs. 
Chapter 3: to investigate regulation and activity of MP expression in different 
stages of PTx -driven CNS infiltration. 
Chapter 4: to investigate regulation of MT-MMPs in EAE and other models of 
neuroinflammation. 
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2.1. Abstract 
Metalloproteinases (MPs) include matrix metalloproteinases (MMPs) and 
metalloproteinase-disintegrins (ADAMs). Their physiological inhibitors are tissue 
inhibitor of metalloproteinases (TIMPs). MPs are thought to be mediators of 
cellular infiltration in the pathogenesis of Multiple Sclerosis (MS) and its animal 
model experimental auto immune encephalomyelitis (EAE). 
We used real-time RT-PCR to profile expression of all 22 known mouse 
MMPs, seven ADAMs and an four known TIMPs in spinal cord from SJLlJ mice 
and from mice with adoptively transferred Myelin Basic Protein (MBP)-specific 
EAE. A significant and greater than 3-fold alteration in expression was observed 
for MMP-8, MMP-IO, MMP-12, ADAM-12 and TIMP-I, which were 
upregulated, and for MMP-15, which was downregulated. Expression levels 
correlated with disease course with all but ADAM-12 returning towards control 
levels in remission. 
To examine potential cellular sources of these strongly affected proteins in 
the inflamed central nervous system (CNS), we isolated macrophages, 
granulocytes, microglia, and T cells by cell sorting from the CNS of mi ce with 
EAE, and analyzed expression by real-time RT-PCR. This identified macrophages 
as a major source ofMMP-12 and TIMP-l. Granulocytes were a major source of 
MMP-8. ADAM-12 was expressed primarily by T cells. Cellular localization of 
MMP-IO, TIMP-I and ADAM-12 in perivascular infiltrates was confirmed by 
immunostaining or in situ hybridization (ISH). Microglia from control mice 
expressed strong signal for MMP-15. Strikingly, the expression of MMP-15 by 
microglia was significantly downregulated in EAE, which was confirmed by 
immunostaining. 
Our study identifies the cellular sources of key MPs in CNS inflammation. 
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2.2. Introduction 
Leukocyte infiltration of the CNS is a hallmark of Multiple Sc1erosis (MS) and 
experimental auto immune encephalomyelitis (EAE), a widely used animal model 
for MS. To infiltrate the CNS parenchyma, leukocytes must migrate across the 
blood-brain barrier (BBB), which, under normal circumstances, restricts the 
entrance of cells and large molecules into the CNS. Disruption of the integrity of 
the BBB accompanies the extensive cellular infiltration and pathology seen in MS 
and EAE and is assumed to be a pre-requisite for disease. 
The functional BBB inc1udes endothelial cells joined by tight junctions 
and a basement membrane made up of extra-cellular matrix (ECM) proteins such 
as laminin, collagen and fibronectin. Leukocyte extravasation to CNS parenchyma 
is facilitated by proteolysis of ECM proteins carried out by a family of Zn ++ and 
Ca ++ dependent proteinases called matrix metalloproteinases (MMPs) (also 
designated matrixins). There are at least 25 MMPs (22 identified in mice), which, 
between them, can de grade virtually aIl components of the ECM (68). The MMPs 
have therefore attracted attention as potential critical mediators of diseases 
involving inflammation of the CNS, inc1uding MS (89, 108), as weIl as in other 
diseases where degradation of ECM is part of the pathogenesis, such as in cancer 
metastasis and rheumatoid arthritis (166). Besides their role in ECM proteolysis, 
MMPs can also act as signaling molecules and regulators of cell fate by shedding 
or c1eaving adhesion molecules, growth factors, chemokines and cytokines (123, 
124) 
Metalloproteinase-disintegrins (ADAMs) (also called adamalysins) are 
another family of metalloproteinases, which potentially can act as proteases, 
signaling molecules and regulators of cell fate. They comprise more than 30 
members with diverse actions (167-169). There are indications that ADAMs are 
involved in regulating inflammatory processes, as exemplified by ADAM-17, 
which can c1eave membrane-bound TNF-a leading to shedding of the more pro-
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inflammatory soluble TNF-a (133); hence the synonym for ADAM-17 is TNF-a 
converting enzyme (T ACE). 
Tissue inhibitors of metalloproteinases (TIMPs) are physiological 
inhibitors of metalloproteinases. There are four known TIMPs and they inhibit 
metalloproteinases by binding to the catalytic site in al: 1 stoichiometry. No 
comprehensive study of the binding of aIl four TIMPs to aIl MMPs and ADAMs 
has been undertaken, but sorne generalizations can be made. TIMPs generally 
inhibit aIl MMPs to various degrees, with the exception that TIMP-l is unable to 
inhibit MMP-14, 15, 16 and 24 (92). These are four of the 6 membrane-bound-
MMPs, the remaining two being MMP-17 and MMP-25. The ADAMs show a 
more restricted pattern of inhibition by TIMPs with only few ADAMs being 
inhibited by TIMPs (170). 
Administration of synthetic broad-spectrum MP-inhibitors alleviated 
symptoms of EAE, presumably by curbing leukocyte infiltration (171-173). 
However, in addition to their detrimental roles, MPs might also have beneficial 
effects in MS. For example, MMPs are suggested to be involved in repair 
processes such as remyelination, as indicated by the finding that MMP-9 is 
necessary for outgrowth of oligodendrocyte processes (93). The use of CUITent 
generation broad-spectrum MP-inhibitors would inhibit such beneficial actions of 
MPs as weIl as their detrimental actions. It is likely that inhibition of specifie 
MPs, or MPs produced by specifie cell types at specifie times in the pathogenesis 
of MS, would be of greater bene fit than using broad-spectrum inhibitors 
indiscriminately. Detailed knowledge of the MP and TIMP expression profiles by 
the cell types involved in CNS infiltration is required to enable such approaches. 
Until now, only a limited number MMPs, ADAMs and TIMPs have been studied 
inMS orEAE. 
In this study, we profiled expression of aIl 22 known mouse MMPs, aIl 
four known TIMPs as weIl as seven ADAMs in spinal cord from un-manipulated 
control mi ce and from mice with EAE at peak disease, using quantitative real-
time RT-PCR. The seven ADAMs chosen aIl have a putative functional protease 
domain and are not restricted to expression in the testis unlike other members of 
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this family (168, 169). We find a significant and greater than three-fold 
upregulation in expression ofMMP-8, MMP-10, MMP-12, ADAM-12 and TIMP-
1, and a significant and greater than three-fold downregulation of MMP-15. We 
have identified macrophages as a major source of MMP-12 and TIMP-l, and 
granulocytes as a major source of MMP-8. None of the celI types we studied by 
PCR emerged as a single major source of MMP-1 0, but low-level expression by 
multiple infiltrating celI types was observed by ISH. Unmanipulated microglia 
expressed MMP-15, and this MMP-15 expression by microglia was significantly 
downregulated in EAE. ADAM-12 was found to be expressed almost exc1usively 
by T celIs. 
2.3. Materials and Methods 
Adoptive transfer EAE 
Female SJLlJ mice (6-8 weeks old) were purchased from Jackson Laboratories, 
Bar Harbor, ME, USA. EAE was induced by passive transfer of MBP-reactive T 
celIs. Donor mice were immunized sc. at the base of the tail with 100 III of an 
emulsion containing 400 Ilg MBP (Sigma, Oakville, Ontario, Canada) and 100 Ilg 
of Mycobacterium tuberculosis H37 RA (Difco, Detroit, Michigan, USA) in 
Freund's Incomplete Adjuvant (Difco) and boosted in the flanks 7 days later with 
the same amount. A single celI suspension was prepared from the draining lymph 
nodes 14 days after the first immunization by passing lymph nodes through a 70 
Ilm celI strainer (Becton Dickinson, Franklin Lakes, NJ, USA), and celIs 
(4x1Q6/ml) were cultured in the presence of 50 Ilg/ml MBP in RPMI 1640 (Gibco, 
Burlington, Ontario, Canada) supplemented with 10% FCS (Sigma), 50 IlM 11-
mercaptoethanol (Sigma), 2 mM L-glutamine (Gibco) and 100 U/ml Penicillin-
Streptomycin (Gibco). After 4 days in culture, cells were collected by 
centrifugation on Ficoll-Paque (Amersham Biosciences, Baie d'Urfe, Quebec, 
Canada), and 4x 106 lymphoblasts were injected into the tail vein of naive mice. 
MBP reactivity of the lymph no de cells was measured by 3H Thymidine (lCN 
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Biomedicals, Irvine, CA, USA) incorporation assay. FolIowing transfer of MBP-
reactive celIs, mi ce were weighed and monitored daily for clinical signs of EAE, 
scored as: 1, flaccid tail; 2, hind limb weakness and pOOf righting ability; 3, one 
hind limb paralyzed; 4, both hind limbs paralyzed with or without forelimb 
paralysis and incontinence; 5, moribund. AlI mice with EAE included in this 
study were sacrificed at peak disease (grade 4). Mice were kept in an SPF 
environrnent. Animal maintenance and aIl experimental protocols were in 
accordance with Canadian Council for Animal Care guidelines and approved by 
McGill University Animal Care Committee. 
Isolation of RNA 
For spinal cord analysis, mice were anaesthetized with a lethal dose of Somnotol 
(MTC Pharmaceuticals, Cambridge, Ontario, Canada) and intracardially perfused 
with ice-cold PBS followed by removal of the spinal cord. Total RNA was 
purified using Trizol RNA isolation reagent (lnvitrogen Life Technologies, 
Carlsbad, CA, USA) according to the manufacturer's protocol for whole tissue 
RNA extraction. For sorted celIs, Trizol was used according to the protocol for 
RNA extraction for low amounts of RNA. 
Cell sorting 
Mice were anaesthetized with a lethal dose of Somnotol (MTC Pharmaceuticals) 
and intracardially perfused with 20 ml ice-cold PBS. Brain and spinal cord were 
colIected and brought into a single celI suspension by passing through a 70 !lm 
celI strainer (Becton Dickinson). After centrifugation with 37% PercolI 
(Amersharn Biosciences), the myelin was removed and celIs resuspended in 
buffer containing rat IgG to block non-specific antibody binding. The cells were 
stained with antibodies as indicated in figure legends. CyC-conjugated 
streptavidin and the antibodies PE-conjugated anti-CD45, biotin-conjugated anti-
CD3, FITC-conjugated anti-Mac-lICDllb and anti-Gr-l were purchased from 
BD-Pharrningen, San Diego, CA, USA. CelIs were isolated using a Becton-
Dickinson F ACSVantage celI sorter (Becton Dickinson Immunocytometry 
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Systems, San Jose, CA, USA) and flow cytometry data were analyzed using 
CellQuest software. 
Reverse transcriptase reaction 
Prior to real-time PCR analysis, total RNA was subjected to a reverse 
transcriptase (RT) protocol. 3 Ilg RNA from each spinal cord sample was 
incubated with M-MLV RT (lnvitrogen Life Technologies) according to 
manufacturer's protocol using random hexamer primers. RNA from sorted cells 
was incubated with SuperScript II RT (lnvitrogen Life Technologies) according to 
manufacturer's proto col using both oligo (dT) and random hexamer primers, and 
glycogen as carrier. 
Quantitative real-time PCR 
For spinal cord analysis and for analysis of T cells and myeloid cens, qPCR was 
done using the ABI Prism 7700 Sequence Detection System according to 
previously described methods (174). Quantitative real-time PCR (qPCR) was 
performed for aIl mouse MMP and TIMP genes (primer and probe sequences in 
(175) and several mouse ADAMs (see Table 1 for primer and probe sequences). 
18S rRNA (primers and probes from Applied Biosystems, Paisley, UK) was used 
as an endogenous control to account for differences in the extraction and reverse 
transcription of total RNA. 
For analysis of sorted celIs, qPCR was performed using the Smart Cycler 
System (Cepheid, Sunnyvale, CA, USA). Each reaction was performed in 25 , ..d 
with 50% TaqMan 2x PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA), 100 nM each of the forward and reverse primer, and 200 nM of probe. 
cDNA was diluted 1: 1000 for 18S rRNA analysis, which served as an endogenous 
control (18S rRNA primers and probes from Applied Biosystems, USA). MMP-8, 
MMP-10, MMP-12, MMP-15, TIMP-1 and ADAM-12 prim ers were synthesized 
by Sigma. Corresponding probes were synthesized at Applied Biosystems, USA. 
Sequences for these primers and probes (175) are identical to the primers and 
probes used for spinal cord analysis (Table 1). Conditions for the PCR were 2 min 
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at 50°C, 10 min at 95°C, and then 40 cycles, each consisting of 15 s at 95°C, and 1 
min at 60°C. To determine the relative RNA levels within the samples, standard 
curves for the PCR were prepared by using the cDNA from one sample and 
making 4-fold seriaI dilutions (8-fold dilutions for 18S rRNA). Standard curves 
for CT (cycle threshold; the cycle at which the detected signal became 
significantly different from background signal) versus arbitrary levels of input 
RNA were prepared, and relative levels of mRNA in each sample were 
determined. CT values were verified to be in the linear amplification range on the 
appropriate standard curves. 
In situ hybridization 
Fulliength murine TIMP-l cDNA was cloned into the pBluescript KS(-) plasmid 
(Stratagene, La Jolla. CA) as previously described (176). The murine MMP-I0 
cDNA was amplified from mouse brain tissue by RT-PCR using the 5' primer: 
GCC CAG CT A ACT TCC ACC TTT and the 3' primer: GAG AGT GTG GAT 
CCC CTT TGG. The resulting 400 bp fragment was cloned into the pCR4-TOPO 
vector using the TOPO TA cloning kit (Invitrogen, Paisley, UK). Plasmids were 
linearized with an appropriate endonuclease, and antisense and sense RNA probes 
for each gene were transcribed in vitro using either a T7 or T3 polymerase (Roche 
Applied Science, Lewes, U.K.) in the presence of digoxigenin (DIG)-labeled 
rUTP (Roche) according to the manufacturer's instructions. 
Frozen brain tissues were sectioned on a cryostat at 6 J..lm thick, with the 
first and fourth sections used for hematoxylin and eosin staining (H&E), the 
second section for antisense staining, and the third for sense staining. ISHs were 
performed as described elsewhere (177) with sorne modifications. Sections were 
first fixed in 4% (w/v) paraformaldehyde (PF A) for 15 min and then incubated in 
O.2M HCI and 0.2% Triton X-lOO for 10 min each, and digested in proteinase K 
(20 J..lg/ml) at 37°C for 5 min. Sections were refixed in 4% (w/v) PFA for 15 min, 
acetylated in 0.1 M triethanolamine with 0.5% (v/v) acetic anyhdride, and 
dehydrated through an alcohol series. Slides were hybridized in 50% (v/v) 
formamide, 4X SSC, 10% (w/v) dextran sulfate, IX Denhardt's solution, with 
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salmon sperm DNA (1 mg/ml) and appropriate riboprobe (100 ng/section) for 20 
hours at 50°C in a sealed humidified chamber. Sections were washed in 2X SSC, 
treated with RNase A (20 flg/ml) and processed for immunological detection of 
the DIG-Iabeled cRNA using anti-DIG antibodies at a dilution of 1 :500 (Roche). 
Color development was allowed to continue until a blue-purple precipitate was 
detected with the antisense probe; the color reaction for slides treated with the 
sense probe was terminated at the same time as for the antisense slides. 
Immunostaining 
Mice were anaesthetized with a lethal dose of Somnotol (MTC Pharmaceuticals) 
and intracardially perfused with 5 ml ice-cold PBS followed by 20 ml 4% PF A 
(Fisher, FairLawn, NJ, USA). Brain and spinal cord were dissected, post-
perfusion fixed 1 hr in 4% PF A, and incubated ovemight in PBS with 20% 
sucrose (EMD Chemicals, Gibbstown, NJ, USA). Tissues were embedded in OCT 
(EMS, Hatfield, PA, USA) and frozen in a 2-methylbutane (EMD Chemicals) 
bath immersed in liquid nitrogen. Immunohistochemical staining was performed 
on 10-flm cryostat sections. Frozen sections were blocked in 10% normal goat 
serum (Vector Laboratories, Burlingame, CA, USA) in PBS for 1 hr at room 
temperature followed by incubation with primary rabbit Abs: MMP-15 
(Chemicon, Temecula, CA, USA) and ADAM-12 (Chemicon) ovemight at 4°C, 
then with biotinylated goat anti-rabbit Ig (Vector Laboratories) for 1 hr at room 
temperature. Sections were treated with 3% H202 to quench endogenous 
peroxidase activity, and then incubated with an avidin-HRP complex (Vector 
Laboratories) following the manufacturer's instructions. HRP activity was 
detected by the use of DAB (Lab Vision, Fremont, CA, USA) as chromagen 
according to the manufacturer' s instructions. Control sections were incubated 
with equal concentration of rabbit immunoglobulin (DAKO, Mississauga, ON, 
Canada) purified from serum of non-immunized rabbits. For H&E staining, 
sections were incubated 5 min in Harris hematoxylin (Surgipath, Winnipeg, MB, 
Canada), followed by 1 min in eosin (Surgipath). 
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Table I. Primer and probe sequences for mouse ADAMsa 
Gene Sequence 
ADAM-IO Forward: GTGCCAGTACAGGCTCTTTGC 
Reverse: CACAGTAGCCTCTGAAGTCATTACATG 
Probe: ACTATCACTCTGCAGCCGGGCTCTCC 
ADAM-12 Forward: ATCAGTGTCTTCGGCGTTCA 
Reverse: GGCAATTCTTCCTGTTGTTACATACC 
Probe: CCATGCAGTGCCACGGCCG 
ADAM-15 Forward: GACCACTCCACAAGCATCTTAGG 
Reverse: GGGAGAATCATGGTCCAAACC 
Probe: TGCCTCCTCGATTGCCCATGAATTG 
ADAM-17 Forward: AAGTGCAAGGCTGGGAAATG 
Reverse: CACACGGGCCAGAAAGGTT 
Probe: CCTGCGCATGCATTGACACTGACAAC 
ADAM-19 Forward: CGGGCCCACCTCGAA 
Reverse: CCGTTTCATTCTGCGAGGTT 
Probe: TGGGCCCTTCAGTTTACACATCAGACCA 
ADAM-28 Forward: TACTGCTTGAAGGGCAAATGTC 
Reverse: TGTCCCACCTTCATTCTGCTT 
Probe: TCCAGGAACCAAGGTTGCAAATACATCATG 
TTAC 
ADAM-33 Forward: CAGGCACTGTCAGAATGCTACCT 
Reverse: CTATTGCAAACCCCACCGTTA 
Probe: TGGAACGTTGCTTGACTGCCTGCC 
a AlI probes are in the 5'-3' orientation. For the probes, a FAM fluorescent 
reporter is coupled to the 5' end, while a TAMRA quencher is coupled to the 3' 
end. 
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2.4. ResuUs 
2.4.1. MMPs-8, 10, 12 and 15, ADAM-12 and TIMP-l are the most strongly 
affected MP genes in severe EAE 
The aim of our study was to identify significant differences in expression levels of 
MMP, TIMP and ADAM genes as a consequence of inflammation in EAE spinal 
cord, and then to localize expression of the se genes to individual cell populations. 
Our criteria for genes to be studied in more detail were that the y showed a 
statistically significant and greater than three-fold difference in expression levels. 
The analysis was done using quantitative real-time RT-PCR and results for spinal 
cord are shown as fold alteration in expression level between mice with EAE and 
control mi ce (Table II). Six genes fulfilled our criteria: MMP-8, MMP-I0, MMP-
12, MMP-15, ADAM-12 and TIMP-l. These genes are marked with arrows in 
Fig. 1 a, which is a graphical representation of the data in Table II. MMP-15 was 
the only gene among the six that showed decreased expression. MMP-15 is one of 
the six membrane-bound MMPs (MMP-14, 15, 16, 17, 24 and 25), of which four 
(MMP-15, 16, 17 and 24) were downregulated in EAE (Table II and Fig. 1 a). 
The analysis of alteration in expression levels of genes clearly shows up 
and downregulation of gene expression but is not informative about the absolute 
levels of expression of the individual genes. A good estimation of this can be 
obtained from the delta cycle threshold (~CT) values obtained from the 
quantitative real-time PCR analysis (Fig. 1 b). A small ~CT value corresponds to a 
high level of expression, and vice versa. It is evident from Fig. 1 b that the large 
fold increase in expression of MMP-8, 10 and 12 in EAE SC reflected a very low 
level of expression in the un-manipulated SC, rather than a high level of 
expression in EAE. By contrast, TIMP-l was expressed at a fairly low level in un-
manipulated SC, but, in EAE, became the most highly expressed of the genes 
studied. MMP-15 fell from an intermediate to a low level of expression. ADAM-
12 falls in the low range in both cases. 
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Table II. Analysis of MP and TIMP expression profiles in CNS of mi ce with 
EAE at peak disease compared to unmanipulated controlsa 
Fold increase in Fold decrease in 
Gene EAE EAE P value 
MMP-la ND ND 
MMP-lb ND ND 
MMP-2 1.6 0.0642 
MMP-3 2.2 0.1248 
MMP-7 1.5 0.3662 
MMP-8 90.1 P<O.OOOI 
MMP-9 2.6 0.094 
MMP-lO 70 0.0183 
MMP-ll 1.3 0.3477 
MMP-12 132.9 0.0134 
MMP-13 1.2 0.6135 
MMP-14 2.2 0.0322 
MMP-15 5.5 0.0026 
MMP-16 2.2 0.0024 
MMP-17 1.9 0.0606 
MMP-19 2.7 P<O.OOOI 
MMP-20 1.1 0.901 
MMP-21 2 0.0821 
MMP-23 2.8 0.0091 
MMP-24 2.9 0.001 
MMP-25 1.9 0.0108 
MMP-28 1.3 0.1868 
ADAM-10 1.05 0.798 
ADAM-12 3.87 0.0036 
ADAM-15 2.3 0.0145 
ADAM-17 2.8 0.0002 
ADAM-19 2.14 0.0018 
ADAM-28 ND ND 
ADAM-33 1.42 0.1019 
TIMP-l 115.1 0.0023 
TIMP-2 1.3 0.1476 
TIMP-3 1.9 0.0344 
TIMP-4 1.2 0.1007 
a N=4 for each group. Genes showing a more than three-fold alteration with a P 
value less than 0.05 in an unpaired t-test were chosen for detailed analysis. ND: 
not detected. 
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2.4.2. Expression of MP genes corre/ates with disease course 
Our screen of a wide range of MMPs, ADAMs and TIMPs showed that 
expression of six genes was altered more than 3-fold in spinal cord of mice with 
severe (grade 4) EAE (Table II and Fig. 1 a). To further characterize the 
expression of these six genes in EAE, we studied the kinetics of their expression 
at onset of disease, at severe disease and after the first episode of symptoms. Fig. 
2 shows the clinical course of EAE in individual mi ce after transfer of MBP-
reactive T cells. As evident from Fig. 2, mice progressed rapidly from onset to 
grade 2, most often ovemight. Mice at grade 2 EAE were therefore used to 
represent onset of disease. Mice in each group in the kinetic study of expression 
were sacrificed at equivalent stage of disease. Fig. 3 reveals a clear correlation 
between increased expression levels and increased severity of symptoms for 
MMP-8, ID, 12 and TIMP-I (Fig. 3a, b, c and f). Notably, expression levels of 
these genes were strongly reduced after remission from symptoms, probably due 
to loss of a significant number of the relevant infiltrating cell types (macrophages 
and granulocytes) expressing these genes after remission. The results for MMP-IS 
indicate an inverse relationship between expression levels and disease severity 
(Fig. 3d), with expression in remitted mice retuming to levels comparable to 
controls. There was a clear upregulation of ADAM-12 in mi ce with severe (grade 
4) EAE (Fig. 3e), but in contrast to the other five genes analyzed, expression of 
ADAM-12 persisted after remission at a level comparable to grade 4 disease. 
2.4.3. Mye/oid cells are the major producer of MPs 
We first screened expression of aIl 22 MMPs, four TIMPs and seven ADAMs in 
two cell populations (T cells and myeloid ceIls) sorted from EAE CNS using flow 
cytometric sorting. The cells were sorted from brain and spinal cord of individual 
mice; we inc1uded brain to retrieve a greater number of cells. The trends in 
expression levels of the analyzed genes were similar between SC and brain 
samples (data not shown). We sorted T cells as CD4Shigh CD3+ ceIls, and a 
population ofCD4Shigh Mac1/CDllb+ ceIls, which inc1udes macrophages and 
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Figure 1. a. Graphical representation of the data ln Table II. Downregulated 
expression is represented by open bars. The vertical lines represent specified fold 
alterations in expression. !lCT (CT: cycle threshold) values for each of the genes 
analyzed are shown as ranges indicated by shading of the boxes. !lCT is the 
difference in CT between the gene of interest and the internaI reference control 
gene 18S rRNA. Arrows indicate the genes chosen for detailed analysis. ND: not 
detected. 
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granulocytes (178) (fig. 4b-c). This aUows us to compare expreSSIOn by 
infiltrating T ceUs and myeloid ceUs. Results of this analysis for genes showing an 
upregulation in SC EAE of 1.2 fold or more (see Table II) are shown in Fig. 5. Of 
the 19 genes analyzed this way, most (10) were expressed at significantly higher 
levels by myeloid ceUs than by T ceUs. Six genes (MMP-3, MMP-IO, MMP-13, 
MMP-25, MMP-28 and ADAM-33) were .expressed at equivalent levels (no 
statisticaUy significant difference). Three genes (MMP-ll, ADAM-12 and 
ADAM-19) were expressed at significantly higher levels by T ceUs than by 
myeloid ceUs. 
2.4.4. MP genes are expressed by specifie cell types 
In order to assess expression of the six most strongly affected genes (MMP-8, 
MMP-I0, MMP-12, MMP-15, ADAM-12 and TIMP-l) in more detail by 
individual cell types, we isolated infiltrating macrophages, granulocytes and T 
ceUs as weU as resident microglia from the CNS of mice with EAE, using flow 
cytometric sorting. As mentioned earlier, the population isolated as CD45high 
Macl/CDllb+ ceUs included both macrophages and granulocytes (Fig. 4c). To 
assess expression from granulocytes alone, we isolated CD45high Gr-l high ceUs, a 
population we have shown to consist of polymorphonuclear leukocytes (Zehntner 
S. P. and Owens T., personal communication) (Fig. 4d). Subtraction of the 
granulocyte contribution from the total allowed estimation of expression by 
macrophages alone. T ceUs were identified as CD45 high CD3+ cells (Fig. 4b) and 
microglia as CD45intermediate Macl/CDllb+ ceUs (179,180). Unlike infiltrating 
leukocytes, microglia can be isolated in significant numbers both from un-
manipulated and inflamed SC (Fig. 4a and c, respectively). 
Fig. 4e-f shows the average proportions of the ceU types isolated from 
CNS that were used in the real-time PCR analysis. The total number of cells in 
CNS increased by 56% in EAE, mainly due to infiltration of macrophages, 
granulocytes and T ceUs. The proportion of microglia remained at 23%, which, 
given the increase in total ceUs, actuaUy reflects an increase in the number of 
microglia in EAE compared to unmanipulated mice. 
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Figure 2. Disease progression after adoptive transfer of EAE. MBP-specific T 
cells were transferred to mice at day O. Daily clinical scores for Il individual 
mice are shown. Mice were sacrificed at different time points (indicated with an 
S). Mice that remitted (graded 0) had no symptoms except residual tail stiffness 
when sacrificed at day 21. S: sacrificed. 
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Fig. 6 shows gene expression levels of the six most strongly affected 
genes, in the four isolated cell types. It is clear that macrophages were the major 
source ofMMP-12 (Fig. 6c) and TIMP-l (Fig. 6f), whereas granulocytes were the 
major source of MMP-8 (Fig. 6a). For MMP-I0, expression was seen by 
microglia and macrophages (and in T cells in only one of four samples) (Fig. 6b). 
None of the cell types investigated stood out as a major producer of MMP-l O. 
ADAM-12 was expressed almost exclusively by T cells (Fig. 6e). Uniquely 
among the genes we analyzed, MMP-15 was strongly expressed by resting 
microglia, and this was reduced 15-fold in EAE (Fig. 6d). 
When expression data from cell subpopulations from EAE SC were 
normalized per relative cell proportions (results not shown), the overall 
conclusions from Fig. 6 were unchanged. That is, TIMP-l was expressed mainly 
by macrophages; MMP-8 mainly by granulocytes with sorne expression by 
macrophages and T ceIls; MMP-IO by microglia and macrophages; MMP-I2 
mai nI y by macrophages with sorne expression by microglia and T ceIls; MMP-I5 
was expressed by microglia with a small contribution from macrophages and 
ADAM-12 was expressed by T cells. 
2.4.5. ADAM-I2 protein is expressed by infiltrating T cells, whereas 
parenchymal MMP-I51evels decrease in EAE 
To verify that the expression of ADAM-12 message localized by flow cytometry 
and PCR to T cells (Fig. 6e) was reflected by production of protein, we used 
immunohistochemistry to analyze production of ADAM-I2 in spinal co rd white 
matter of mi ce with EAE (Fig. 7a, b). By comparison with staining of the same 
infiltrate in a separate section with control rabbit IgG (Fig. 7e), we found that 
about 50% of cells in perivascular infiltrates were producing ADAM-I2. Analysis 
of the ceIl proportions in EAE CNS (Fig. 4f) showed that infiltrating T ceIls 
account for about 50% of the infiltrating ceIls. The fact that about half of the 
infiltrating ceIls stained positive for ADAM-12 and had a round morphology 
suggests that these ceIls are T ceIls. 
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Figure 3. Kinetics of MP gene expression during EAE. Expression levels of 
MMPs 8, 10, 12 and 15, ADAM-12 and TIMP-l ln spinal cord from 
unmanipulated mi ce and mi ce with early onset (Grade 2) and severe, established 
(Grade 4) EAE, and mi ce in remission, were measured by real-time peRo 
Significance of comparisons to unmanipulated mice was determined using an 
unpaired t-test. An unpaired t-test was also used to compare Grade 4 mice to the 
remitted group. N=4 for aIl groups except remitted mi ce (N=3). *:P<0.05; 
**:P<O.Ol; *** :P<O.OOl; NS: not significant. Error bars represent SEM. 
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In whole spinal cord, we found MMP-15 message to be downregulated 
5.5-fold in EAE (Table II and Fig. la). In contrast to ADAM-12, anti-MMP-15 
antibody did not stain cells within infiltrates in EAE spinal cord more intensely 
than control serum (Fig. 7c, e). This is consistent with cell sorting data that 
infiltrating cells in EAE express virtually no MMP-15 (Fig. 6d). The analysis of 
MMP-15 expression by sorted cells pointed to a downregulation of MMP-15 
expression by microglia in EAE. Immunostaining showed a general reduction of 
MMP-15 staining intensity between spinal cord white matter in unmanipulated 
control mi ce (Fig. 7d) and a comparable uninfiltrated area in mice with EAE (Fig. 
7f). This reduction of staining intensity was evident both on cell bodies and in the 
stroma, likely corresponding to cell processes, thereby indicating that the level of 
MMP-15 protein is indeed reduced in spinal cord ofmice with EAE. 
2.4.6. MMP-IO and TIMP-l expression localizes to perivascular infiltrates 
Expression analysis from sorted cells did not provide clear information whether 
the increase in MMP-IO expression in CNS was due to infiltrating cells, or 
whether another cell type was responsible (Fig. 6b). To address this question, we 
used ISH to analyze MMP-lO expression (Fig. 8). We also analyzed TIMP-I 
expression, which had been shown to be expressed by cell-sorted macrophages 
(Fig. 6f). Brain sections from the same mice whose spinal cords were used for the 
initial screening of gene expression (Fig. 1) were analyzed by ISH. These mice 
had severe EAE (grade 4) and numerous cerebellar infiltrates could be identified 
by H&E staining (Fig. 8a). Sections were hybridized with anti-sense and control 
(sense) probes for TIMP-l or MMP-IO. A uniformly strong signal for TIMP-l 
was detected in about half of the infiltrating cells (Fig. 8b). By contrast, MMP-IO 
message was expressed by a majority of infiltrating cells, but at variable levels of 
intensity (Fig. 8d). 
For both TIMP-I and MMP-IO, other cellular sources of message, most 
notably neurons in the granular cell layer and Purkinje cells, were observed in 
cerebellum (not shown). Cells associated to blood vessels, with morphology 
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Figure 4. Flow cytometric analysis of cell populations in unmanipulated (a) and 
EAE CNS (b-d). Panels a and c show staining for PE-CD45 versus FITC-
Mac lICD Il b. Panel b shows PE-CD45 versus CD3-biotin coupled to 
streptavidin-CyC. Panel d shows PE-CD45 versus FITC-Gr-l. Boxes are drawn to 
identify microglia (a, c), T cells (b), macrophages and granulocytes (c) and 
granulocytes (d). Fluorescence levels are matched between panels a and band 
between panels c and d. Panels e-f show average numbers and proportions of cells 
sorted from CNS preparations, (e): unmanipulated controls (N=8), (f): EAE 
(N=16 for microglia and macrophages, N=6 for neutrophils and T cells). Mac.: 
Macrophages; Gran.: granulocytes. 
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similar to endothelial ceIls, were also positive for MMP-I0 (data not shown). 
There was no difference in ISH signal intensity for neuronal or endothelial 
expression between EAE samples and controls. We conclude that the increase in 
message levels for MMP-l 0 in EAE was due to combined expression by multiple 
types of infiltrating cells. 
2.5. Discussion 
To our knowledge, this is the first and most comprehensive study of expression of 
aIl known mouse MMPs and TIMPs, as weIl as seven ADAMs, in CNS tissue 
from animaIs with EAE. This is also the first analysis of expression of MMPs, 
ADAMs and TIMPs in cell populations sorted from the CNS of mi ce with EAE. 
Our findings show distinct patterns of expression, which likely reflect functional 
differences in the se genes in CNS inflammation. 
Clearly, macrophages are an important source of MP and TIMP expression 
in EAE. Macrophage infiltration is required for EAE, and, if blocked, prevents 
disease (181, 182). Our study shows fairly high expression by macrophages of aIl 
but two (MMP-I0 and ADAM-12) of the six most strongly affected genes. The 
finding that TIMP-l was expressed by macrophages suggests a potential 
regulatory role for macrophages in EAE and MS by controlling the MPITIMP 
ratio and thereby controlling the level of MP activity. Also astrocytes would be 
suspected to play a role in controlling the MP/TIMP ratio, as activated astrocytes 
have been demonstrated to express TIMP-l in EAE (183). 
The MMP-9/TIMP-l ratio has received much attention since the finding 
that serum MMP-9/TIMP-l ratio is increased in patients with active MS, mainly 
due to increased MMP-9 levels (110, 184). Hence, MMP-9 has become a 
candidate in the pathogenesis of MS and EAE. It has been shown that MMP-9 
deficient mice younger than 4 weeks were less susceptible to EAE, but that adult 
mice were unaffected (185). MMP-9 has previously been reported to be 
upregulated in both mouse and rat EAE (173, 183). In a kinetic study (173), the 
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Figure 5. Relative expression of selected genes by T cells (T) and myeloid cells 
(M) (macrophages and granulocytes) from EAE CN8 at peak disease. N=6 for 
each group. Values on the ordinate are relative levels of gene expression 
compared to expression of 188 rRNA. The values are arbitrary and cannot be 
compared between different genes. 
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upregulation of MMP-9 was seen at onset of disease and had virtually disappeared 
when the rats reached maximum disease. In our study, we found a 2.6 fold 
upregulation of MMP-9 (Table II), but it was not significant and was not chosen 
for further study. This relatively small increase in MMP-9 expression is probably 
due to the fact that the mice analyzed in our study were at an advanced stage in 
the disease, when an early large rise in MMP-9 expression will have subsided. 
MMP-7 has previously been found to be upregulated in rat models of EAE (173, 
186). We found a non-significant 1.5-fold decrease in MMP-7 expression in 
grade 4 disease. However, our finding of no upregulation of MMP-7 is consistent 
with an earlier observation that MMP-7 was not upregulated in mouse EAE (183). 
This points to a possible species difference between mice and rats with respect to 
MMP-7 expression in EAE. 
We find that, whereas T cells are a minor source ofMMP-8 and MMP-12, 
they are virtually the only source of ADAM-12 among the infiltrating cells (Fig. 
6e). The cellular sources of ADAM-12 as weIl as its functions are not weIl 
studied. A study of ADAM-12 deficient mice suggested that ADAM-12 plays a 
role in adipogenesis and myogenesis (187). To our knowledge, the only previous 
demonstration of ADAM-12 expression in the CNS identified oligodendrocytes as 
sources of ADAM-12 (188). These could be the cells responsible for the 
expression of ADAM-12 we found in the unmanipulated CNS (Fig. lb). ADAM-
12 was the only gene of the six analyzed that was expressed at levels comparable 
to severe disease after remission from disease (Fig. 3e). One may speculate that 
this is due to persisting T cells in the CNS after remission. Our demonstration of 
expression of this gene by T cells could indicate a novel role for ADAM-12 in T 
cell function. 
The differential expression of MPs by infiltrating T cells and myeloid cells 
is of interest. In a study of MMP expression by subsets of human leukocytes 
isolated from blood; monocytes were found to express more MMP members than 
T cells or B cells, and to have higher migratory potential (189). In our study, we 
find myeloid cells to be the major source of MP message compared to T cells, 
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Figure 6. Relative expression of selected genes in cell populations sorted from 
CNS. N=7 for unmanipulated microglia, and N=lO for EAE microglia. N values 
for macrophages + granulocytes, granulocytes alone and T cells are 8, 6 and 4, 
respectively. For MMP-lO Cb), only one out of four samples showed detectable 
expression in T cells. Where possible, expression level differences between 
control microglia and EAE microglia were analyzed using an unpaired t-test. 
Mac.: Macrophages; Gran.: Granulocytes; NS: not significant; ND: not detected; 
**: P<O.Ol. 
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with MMP-ll, ADAM-12 and ADAM-19 as exceptions (Fig. 5). However, both 
cell populations were isolated from the CNS and have therefore demonstrated 
capacity to infiltrate, and both T cells and myeloid cells co-Iocalize within CNS 
infiltrates. One could speculate that the differences in MP expression reflect 
different timings for entry of T cells and myeloid cells into the CNS. If a 
particular cell type were responsible for extensive breakdown of the BBB at 
initiation of inflammation, then other cells, with a smaller or different arsenal of 
MPs, would have an easier route into the CNS. The sequence of cellular 
infiltration in EAE could be orchestrated by changing chemokine profiles over the 
course of disease (190). 
From Fig. 6a, it is evident that granulocytes were a major source of MMP-
8 (also named neutrophil collagenase), consistent with previous findings (191). In 
addition to the mRNA messages detected in our study, granulocytes may 
contribute to the MP load by releasing MPs from pre-formed vesicles upon 
infiltration, without need for de novo MP synthesis. 
In our analysis, we also included microglia, the resident macrophage-like 
cells in the CNS. Microglia have been implicated as critical cells in MSIEAE 
pathogenesis (192, 193), perhaps through production of MMPs (194). We found 
that microglia expressed MMPs 10, 12 and 15 in EAE. These cells share bone 
marrow origin and many functional properties with macrophages, so shared 
expression of MMPs would be expected. The downregulation of membrane-
associated MMP-15 by microglia was a striking demonstration of a specifie 
downregulation of an MMP by a specifie cell type in EAE. This finding raises 
questions regarding the function of this membrane-associated MMP. Since it is 
downregulated in EAE, it would not appear to play a role in facilitating 
infiltration. Indeed, four out of the six membrane-associated MMPs were 
downregulated in EAE (Table II and Fig. 1 a). It will be interesting to determine 
how many are expressed by microglia and whether membrane-associated MMPs 
play a special role in microglial biology. A study of membrane-associated MMPs 
in gliomas showed them to generally be elevated (174). The functional 
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Figure 7. Immunostaining for ADAM-12 and MMP-15 in EAE. Sequential 
sections from a perivascular infiltrate in spinal cord white matter of a mouse with 
EAE were stained with H&E (a), anti-ADAM-12 antibody (b), anti-MMP-15 
antibody (c) and control rabbit immunoglobulin (e). An equivalent area of spinal 
cord white matter from an unmanipulated mou se was stained with anti-MMP-15 
antibody (d). Panel (f) shows MMP-15 staining for an uninfiltrated area adjacent 
to the infiltrate shown in panels a-co Results shown are representative of four mice 
with EAE and four unmanipulated mice. Original magnification: 63X. 
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consequences of this contrasting response of membrane-associated MMPs in the 
context of different CNS diseases remain to be elucidated. 
We also note an increase in absolute numbers of microglia in the CNS in 
EAE (Fig. 4e-f), which is consistent with an earlier study (195). This increase is 
likely due to proliferation of resident microglia as a consequence of activation in 
the inflammatory milieu, although a contribution from immigrating blood-derived 
cells cannot be excluded (196, 197). One can speculate whether the change from 
resting to activated microglia is reflected in their expression profiles of 
membrane-associated MMPs, including the downregulation of MMP-15. Fig. 3d 
shows that MMP-15 levels after remission from EAE retum to a level comparable 
to unmanipulated controls. This may indicate a change in the activation status of 
the microglia that produce MMP-15, retuming to a more resting state with higher 
MMP-15 expression after remission 
The MS therapeutic IFN~ is proposed to work in part by inhibiting MMPs, 
as indicated by a decrease in transcription of MMP-7 and 9 in peripheral blood 
leukocytes from patients with relapsing-remitting MS receiving IFN~ treatment 
(198). Likewise, the attenuation of EAE symptoms in mi ce treated with the 
antibiotic Minocycline may be mediated in part by the MMP inhibitory effect of 
this drug, as Minocycline decreases transcription levels of MMPs and inhibits T 
cell migration across a fibronectin membrane (104). The use of synthetic broad-
spectrum MP inhibitors in MS might be problematic given the current lack of 
knowledge about potential beneficial and detrimental roles of specific MPs in 
CNS inflammation. The use of such drugs in clinical trials involving cancer 
patients was terminated due to low efficacy and serious side effects (98). Our 
study provides comprehensive information about MP and TIMP expression in 
EAE as weIl as information about cell type specific expression of MPs and 
TIMPs. We anticipate that our findings will aid in the development of rational MS 
therapies based on manipulating specific MP and TIMP action. 
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Figure 8. ISH for TIMP-I and MMP-lO expression ln EAE. Perivascular 
infiltrates in cerebellar white matter of mice with EAE were identified using H&E 
staining (a). Infiltrates were hybridized on separate sections with TIMP-I anti-
sense probe (b) and MMP-IO anti-sense probe (d). Panels c and e show lack of 
hybridization with TIMP-I and MMP-IO sense probes, respectively. Results 
shown are representative ofthree mice with EAE. Original magnification: 63X. 
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PREFACE TO CHAPTER III 
The following chapter builds on findings from Chapter 2 (199), which identified 
pro minent expression and cellular sources of five MP and one TIMP genes in 
EAE based on a comprehensive screen of MP expression. It addresses whether 
these same MPs, strongly implicated in EAE, are also involved in another model 
of neuroinflammation. Transgenic mice that overexpress the chemokine CCL2 in 
the CNS have pronounced accumulation of leukocytes in the perivascular space, 
but are asymptomatic until challenged with PTx. Encephalopathy triggered by 
PTx is associated with infiltration across the glia limitans. With this model it is 
thus possible to distinguish processes involved in migration across the 
endothelium from those involved in crossing the glia limitans. The experiments 
described in Chapter 3 test the hypothesis that MPs are involved in the PTx-
induced leukocyte transmigration across the glia limitans in CCL2 Tg mice, by 
applying the broad-spectrum MP-inhibitor BB-94. This study also has relevance 
to the role of microbial involvement in the pathogenesis of MS, by investigating 
synergy between a pathogenic stimulus and an inflammatory chemokine. 
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3.1. Abstract 
Leukocytes accumulate spontaneously in the perivascular space in brains of 
transgenic (Tg) mice that overexpress CC chemokine ligand 2 (CCL2) under 
control of a CNS-specific promoter. The CCL2-Tg mice show no clinical 
symptoms, ev en though leukocytes have crossed the endothelial basement 
membrane of the blood-brain barrier (BBB). Pertussis toxin (PTx) given 
intraperitoneally induced encephalopathy and weight loss in CCL2-Tg mice. 
We used flow cytometry, USPIO-enhanced magnetic resonance imaging 
and immunofluorescent staining to show that encephalopathy involved leukocyte 
migration across the astroglial basement membrane of the BBB into the brain 
parenchyma, identifying this as the critical step in inducing clinical symptoms. 
Metalloproteinase enzymes (MPs) are implicated in migration of 
leukocytes across the blood-brain barrier. Unmanipulated CCL2-Tg mice had 
elevated expression of TIMP-l, MMP-I0 and 12 mRNA in the brain. PTx further 
induced expression of TIMP-l, ADAM-12 and MMPs 8 and 10 in brains of 
CCL2-Tg mice. Levels of microglial-associated MMP-15 were not affected in 
control or PTx-treated CCL2-Tg mice. PTx also upregulated expression of 
proinflammatory cytokines IL-lp and TNFa mRNA in CCL2-Tg CNS. 
Weight loss and parenchymal infiltration induced by PTx were 
significantly inhibited by the broad-spectrum MP inhibitor BB-94/Batimastat. 
Our finding that MPs mediate PTx-induced parenchymal infiltration to the 
chemokine-overexpressing CNS has relevance for the pathogenesis of hum an 
diseases involving CNS inflammation, such as multiple sclerosis. 
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3.2. Introduction 
Multiple sclerosis (MS) is a common neurological disease that is characterized by 
demyelination and inflammation of the CNS. The cause of MS is unknown, but 
may be the result of an environmental stimulus in genetically predisposed 
individuals (2). There is an established link between genotype and disease 
susceptibility to MS, and microbial infections can precipitate attacks in MS 
patients (3, 21, 200). Tg mice in which all T cell receptors recognize a myelin 
basic protein (MBP) epitope only developed inflammatory demyelinating disease 
if given PTx or kept in a non-sterile environment (201). PTx is derived from 
Bordetella pertussis, the causative agent ofwhooping cough, and is routinely used 
as adjuvant to induce experimental autoimmunity, possibly substituting for critical 
environmental cues in the pathogenesis of auto immune disease. 
Chemokines are small chemoattractant cytokines with the ability to direct 
cellular migration. CCL2, previously named monocyte chemoattractant protein-l 
(MCP-l), is critical for cellular entry to the CNS in MS and experimental 
auto immune encephalomyelitis (EAE), an animal model of MS (202). Blockade 
of CCL2 function in systems of non-immune mediated CNS infiltration curbs 
migration of leukocytes to sites of damage (150, 203, 204). Transgenic expression 
of CCL2 targeted to oligodendrocytes leads to perivascular accumulation of 
leukocytes in the brain without clinical symptoms (34). Transgenic mice 
overexpressing CCL2 in astrocytes are also unaffected until six months of age, 
after which they develop delayed encephalopathy (205). If PTx is injected into 
these mice at an early age (8-10 weeks old), it induces a condition described as 
PTx-induced reversible encephalopathy dependent on MCP-l/CCL2 
overexpression (PREMO) (206). Both PREMO and delayed encephalopathy are 
dependent on a functioning CCR2 (205, 206). 
The BBB restricts the entrance of cells and macromolecules into the CNS. 
It consists of a number of separate barri ers. Endothelial tight junctions are 
responsible for limiting passage of macromolecules such as dyes. There is an 
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endothelial basement membrane and a separate astroglial basement membrane, 
the latter associated with the glia limitans (29). In the inflamed CNS, the BBB is 
crossed by leukocytes, which enter the CNS parenchyma. The actual mechanism 
behind cellular crossing of the BBB remains to be fully explained (207), but is 
likely to involve degradation of extracellular matrix proteins in the BBB by MPs. 
MPs have been implicated in virtually aIl CNS inflammatory diseases (89, 108). 
Twenty two matrix metalloproteinases (MMPs) have been identified in 
mice, and collectively they can degrade aIl components of the extracellular matrix 
(66, 68). Six MMPs are membrane-bound (MT-MMPs). Metalloproteinase-
disintegrins (ADAMs) are another family of MPs, which comprise more than 30 
members (168). There are four tissue inhibitors of metalloproteinases (TIMPs). A 
series of papers have demonstrated that administration of synthetic broad-
spectrum MP-inhibitors alleviates symptoms ofEAE (171-173). 
In this study, we examined the role of MMPs in PTx-induced 
encephalopathy in CNS-specific CCL2 Tg mice. We show that crossing of the 
astroglial basement membrane, not the endothelial basement membrane, was the 
critical step inducing clinical symptoms. The parenchymal brain infiltration 
induced by PTx was associated with changes in expression of MP genes and could 
be alleviated by treatment with a broad-spectrum MP inhibitor. 
3.3. Materials and Methods 
Mice 
Transgenic mice expressing the chemokine CCL2 in the CNS under control of a 
myelin basic protein (MBP) promoter (34) were obtained from Bristol-Myers 
Squibb (New Brunswick, New Jersey) and maintained as a colony at the Montreal 
Neurological Institute. Male and female 8-12 week old transgenics and wild-type 
C57BL/6 (Jackson Laboratory, Bar Harbor, Maine) were used for an, experiments. 
Mice were bred and maintained in a specific pathogen-free environment. Animal 
breeding, maintenance and aIl experimental protocols were performed in 
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accordance with Canadian Council for Animal Care guidelines as approved by the 
Mc Gill University Animal Care Committee. 
Administration of pertussis toxin and BB-94 
Pertussis toxin (10 !lg/kg) (Sigma, o akville , Ontario) or HBSS (Invitrogen Life 
Technologies, Carlsbad, Califomia) were injected ip. at day O. Mice were weighed 
and monitored daily. BB-94 (Vemalis, a kind gift from Dr. Yong, University of 
Calgary) was injected ip. as a suspension of 3 mg/ml in PBS containing 0.01 % 
Tween-80. To increase solubility, the suspension was sonicated 3x10 seconds on 
ice. Mice were treated with BB-94 (50 mg/kg per dose) or vehicle at 1 and 4 hours 
after injection with PTx, and once per day thereafter. 
Cell sorting 
Mice were anaesthetized with Somnotol (MTC Pharmaceuticals, Cambridge, 
Ontario) and intracardiaIly perfused with 20 ml ice-cold PBS. Brain and spinal 
cord were coIlected and a single ceIl suspension generated by passing through a 
70 !lm cell strainer (BD Biosciences Pharmingen, Mississauga, Ontario). After 
centrifugation on 37% Percoll (Amersham Biosciences, Baie d'Urfe, Quebec), the 
mye lin was removed, cells were washed in HBSS and incubated in supematant 
from the anti-FcR 24G2 (anti CD16/32) hybridoma containing an additional 2 % 
fetal calf serum (FCS) (Sigma) and hamster IgG (50 !lg/ml) (Cedarlane, Homby, 
Ontario) on ice for 20 min. to block non-specific antibody binding. The cells were 
stained on ice for 30 min. with antibodies as indicated in figure legends. Cy5-
conjugated streptavidin and the antibodies phycoerythrin (PE)-conjugated anti-
CD45, biotin-conjugated anti-CD3, fluorescein isothiocyanate (FITC)-conjugated 
anti-CD11b and anti-Gr-1 were purchased from BD Biosciences Pharmingen. The 
cells were washed in HBSS with 2% FCS and sorted using a Becton-Dickinson 
F ACSVantage ceIl sorter (Becton Dickinson Immunocytometry Systems, San 
Jose, Califomia). Flow cytometry data were analyzed using CeIlQuest software. 
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Isolation of RNA 
Total RNA was purified using Trizol RNA isolation reagent (lnvitrogen Life 
Technologies) according to the manufacturer's protocol for whole tissue RNA 
extraction. For sorted cells, Trizol was used according to the manufacturer's 
protocol for RNA extraction for low amounts of RNA. 
Reverse transcriptase reaction 
RNA (3 f.lg) from each brain sample was incubated with M-ML V reverse 
transcriptase (RT) (lnvitrogen Life Technologies) according to manufacturer's 
protocol using random hexamer primers. RNA from sorted cells was incubated 
with SuperScript II RT (Invitrogen Life Technologies) according to the 
manufacturer's protocol using random hexamer primers, and glycogen as carrier. 
Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was done using the ABI Prism 7000 Sequence 
Detection System according to our previously described method and probe and 
primer sequences (199). Expression of 18S rRNA (primers and probes from 
Applied Biosystems, Foster City, California) in cDNA samples diluted 1: 1 000 
was used to control for differences in the extraction and reverse transcription of 
total RNA. AlI other primers were synthesized by Sigma. Corresponding probes 
were synthesized at Applied Biosystems. Each reaction was performed in 25 f.ll 
with 50% TaqMan 2x PCR Master Mix (AppliedBiosystems), 100 nM each of the 
forward and reverse primer, and 200 nM of probe. Conditions for the PCR were 2 
min at 50°C, 10 min at 95°C, and then 40 cycles, each consisting of 15 s at 95°C, 
and 1 min at 60°C. To determine the relative RNA levels within the samples, 
standard curves for the PCR were prepared by making 4-fold seriaI dilutions (8-
fold dilutions for 18S rRNA) of cDNA. Standard cUrves for CT (cycle threshold; 
the cycle at which the detected signal became significantly different from 
background signal) versus arbitrary levels of input cDNA were prepared, and the 
expression level of mRNA in each sample was determined. CT values were 
verified to be in the linear amplification range on the appropriate standard curves. 
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The relative expression level for each sample was calculated by dividing the 
expression level of the target gene by the expression level of 18S rRNA. 
Immunofluorescence staining 
Mice were anaesthetized with Somnotol (MTC Pharmaceuticals) and 
intracardially perfused with 5 mlice-cold PBS followed by 20 ml 4% PF A 
(Fisher, Nepean, Ontario) in PBS. Brains were dissected, fixed for 1 hr in 4% 
PFA in PBS at 4°C, incubated ovemight in PBS with 20% sucrose (EMD 
Chemicals, Gibbstown, New Jersey) at 4°C. Brains were freeze-embedded in 
OCT (Cedarlane) and cut in twelve micron cryostat sections. The following 
primary antibodies were used: Rabbit anti -mouse Laminin-l (Cedarlane) and rat 
anti-mouse CD45 (Serotec, Homby, Ontario). Cryostat sections were fixed with 
4% PF A followed by 1 % Triton X treatment for 20 min. They were then blocked 
with 20% goat serum in PBS for 1 hr. Endogenous biotin was blocked with a 
biotin block kit (Vector laboratories, Burlingame, Califomia) according to the 
manufacturer's instructions. Sections were incubated with primary antibodies 1 hr 
at room temperature. Biotinylated goat anti-rabbit (Vector Laboratories) and goat 
anti-rat Alexa555 (Molecular Probes, Eugene, Oregon) were added for 45 min, 
followed by streptavidin-Alexa488 (Molecular Probes). Nuclei were stained with 
Hoechst staining reagent (Molecular Probes) for 10 min. As negative controls for 
primary antibodies, rat gamma globulin (Jackson Immunoresearch, West Grove, 
Pensylvania) and rabbit immunoglobulin (DAKO, Mississauga, Ontario) were 
used at equivalent concentrations. AIl antibodies were used at empiricaIly-
determined optimal dilutions. Sections were photographed using a Leica DMIRE2 
fluorescent microscope (Lei ca Microsystems, Richmond Hill, Ontario) 
Prussian blue and H&E staining 
Mice were anaesthetized with Somnotol (MTC Pharmaceuticals) and 
intracardially perfused with 5 ml ice-cold PBS followed by 20 ml 4% PF A 
(Fisher) in PBS. Brains were dissected, fixed for 1 hr in 4% PFA in PBS at 4°C 
and then embedded in paraffin. Five micron sections of paraffin-embedded brains 
66 
were cut on a microtome. The Prussian blue stain was performed to detect ferric 
iron. Briefly, brain sections were incubated at room temperature for 30 minutes in 
a solution of 5% potassium ferrocyanide (American Chemicals, Montreal, 
Quebec) and 5% hydrochloric acid (Anachemia, Montreal, Quebec) followed by 
counterstaining for 5 minutes in Nuclear Fast Red (Sigma). For H&E staining, 
sections were incubated 10 min in Harris hematoxylin (Surgipath, Winnipeg, 
Manitoba), followed by 1 min in eosin (Surgipath). 
USPIO-enhanced MRI 
T2-weighted images were acquired using a Bruker Biospec 7T/21cm spectrometer 
with a 2cm diameter quadrature volume coil (National Research Council, Institute 
for Biodiagnostics, Winnipeg, Manitoba) using a spin-echo multi-slice multi-echo 
sequence with 12 slices spanning the brain (echo time 26.8ms, repetition time 
2540ms, FOV 2.5x2.5 cm2, slice thickness 0.75mm, matrix 256x256, signal 
averages 4). Anesthesia was induced using 5% halothane in 70% nitrous 
oxide/30% oxygen and maintained at 1.5-2% halothane during the imaging 
session. PTx (10 or 20 ).tg/kg) was injected ip. on day 0 followed by a tail vein 
injection of 15 mg/kg of the USPIO ferumoxytol (Advanced Magnetics, 
Cambridge, Massachusetts) that was re-administered every 24 hours. No 
differences were observed between mi ce injected with different doses of PTx. The 
first imaging session took place at least a week before the injection of PTx and 
subsequent imaging was performed daily post PTx. Control experiments were 
performed either on Tg mice injected daily with USPIO but not PTx, or on WT 
mice injected with both PTx and USPIO. 
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3.4. ResuUs 
The CCL2 Tg mlce used in this study overexpress the chemokine CCL2 
specifically in the CNS under control of a truncated MBP promoter (34). CCL2 is 
produced throughout the white matter and leukocytes accumulate spontaneously 
in the perivascular space around CNS vessels in white matter areas without 
parenchymal infiltration (34). No accompanying clinical symptoms are observed. 
3.4.1. PTx induces encephalopathy and weight loss in CCL2 Tg mice 
We used PTx to induce encephalopathy in CCL2 Tg mice. PTx caused Tg mice to 
lose weight compared to Tg mice injected with HBSS only. PTx-injected Tg mi ce 
showed a statistically significant (P<0.05) weight loss starting at day 2 and lasting 
throughout a 5 day period with maximum weight loss at day 4. The weight loss 
range was between 5 and 15%. Significant weight loss was not observed in WT 
control mice injected with PTx or in Tg mice that received HBSS. Clinical 
symptoms induced by PTx in Tg mi ce included tremor,inactivity, limb clasping 
and/or death. These were variably seen in 22% of PTx-treated mice, although this 
did not correlate to underlying histopathology. Clinical symptoms were not 
observed in any of the above mentioned controls (a total of 12 WT and 21 Tg 
controls). 
3.4.2. CD45high cells are recruited to the brain of PTx-treated Tg mice 
Flow cytometry revealed a large number of leukocytes (CD45high) in the CNS of 
CCL2 Tg mi ce (Fig. lA, left panel). The combination of CD45 and CD11b 
staining rnakes it possible to distinguish CNS-resident rnicroglia (CD4Sdim 
CD Il b +) and a population consisting of blood-derived macrophages and 
granulocytes (CD45high CD Il b +) (180). These flow ~ytometry profiles did not 
change dramatically following administration of PTx (Fig. lA, right panel). 
However, the total number of cells was significantly higher in the PTx-injected 
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Figure 1. Flow cytometric analysis. 
A. Cells isolated from CNS of PTx-injected CCL2 Tg mi ce or HBSS-injected 
controls were stained as indicated and sorted. B. Quantification of results from 
flow cytometric analysis. Cell numbers were calculated as proportions multiplied 
by total number of cells, estimated by counting on a hemocytometer. Mice were 
sacrificed at day 5 post PTx injection. n = 4-8; *:P<O.05; NS: not statistically 
significant; C: controls. Error bars represent SEM. 
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mice (3.8S±0.77 x 106 compared to 2.38±0.39 X 106 in the HBSS-injected mice, 
an increase of 62%, P<O.OS). When numbers of individual cell types were 
compared (Fig. lB), it was clear that the increase in total cell number in PTx-
treated mice was mainly due to an increase in CD4Shigh CD Il b + ceIls, which 
doubled in number. The vast majority of the se cells were macrophages, since we 
observed less than 1 % granulocytes, identified by Gr-l staining (not shown). T 
cells were isolated as CD4Shigh CD3+ cells (not shown). There was a 3-fold 
increase in T cells, yet T cells remained a relatively small proportion of the 
infiltrate. Microglial numbers were unchanged. 
3.4.3. Brain parenchymal infiltration in PTx-treated Tg mice 
Infiltration into the brain was followed over the course of a week, using ultra 
small superparamagnetic iron oxide (USPIO)-enhanced magnetic resonance 
imaging (MRI). The dextran-covered USPIO particles are injected into the blood 
and engulfed by actively phagocytosing cells. Cellular infiltration of US PIO-
loaded cells can be followed on T2-weighted MRI, where the iron in the USPIO 
particles results in an area with low signal intensity on the scan (208, 209). 
USPIO was injected on day 0 and every 24 hours thereafter. The mice were 
imaged every day and results for one mouse are shown in Fig. 2A. There was a 
clear development of lesion areas on the MRI scans with low signal intensities 
due to magnetic susceptibility effects representing infiltration of USPIO-Ioaded 
cells (Fig. 2A, arrowheads). These areas became noticeable starting on day 2 or 3 
and persisted to day 7. The development of les ions was dynamic, with sorne 
lesion areas eventually decreasing in size. No lesions were observed in any WT 
control mice injected with PTx and USPIO (Fig. 2B) or in any CCL2 Tg mice 
receiving USPIO, but HBSS instead of PTx (Fig. 2C). 
Infiltrating USPIO-Ioaded cells were visualized in situ by prussian blue 
staining, which stains iron (and therefore USPIO) blue in tissue sections. In Tg 
mi ce receiving PTx and USPIO, blue stained cells were seen around vessels and 
in the surrounding parenchyma (Fig. 2D, arrows), corresponding to areas of low 
signal intensity on MRI scans. The lesion area on the scan appears larger than the 
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Figure 2. USPIO-enhanced MRI. 
E. CCL2 Tg 
+HBSS 
F. WT 
+ PTx 
A. Images from day 0 to 7 of the brain of a CCL2 Tg mouse injected with PTx on 
day O. USPIO contrast agent was injected every day starting on day O. The image 
from day 0 is taken before administration of USPIO and PTx. B. Day 5 scan of 
WT control mouse injected with PTx. C. Day 5 scan of Tg mouse injected with 
HBSS as control. AlI scans are coronal in position bregma -0.5 mm. D. Prussian 
blue (PB) staining of a paraffin-embedded section at the same position as scans 
shown in Panel A. The mouse shown in Panel A was sacrificed at day 7 and the 
brain used for the staining in Panel D. E. PB staining of a Tg mouse injected with 
USPIO but with HBSS instead of PTx, sacrificed at day 5. F. PB staining of a WT 
mouse injected with both PTx and USPIO, sacrificed at day 5. Results shown are 
representative of at least 4 mice in each treatment group. 
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actual infiltrated area because of "blooming" of the MRI signal (210). No prussian 
blue staining was observed in Tg mice receiving USPIO but no PTx (Fig. 2E), or 
in WT mice receiving both PTx and USPIO (Fig. 2F), indicating that parenchymal 
infiltration of cells that actively phagocytosed USPIO requires signaIs from both 
PTx and CCL2. Based on the observation that mice, showed maximal weight loss 
at day 4, and that USPIO-enhanced MRI showed dynamic lesions increasing up to 
day 7, we decided to sacrifice animaIs at day S for further analysis. At this time, 
weight loss and the size of lesions on MRI scans were both prominent. 
3.4.4. Induction ofproinflammatory cytokines and metalloproteinases 
We analyzed expression of two proinflammatory cytokines and 6 MP genes using 
real-time PCR (Fig. 3). The transgenic expression of CCL2 alone induced IL-1 ~ 
and TNFa expression compared to WT mice. Both were further upregulated in the 
PTx-treated Tg mice. The six metalloproteinase genes included ADAM-12, three 
secreted MMPs: MMP-8, -10 and -12, the membrane-bound MMP-1S as well as 
the physiological MP inhibitor TIMP-l. These six genes were chosen on the basis 
of their selective involvement in leukocyte trafficking in EAE, where expression 
of MMP-8, 10, 12, ADAM-12 and TIMP-1 were markedly induced, whereas 
MMP-1S was downregulated (199). Expression of MMP-10, -12 and TIMP-1 
were inherently significantly higher in the Tg mice compared to WT mice. MMP-
8, -10, ADAM-12 and TIMP-1 were significantly upregulated in Tg mice by PTx. 
MMP-12 was not significantly upregulated by PTx in Tg mice (P<0.07). 
Expression of the membrane-bound MMP-lS was unaffected in all cases. 
3.4.5. Distinct cell types express specifie metalloproteinase genes 
We have previously shown that MMP-8 is primarily expressed by infiltrating 
CD4Shigh CDllb+ cells, that MMP-lS is primarily expressed by microglia, and 
that ADAM-12 is exclusively expressed by T cells among the infiltrating cells in 
EAE (199). We analyzed expression ofthese three MPs in cells sorted from 
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Figure 3. Real-time peR analysis of expreSSIOn of cytokine and 
metalloproteinase mRNAs in brain. 
Values on the Y-axis, normalized to expression of 18SrRNA, are arbitrary and 
cannot be compared between panels. AIl mice were sacrificed at day 5 post PTx 
injection. n = 5 for aIl groups. NS: not statisticaIly significant; C: control; *. 
P<O.05. Error bars represent SEM. 
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CCL2 Tg mi ce (Fig. 4). We found upregulated expression of MMP-8 in the 
CD45high CD 11 b + population. MMP-15 was expressed almost exclusively by 
microglia and levels were unaffected by PTx injection. ADAM-12 was 
specifically expressed by T cells among the populations that were sorted, and did 
not show significant change in expression after PTx injection. 
3.4.6. The metalloproteinase inhibitor BB-94 curbs PTx-induced weight loss 
and parenchymal infiltration 
BB-94 is a synthetic broad-spectrum MP inhibitor, which acts by competitive 
reversible binding to the catalytic site of MPs (211). Treatment of PTx-injected 
CCL2 Tg mice with BB-94 curbed weight loss, weights of treated animaIs being 
significantly higher than the weights of untreated mice starting on day 3 and 
lasting to day 5 (Fig. 5). To assess the effect of the MP-inhibitor on the PTx-
induced parenchymal infiltration, we stained for CD45 and laminin-1 in sections 
of brains from PTx-injected Tg mice treated with BB-94 or PBS, as weIl as 
control Tg mice receiving only PBS (Fig. 6A). Laminin-1 stains both the 
endothelial basement membrane (Fig. 6A, left panel, thin arrow) and the astroglial 
basement membrane (Fig. 6A, left panel, thick arrow) of the BBB. CD45 is 
expressed at high levels on infiltrating leukocytes (Fig. 6A, middle panel, 
arrowheads, and Figure lA). Consequently, this staining allows us to identify the 
location of leukocytes in relation to the BBB. We counted infiltrating ce Ils within 
a 1 00 ~m distance of the astroglial basement membrane around distinct infiltrated 
vessels. In control Tg mice, numbers of infiltrating cells were at a basallevel (Fig. 
6A, left panel). Injection of PTx caused striking parenchymal infiltration 
associated with infiltrated blood vessels (Fig. 6A, middle panel). Treatment with 
BB-94 aboli shed this parenchymal infiltration (Fig. 6A, right panel). Counting 
CD45-positive cells within a distance of 1 00 ~m from the astroglial basement 
membrane of infiltrated vessels on each section demonstrated that BB-94-
treatment reduced PTx-induced brain infiltration to a level close to basal level 
(Fig.6B). 
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Figure 4. Real-time PCR analysis of MP mRNA expression in sorted cell 
populations. 
Grey bars represent cells from mice that received HBSS; black bars represent 
cells from PTx-injected mice. Values on the Y-axis, normalized to 18SrRNA, are 
arbitrary and cannot be compared between panels. AlI mi ce were sacrificed at day 
5 post PTx injection. n = 3-5; C: control; NS: not statistically significant; ND: not 
detected; * :P<O.05. Error bars represent SEM. 
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3.5. Discussion 
The process of cellular entry to the inflamed CNS parenchyma involves leukocyte 
migration across endothelial and astroglial barriers, and the perivascular space 
between them, driven by multiple stimuli that include chemokines and action of 
proteases. In the system we have studied, unmanipulated CCL2 Tg mice contain 
large numbers of CD45high leukocytes in the perivascular space surrounding CNS 
vessels. The bacterial toxin PTx induced leukocytes to cross the astroglial 
basement membrane in Tg mice, and this led to weight loss and clinical 
symptoms. Hence, the combination of a bacterial product and chemokine 
overexpression resulted in parenchymal infiltration. This demonstrates that 
exposure of a primed CNS milieu to an environmental stimulus can result in 
disease, in this case encephalopathy. Gene expression oftwo MPs was induced by 
the chemokine CCL2 and one of these and two others were further induced by 
PTx. Because CNS infiltration could be curbed by treatment with an MP inhibitor, 
the PTx-induced expression of effector molecules such as metalloproteinases 
likely promotes brain infiltration. The molecular mechanisms behind this action of 
PTx remain to be established, but the involvement of innate immune receptors 
such as Toll-like receptors is an interesting possibility (165, 212). 
The symptoms we observed following PTx-injection in CCL2 Tg mi ce 
were similar to, but less severe than, the PREMO condition described by Huang et 
al. to occur in astrocyte-directed CCL2 Tg mice challenged with CF A sc. and 
twice with 500 ng PTx iv. (206). In the present study, we used a lower dose of 
PTx (10 Ilg/kg ip. per mouse once) and no CFA. Consequently, we observed 
lower incidence, less severe symptoms and a lower mortality. The symptoms and 
deaths in our experiment occurred in a non-predictable pattern with sorne mi ce 
dying without showing previous symptoms, and sorne mice recovering from 
symptoms. 
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Figure 5. Weight loss following PTx injection. 
Mice were injected with PTx ip. on day O. BB-94 or PBS were then injected ip. at 
lhr, 4 hr and thereafter every 24 hr post PTx injection. Control mice received 
appropriate vehicles for PTx and BB-94. Mice were sacrificed on day 5. n = 6-12; 
*, P<O.05. Error bars represent SEM. 
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We previously demonstrated that expression of a number of MP genes was 
altered in spinal cord of mi ce with adoptive transfer EAE (199). Although EAE 
and the encephalopathy induced by PTx in CCL2 Tg mice are different 
pathologies, they share the process of parenchymal infiltration and may share 
fundamental mechanisms of leukocyte migration across the BBB. In the spinal 
cord of mice with EAE, MMP-8, 10, 12, ADAM-12 and TIMP-1 are aU 
upregulated more than 3-fold, whereas MMP-1S is downregulated more than 3-
fold. Comparison of the findings in EAE and in infiltration driven by the 
synergistic effects of PTx and a chemokine may be instructive for understanding 
mechanism of CNS inflammation. 
MMP-8 is strongly expressed by granulocytes in EAE (199). In CCL2 Tg 
mice, less than 1 % of CNS cells analyzed by flow cytometry are granulocytes 
(CD4Shigh Gr! +). It is more likely CD4Shigh CD Il b + macrophages which 
upregulate MMP-8 mRNA levels foUowing PTx administration. It has elsewhere 
been demonstrated that monocytes/macrophages can express MMP-8 (213). The 
upregulation of MMP-lO and ADAM-12 following PTx administration is 
consistent with EAE studies, reflecting the recruitment of macrophages and T 
cells. The expression level of the macrophage-specific MMP-12 was inherently 
higher in Tg mice compared to WT, but neither PTx nor the leukocyte infiltration 
that it induced, led to significantly increased MMP-12 expression. This may 
reflect differential regulation of infiltrating macrophages compared to EAE, where 
MMP-12 is the most highly upregulated MMP (199, 214). Interestingly, Weaver 
and coUeagues found that MMP-12 null mice developed more severe EAE than 
WT mice, indicating that the role of MMP-12 in CNS infiltration is complex. 
TIMP-1 is an inhibitor of most MPs (92), and is expressed by macrophages (199) 
and astrocytes (183) in EAE. The higher level ofTIMP-1 in Tg mice compared to 
control, and the PTx-induced upregulation, probably reflects CCL2- or PTx-
driven influx of monocytes/macrophages in the Tg mice and/or a response by 
astrocytes, which were unavailable to us by flow cytometric analysis. 
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A. Laminin-l (green) and CD45 (red) staining in brain stem white matter of 
sagittal brain cryosections. No staining was observed with species-matched 
immunoglobulin (not shown). Mice were sacrificed at day 5 post PTx injection. 
The dotted line around vessels is drawn to indicate a distance of 100 !-lm from the 
astroglial basement membrane. B. Quantification of parenchymal infiltration. 
CD45+ cells surrounding isolated infiltrates within a 100 !-lm distance of the outer 
(astroglial) basement membrane of the BBB were counted in a blinded fashion. 
Five to seven infiltrated vessels were randomly selected throughout the white 
matter on at least 4 separate sagittal brain sections from each animal and counted. 
Counted cells were verified as such by Hoechst staining for nuclei. The results 
represent 5 mice from each treatment group. *, P<0.05. Error bars represent SEM. 
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Although it is a possibility that glial cells contributed to the production of 
MPs in response to PTx in Tg mice, we consider this unlikely. The size of PTx 
(117 kDa) should normally prevent it from readily crossing the BBB to enter the 
parenchyma and affect glial cells directly. Furthermore, the finding that sorted 
microglia, in contrast to macrophages, from Tg mi ce did not upregulate MMP-8 
argues against involvement of glial cells in the brain parenchymal infiltration. 
Also, expression of microglial membrane-bound MMP-15, which we previously 
found to be downregulated by microglia in EAE (199), was not altered in the Tg 
mice or by PTx administration. Finally, we observed no change in microglial ceIl 
numbers in PTx-treated Tg mice. 
PTx upregulated expression of the proinflammatory cytokines TNFa and 
IL-1 p in Tg mice. Both IL-1 p and TNF a are associated with weight loss (215) 
and the increased expression level of the se cytokines might contribute to the 
observed PTx-induced weight loss in Tg mice. In addition, proinflammatory 
cytokines could increase leukocyte migration by a direct effect on the BBB (216, 
217). 
Pertussis toxin is classicaIly considered to open the blood-brain barrier 
(162). However, EAE can be induced in sorne mouse strains independently of 
PTx and its role in EAE is likely more complex than increasing vascular 
permeability (165). This is supported by findings in EAE, where opening of the 
BBB in mi ce was found to be independent of PTx, although PTx did enhance 
severity of disease (218). In our study, administration of PTx did not increase 
expression of any of the investigated genes in the brains of WT mice. Nor did it 
induce weight loss or clinical symptoms in WT mice. Only in the case of 
overexpression of CCL2 in brains of Tg mi ce did PTx have an effect, presumably 
either by acting on the aIready accumulated leukocytes, or on leukocytes in blood, 
which were then attracted to the brain by CCL2 chemokine. The synergizing 
effects of a chemokine-rich brain environment and exposure to the environmental 
stimulus PTx result in dramatic upregulation of proinflammatory and 
metaIloproteinase genes, accompanied by clinical symptoms. 
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CCL2 Tg mi ce have large numbers of leukocytes accumulated in the 
perivascular space, and the fact that perivascular accumulation of leukocytes does 
not cause disease is of interest. Similar observations were made when EAE was 
induced in TNFa deficient mice (35), and in mice in which peripheral 
macrophages have been depleted (36). Perivascular accumulation of leukocytes is 
therefore not in itself enough to cause pathology. In this context, it is important to 
take into consideration that the barrier to cellular entry to the CNS actually 
comprises two separate barriers: endothelial and astroglial (29). The endothelial 
barrier allows leukocyte transit in states of perivascular accumulation without 
accompanying clinical symptoms. Migration across the endothelial basement 
membrane alone is not sufficient to initiate clinical symptoms. The critical event 
for disease is the PTx-induced migration across the astroglial basement membrane 
leading to parenchymal infiltration. 
Our results show that leukocyte migration across the astroglial basement 
membrane is dependent on action of MPs, as it could be blocked by treatment 
with an MP inhibitor. Whether endothelial basement membrane transmigration is 
also MP-dependent was not addressed in our study, since it had occurred before 
administration of inhibitor. In vitro studies of human leukocyte migration across 
endothelial basement-like barriers suggest that MPs do play a role in this step 
(189,219,220). Our study emphasizes the need to distinguish between the two 
basement membranes of the BBB in the context of CNS infiltration. The 
particular MP profiles needed to cross the endothelial basement membrane and 
the astroglial basement membrane may not be the same, as the two membranes 
are structurally different and distinct in their composition of extracellular matrix 
proteins, especially laminin isoforms (29, 221). 
Our results demonstrate that exposure to the environmental agent pertussis 
toxin in concert with CNS chemokine expression can promote parenchymal brain 
infiltration through an effect on metalloproteinases. This illustrates potential 
interplay between infection and inflammation in promoting CNS auto immune 
disease. We also demonstrate that it is MP-dependent leukocyte migration across 
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the astroglial basement membrane of the BBB, not across the endothelial 
basement membrane, which is the critical event in inducing disease. 
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PREFACE TO CHAPTER IV 
In Chapter 2 (199) it was established that four out of six MT-MMPs were 
downregulated in EAE. Chapter 4 extends this finding, by studying the expression 
of MT-MMPs in detail, both in EAE and in non-immune models of 
neuroinflammation. These other models include the PTx-driven parenchymal 
infiltration in CCL2 Tg mice described in Chapter 3, and a model of CNS injury, 
where the entorhinal cortex is subjected to a stab wound. Furthermore, Chapter 4 
addresses the hypothesis that IFNy may control downregulation of certain MT-
MMPs, by examining MT-MMP expression in IFNy Tg mice, in IFNy-/- mice 
with EAE, and in cultured microglia. 
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4.1. Abstract 
Matrix metalloproteinases (MMPs) are a large family of proteinases involved in 
de gradation of extracellular matrix and processing of bioactive molecules. We 
showed previously that four of the membrane type (MT)-MMPs (MMP-15, 16, 17 
and 24) were downregulated in spinal cord of mi ce with severe experimental 
autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis 
(MS), whereas the two remaining MT-MMPs (MMP-14 and 25) and the majority 
of secreted MMPs were upregulated. 
In this study, we used flow cytometric cell sorting and real-time RT-PCR 
to demonstrate that aIl but one of the MT-MMPs are constitutively expressed by 
microglia, the resident antigen presenting cell in the CNS. Microglia isolated from 
mice with severe EAE showed statistically significant downregulation of the 
MMP-15, 17 and 25. We then investigated the relationship of MT-MMP 
expression with CNS infiltration and IFNy expression, since these are 
characteristics of both MS and EAE. 
Pertussis toxin-induced parenchymal CNS infiltration in transgenic mice 
overexpressing CCL2 specifically in the CNS caused no significant change in 
expression of IFNy or MT-MMPs. After entorhinal cortex stab lesion, which 
results in prominent influx of leukocytes to the injured area without IFNy 
production, MMP-15, 17 and 25 were significantly downregulated. 
Five of the MT-MMPs were downregulated in transgenic mice that 
specifically overexpress IFNy in the CNS, whereas MMP-25 was upregulated. We 
noted no change in MT-MMP expression in IFNy-/- mice with EAE. IFNy did not 
regulate micro glial expression ofMT-MMPs in vitro. 
We conc1ude that expression of MT-MMPs in vivo IS differentially 
regulated in models of neuroinflammation, and that presence of IFNy in sorne 
cases correlates with MT-MMP expression. 
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4.2. Introduction 
Matrix metalloproteinases (MMPs) are proteinases implicated in all diseases 
involving neuroinflammation, inc1uding multiple sc1erosis (MS) (89, 108). MMPs 
are considered to facilitate cellular infiltration of the central nervous system 
(eNS) by degrading extracellular proteins, inc1uding those present in the 
neurovascular unit composed of endothelial cells connected by tight junctions, 
and the glia limitans. Inhibition of MMP activity with broad-spectrum synthetic 
inhibitors alleviates symptoms of experimental auto immune encephalomyelitis 
(EAE), an animal model of MS (171-173, 222). 
There are 23 matrix metalloproteinases (MMPs) identified in mice 
(inc1uding two forms of MMP-1). Of these, six (MMP-14-17 and 24-25) are 
membrane-bound and referred to as membrane-type matrix metalloproteinases 
(MT-MMPs). MMP-17 and 25 are glycosylphosphatidylinositol (GPI)-anchored 
whereas the other four are type 1 transmembrane proteins with short cytoplasmic 
domains of about 20 amino acids. MMP-23 is anchored to the cell membrane as a 
type 2 transmembrane protein. In contrast to the MT-MMPs, it is not active in its 
bound form, but is secreted and activated in one single proteolytic step (223). Like 
secreted MMPs, MT-MMPs can c1eave extracellular matrix molecules as well as 
chemokines, cytokines and growth factors (90, 124). MT-MMPs are generally 
thought to play important regulatory roles because of their ability to c1eave 
substrates in immediate vicinity to the cell membrane, where the c1eaved products 
can influence the cell. In addition, MT-MMPs are known to c1eave and activate 
secreted MMPs, which was first described for activation of MMP-2 by MMP-14 
through interaction wjth tissue inhibitor of metalloproteinases-2 (TIMP-2) (224, 
225). 
Expression of MMPs can be regulated by cytokines, chemokines, growth 
factors, and ECM proteins such as collagen (226-228). IFNy is a prominent 
cytokine in EAE, and its expression in CNS is reported to increase with severity 
and decrease with remission of symptoms (179, 229, 230). Expression of other 
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proinflammatory cytokines such as TNFa and IL-lp also paraUel EAE symptoms 
(231-233). It has previously been determined that the presence of IFNy alone did 
not cause parenchymal infiltration or activation of glial cells in the IFNy Tg mice 
used in this study (234), where INFy is expressed in oligodendrocytes under 
control of the MBP promoter. 
In addition to inflammatory conditions, MMPs are important in cancer 
where they facilitate cellular traffic across basement membranes and within 
tissues, as weIl as cleave bioactive molecules (66, 123). It has been recognized for 
more than 20 years that MT-MMPs could be important in cancer, since they 
promote angiogenesis and invasion (235,236). MT-MMPs are in fact expressed in 
most cancer types and can in many cases be correlated with malignancy (90). 
Several studies have demonstrated importance of MMPs in animal models of 
cancer, but MMP inhibitors have so far not been successful in clinical cancer 
trials (98). This is likely because the broad-spectrum inhibitors used failed to 
specifically target detrimental effects of MMPs, and also inhibited beneficial 
effects (100). This illustrates the potential benefit of understanding the differences 
between MMPs in greater depth. 
The particular roles and substrate specificities of MT-MMPs have not 
been described in detail, and the role of MT -MMPs in neuroinflammation is 
unclear. We previously showed that the majority of MT-MMPs, with the 
exceptions of MMP-14 and MMP-25, are downregulated in spinal cord of mice 
with adoptively transferred EAE (AT-EAE) at peak disease (199). This 
downregulation is in contrast with the general upregulation of secreted MMPs. 
The same result was obtained in MOG35-55 induced EAE (214). The functional 
consequence ofthis specific pattern ofMT-MMP expression is unknown. 
In this study, we report differential regulation of MT-MMPs III 
neuroinflammation. In particular, we de scribe differences in expression of MT-
MMPs by microglia and infiltrating cells in EAE. Finally, we show that regulation 
ofMT-MMPs in sorne cases correlates with expression ofIFNy. 
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4.3. Materials and Methods 
Mice 
Wild-type (WT) SJL/J (SJL) and C57BL/6J (B6) were obtained from Jackson 
Laboratory, Bar Harbor, Maine or from Charles River Canada (St. Constant, QC, 
Canada). Transgenic mi ce expressing the chemokine CCL2 in the CNS under 
control of a mye lin basic protein (MBP) promoter (34) were obtained from 
Bristol-Myers Squibb (New Brunswick, New Jersey) and maintained as a colony 
at the Montreal Neurological Institute. Generation of IFNy Tg mice of the VT1 
line expressing IFNy in the CNS under control of a truncated MBP promo ter was 
described previously (234). IFNyR-I- mi ce were originally donated by Dr. David 
Willenborg (Canberra Hospital, Australia). For EAE, female 6-12 weeks old mice 
were used. Mice for ECL were females and weighed 20-25g. For other 
experiments, 6-12 weeks old mice of mixed sex were used. Mice were bred and 
maintained in a specific pathogen-free environment. Animal breeding, 
maintenance and aH experimental protocols were performed in accordance with 
Canadian Council for Animal Care guidelines as approved by the McGill 
University Animal Care Committee. 
Actively induced EAE 
B6 mice were immunized sc. at the base of the tail with 1 00 ~l of an emulsion 
containing 1 00 ~g MOG35-55 (Sheldon Biotechnology, Montreal, Canada) and 1 
mg of Mycobacterium tuberculosis H37 RA (Difco, Detroit, Michigan, USA) in 
Freund' s incomplete adjuvant (Difco) and boosted in the flanks 7 days later with 
the same amount. 15 ~g/kg PTx was administered ip. on day 0 and 2. SJL mi ce 
were immunized sc. at the base of the tail with 100 fAl of an emulsion containing 
100 ~g PLp139-151 (Sheldon Biotechnology) and 200 ~g of Mycobacterium 
tuberculosis H37 RA (Difco) in Freund's incomplete adjuvant (Difco) and 
boosted in the flanks 7 days later with the same amount. Mice were weighed and 
monitored daily for clinical signs of EAE, scored as: 1, flaccid tail; 2, hind limb 
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weakness and poor righting ability; 3, one hind limb paralyzed; 4, both hind limbs 
paralyzed with or without forelimb paralysis and incontinence; 5, moribund. 
Adoptive transfer EAE (AT-EAE) 
AT-EAE in SJL mice was induced by passive transfer ofMBP-reactive T cells as 
described previously (199). AT-EAE in B6 mice was induced by passive transfer 
of MOG35-55 -reactive T cells. B6 mice were immunized as for active EAE and 
lymph no de cells were cultured in the presence of 10 Ilg/ml MOG35-55 (Sheldon 
Biotechnology, Montreal, Canada) and 5 U/ml IL-2 (Biosource, Nivelles, 
Belgium). Otherwise, culture conditions were as described for SJL AT-EAE. 
10x106 lymphoblasts were transferred into the tail vein. Recipient mice received 
15 Ilg/kg PTx ip on day 0 and 2 after transfer, and were followed and scored as 
described for active EAE. 
Administration ofpertussis toxin to CCL2 Tg mi ce 
Pertussis toxin (10 Ilg/kg) (Sigma, Oakville, Ontario) in Hank's balanced salt 
solution (HBSS) (Invitrogen Life Technologies, Carlsbad, Califomia) was 
injected ip. at day o. Mice were monitored daily until sacrifice at day 5. 
Flow cytometry and cell isolation 
Cells from CNS of mi ce were analyzed using flow cytometry as described (199), 
except EC samples, which were not subjected to a Percoll gradient in order to 
make analysis from individual samples possible. For flow cytometric analysis of 
cultured microglia, cells were washed in HBSS and incubated in supematant from 
the anti-FcyR 24G2 (anti CD16/32) hybridoma with hamster IgG (50 !-tg/ml) 
(Cedarlane, Homby, Ontario) and 2% added FBS on ice for 20 min. to block non-
specific antibody binding. Cells were stained on ice for 30 min. with 
phycoerythrin (PE)-conjugated anti-CD45 and fluorescein isothiocyanate (FITC)-
conjugated anti-CD Il b (BD Biosciences Pharmingen). The cells were washed in 
HBSS with 2% FCS and analyzed using a Becton-Dickinson F ACScan or a 
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F ACScalibur (Becton Dickinson Immunocytometry Systems, San Jose, 
California). Flow cytometry data were analyzed using CellQuest software. 
Isolation of RNA 
Total RNA was purified using Trizol RNA isolation reagent (Invitrogen Life 
Technologies) according to the manufacturer's protocol for whole tissue RNA 
extraction. For sorted cells, Trizol with added glycogen (Invitrogen Life 
Technologies) was used according to the manufacturer's protocol for RNA 
extraction for low amounts of RNA. 
Reverse transcriptase reaction 
RNA (3 /-lg) from each tissue sample was incubated with M-MLV reverse 
transcriptase (RT) (Invitrogen Life Technologies) according to the manufacturer's 
protocol using random hexamer primers. RNA from sorted cells was incubated 
with SuperScript II RT (Invitrogen Life Technologies) according to the 
manufacturer's protocol using random hexamer primers. 
Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was done using ABI Prism 7000 or 7300 
Sequence Detection Systems according to our previously described method and 
MMP probe and primer sequences (199). IL-I ~ probe: AGC TGG AGA GTG 
TGGAT. IL-I~ forward primer: CTT GGG CCT CAA AGG AAA GAA. IL-I~ 
reverse primer: AAG ACA AAC CGT TTT TCC ATC TTC. TNFa probe: CTC 
ACA CTC AGA TCAT. TNFa forward primer: CCA AAT GGC CTC CCT 
CTCAT. TNFa reverse primer: TCC TCC ACT TGG TGG TTTGC. IFNy probe: 
TCA CCA TCC TTT TGC CAG TTC CTC CAG. IFNy forward primer: CAT 
TGA AAG CCT AGA AAG TCT GAA T AAC. 
Brain stab lesion 
Un der anesthesia, B6 mice were placed into a stereotactic apparatus (Kopf, 
Tujunga, CA) for wireknife transection of axons in the entorhinal cortex (EC), as 
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previously described (150). This induces a mechanical stab injury of the EC. 
Twenty-four hours following surgery, mice were perfused with PBS, the EC was 
dissected, and approximately 2 mm of tissue surrounding the wireknife lesion was 
coUected. For uninjured controls, the EC was dissected from either the contra 
lateral hemisphere of the brain or else from unmanipulated mice. 
Isolation and culturing of microglia 
Female SJL mice (8-10 weeks old) were perfused with 20 ml ice-cold PBS, then 
brains and spinal cords were dissected and coUected in HBSS. The tissue was 
dissociated through a 70 /-lm cell strainer (BD Biosciences Pharmingen) and 
suspended in 70% isotonic Percoll (Amersham Biosciences, Baie d'Urfe, 
Quebec). Myelin was removed after centrifugation through a Percoll gradient, and 
ceUs were collected at the interface between 30 and 37% Percoll. Cells were 
washed and resuspended in RPMI 1640 (Gibco, Burlington, Ontario, Canada) 
supplemented with 10% FCS (Sigma), 50 /-lM p-mercaptoethanol (Sigma), 2 mM 
L-glutamine (Gibco), 100 U/ml penicillin and 100 /-lg/ml streptomycin (Gibco). 
FinaIly, ceUs were diluted to 1 x 1 06 ceUs/ml and plated in a 96 weIl plate at a 
density of 2x 105 ceIls per weIl. An aliquot of ceUs were stained with anti-CD45 
and anti-CD Il b antibodies for verification as CD45dim CD Il b+ microglia. Purity 
was 95%. Approximately 2.5x 1 05 microglia were obtained per mouse. Microglia 
were left overnight to settle and thereafter treated with mouse IFNy (Sigma) or 
LPS (Sigma) for 16 hours. The supernatant was removed and microglia were 
lysed in Trizol for RNA isolation. 
4.4. ResuUs 
4.4.1. MT-MMP expression during EAE 
Given the previous finding by ourselves (199) and others (214), that four of the 
six MT-MMPs (MMP-15, 16, 17 and 24) are downregulated in spinal cord of 
mi ce with EAE at peak disease, we decided to study the expression of aIl six MT-
MMPs during various stages of relapsing-remitting AT-EAE: early (grade 2), 
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peak (grade 4), and mice that had remitted from symptoms. The expreSSIOn 
profiles for the downregulated MMPs followed disease progression with restored 
expression after remission of symptoms (Fig. 1, panels B-E). Similar results for 
MMP-15 have been published by us previously (199), and are confirmed here. 
MMP-14 (Fig. lA) showed early downregulation in grade 2, but upregulation at 
peak disease with sustained upregulation after remission. By contrast MMP-25 
(Fig. 1 F) was upregulated both in early and peak disease, and also with sustained 
expression after remission. Expression of IFNy followed disease course (Fig. 10). 
In addition, we analyzed expression of MT -MMPs in both actively induced and 
adoptively transferred M0035-55 EAE in B6 mice at peak disease (Fig. 2). Sorne 
differences in fold regulation were observed compared to AT-EAE in SJL mice, 
but we confirmed detection of IFNy, statistically significant upregulation of 
MMP-14 and 25, and downregulation ofMMP-15, 16, 17 and 24 in both models. 
This shows that the pattern of MT-MMP regulation in EAE at peak disease is 
independent of mouse strain, mye lin antigen and method of disease induction. 
4.4.2. Cellular sources of MT-MMP expression in EAE 
We investigated cellular sources of MT-MMP expression at peak disease, 
focusing on infiltrating immune cells and microglia (Fig. 3). Microglia were 
defined as CD45dim CDllb+, macrophages and granulocytes as CD45high 
CDll b+, and T cells as CD45high CD3+. Microglia are present in both control 
mi ce and mice with EAE, whereas infiltrating cells are only available in sufficient 
numbers from mice with EAE. We observed a significant downregulation by 
microglia in EAE of MMP-15, 17 and 25 (Fig. 3B, D and E), as well as a 
contribution from infiltrating cells. This confirms results for MMP-15 published 
previously (199). Expression of MMP-14 and 16 by microglia (Fig. 3A and C) 
were not significantly altered in EAE. There was a contribution to whole brain 
levels of message for both by infiltrating cells, especially MMP-14 expression by 
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Figure 1. MT-MMP and IFNy gene expression during AT-EAE in SJL mice. 
Gene expression levels of MT-MMPs and IFNy in spinal cord from 
unmanipulated SJL mice, mice with early onset (grade 2), severe EAE (grade 4), 
and mice after remission, were measured by real-time peR. Values on the Y-axis 
are relative to expression of 18S rRNA, and normalized to the expression level of 
the unmanipulated group (except for IFNy). The values are arbitrary and cannot be 
compared between panels. N = 3-6. Significance of comparisons to 
unmanipulated mice was determined using a two-tailed t-test. A two-tailed t-test 
was also used to compare mi ce with severe EAE to the remitted group. *:P < 0.05; 
NS: not significant; ND: not detected; Unm.: unmanipulated; Gr.: grade. Error 
bars represent SEM. 
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macrophages and granulocytes. Expression levels of MMP-24 by sorted cells 
were too low for analysis. 
4.4.3. Correlations between MT-MMP and IFNyexpression in EAE 
As previously published (179, 229, 230), expression of the proinflammatory 
cytokine IFNy, which is expressed by activated T cells in EAE, paralleled disease 
severity (Fig. IG). We tested if there was a correlation between expression of 
MT-MMPs and IFNy by plotting expression levels of MT-MMPs in individual 
samples against expression level of IFNy in the same samples (Fig. 4). There was 
a significant positive correlation between expression of MMP-14 and IFNy 
expression (Fig. 4A). In contrast, there was a significant negative correlation for 
MMP-15, 16 and 17, which were downregulated at peak disease (Fig. 4B-D). 
There was no correlation between MMP-24 or MMP-25 and IFNy (Fig. 4E-F). 
4.4.4. MT-MMPs expression is unchanged by PTx-induced parenchymal 
infiltration in CCL2 Tg mice 
Leukocytes spontaneously accumulate in the perivascular space in the CNS of 
transgenic mice which express the chemokine CCL2 in the CNS under control of 
a truncated MBP promoter (34). Systemic administration of PTx caused 
parenchymal infiltration in CCL2 Tg mice, accompanied by weight loss and 
occasional clinical symptoms (Chapter 3). A similar finding has been described 
using another CNS-specific CCL2 Tg mou se (206). Contrary to WT, 
unmanipulated CCL2 Tg mice showed a basal level of IFNy expression in brain 
(Fig. 5A), but this was unchanged by systemic administration of PTx. 
Unmanipulated CCL2 Tg mice also showed a significantly higher expression of 
MMP-14 and 17 compared to WT (Fig. 5B and D), whereas none of the other 
MT-MMPs were significantly altered. Administration ofPTx to WT mice led to a 
small but statistically significant upregulation of MMP-24 expression, but there 
was no change in the remaining MT-MMPs. Importantly, none of the MT-MMPs 
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Figure 2. MT -MMP gene expression in active and AT -EAE in B6 mice. 
Gene expression levels ofMT-MMPs in spinal cord from unmanipulated B6 mi ce 
and mi ce with severe (grade 4) EAE were measured by real-time PCR. EAE was 
induced either by immunization with MOG35-55 in CFA (active) or adoptive 
transfer of MOG35-55 specific T cells (AT -EAE). Values on the y -axis are relative 
to expression of 18S rRNA, and normalized to the expression level of the 
unmanipulated group (except for IFNy). The values are arbitrary and cannot be 
compared between panels. N = 4 or 5. Significance of comparisons to 
unmanipulated mi ce was determined using a two-tailed t-test. *:P < 0.05; ND: not 
detected; Unm.: unmanipulated; Gr.: grade; Act.: active. Error bars represent 
SEM. 
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were significantly affected by PTx in CCL2 Tg mice, even though this leads to 
parenchymal infiltration (Chapter 3). Equivalent results for MMP-15 are not 
shown here, but are reported in Chapter 3; there were no changes in MMP-15 
expression in any of the groups. In contrast to the MT -MMPs, a number of 
secreted MMPs were upregulated upon PTx injection in CCL2 Tg mice (Chapter 
3). 
4.4.5. MT-MMPs a/ter brain stab lesion 
24 hours after stab lesion in the EC, we observed considerable infiltration of 
CD45high cells (Fig. 6). The majority of the infiltrating cells (3.58±0.29 % of total 
cells compared to 0.05±0.01 % in control EC, n=4) were macrophages or 
granulocytes, defined as CD45 high CD Il b+ (Fig. 6A, upper right quadrants), and a 
smaller proportion (0.22 ± 0.01 %, compared to 0.02 ± 0.01 % in control EC, n=4) 
were T cells defined as CD45high TCRp+ (Fig. 6B, inserted boxes). The 
proinflammatory cytokines TNF a and IL-1 p were upregulated following stab 
lesion, as weIl as in EAE (Fig. 7 A-B). Apart from a low level in one out of five 
samples, IFNy was not detected following lesion, which is in contrast to EAE 
(Fig. 7C). No change in expression of MMP-14, 16 and 24 was noted following 
stab lesion, whereas MMP-15, 17 and 25 were significantly downregulated (Fig. 
7D-I). 
4.4.6. IFNydoes not regulate microglial MT-MMP expression in vitro 
We isolated microglia from CNS of adult SJL mi ce and IFNyR-/- mice on SJL 
background. Cell preparations were determined by F ACS to contain 95% 
microglia (Fig. 8A). The microglia were then treated with varying concentrations 
of IFNy, or with LPS. As expected, the microglia responded to LPS by 
upregulating expression of IL-1p (data not shown) and TNFa, and to IFNy by 
upregulating TNFa, as measured by real-time PCR (Fig. 8B). However, no 
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Figure 3. MT-MMP mRNA expression in cell populations sorted from CNS. 
Cell populations were sorted from whole CNS preparations based on flow 
cytometric detection of surface markers: Microglia as CD45dim CDllb+, 
macrophages and granulocytes as CD45high CDll b+, and T cells as CD45high 
CD3+. Values on the Y-axis are relative to expression of 18S rRNA, and 
normalized to the expression level of the unmanipulated microglia. The values are 
arbitrary and cannot be compared between panels. N = 4-8. Significance of 
comparison between microglial groups was determined using a two-tailed t-test. 
*:P < 0.05; NS: not significant; Mic.: microglia; T: T cells. Error bars represent 
SEM. 
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statistically significant change in expression of MMP-15 (Fig. 8C) or any other 
MT-MMP (data not shown) in response to IFNy or LPS treatment was observed. 
4.4.7. MT-MMPs in IFNy-/- and IFNy Tg mice 
All MT-MMPs except MMP-25 were significantly downregulated in spinal cord 
of IFNy Tg mi ce expressing IFNy specifically in the CNS (Fig. 9). No statistically 
significant difference in expression of any of the MT-MMPs was observed when 
EAE was actively induced in IFNy-/- mi ce (Fig. 9). 
4.5. Discussion 
Our aim was to study the relationship of MT -MMP expreSSIOn with CNS 
infiltration and IFNy expression. The expression patterns of the MT-MMPs from 
the described in vivo models are summarized in Table I. It is c1ear, that individual 
MT-MMPs are differentially regulated in neuroinflammation. IFNy expression 
correlates with expression of sorne MT-MMPs, but not aIl. Other factors must 
also play a role. 
Expression of MT-MMPs can be regulated by growth factors and 
cytokines (226, 227). Interaction with extracellular matrix might also be 
important, and it was shown that TNFa only stimulated fibroblasts to upregulate 
MMP-14 when the fibroblasts were grown in collagen (237). Transcription factors 
also play a role, as TNFa-mediated upregulation of MMP-14 expression was 
dependent on NFKB activation; and binding of another transcription factor, Egr-l, 
to the MT-MMP promoter sequence can enhance MMP-14 transcription (238). 
However, the promoter sequence of MMP-14 lacks the TATA box and binding 
sites for AP-l and ETS transcription factors found in promoter regions of most 
secreted MMPs. (239-242), so it is possible that differences exist between 
regulation of secreted and MT-MMPs. To our knowledge, detailed information 
for promoter sequences for MT-MMPs other than MMP-14 is lacking. 
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Figure 4. Correlations between expression ofMT-MMPs and IFNy in EAE. 
Spinal cord gene expression levels of MT-MMPs are plotted against expression 
levels ofIFNy from the samples used to generate Fig. 1 (unmanipulated, early and 
severe EAE, and after remission). A t test was used to determine if the slope of 
the linear regression line was different from zero with 95 % probability. P<O.05 
indicates significant correlation. r: correlation coefficient. NS: not significant. 
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MMP-14 is the best studied among the MT-MMPs. MMP-14-1- mi ce have 
defects in angiogenesis, and severe skeletal disorders resulting in dwarfism and 
death within 3 months (243, 244). MMP-14 activates MMP-2 via TIMP-2 (224, 
225), and activation of MMP-2 is deficient in MMP-14-/- mice. However, lack of 
activated MMP-2 cannot fully account for the severe phenotype in MMP-14-/-
mice, since MMP-2-/- mi ce develop normally except for a delay in growth (245). 
However, angiogenesis was suppressed in MMP-2-1- mice. Overexpression of 
MMP-14 in mammary glands leads to tumor development (246), indicating a 
deleterious effect of excessive MMP-14 expression. We observed upregulated 
MMP-14 expression in EAE at peak disease (Fig. 1 and 2), which, at least in part, 
could be explained by its expression in infiltrating cells, especially macrophages 
and granulocytes (Fig. 3). We observed basal expression ofMMP-14 by microglia 
which was not altered in EAE. MMP-14 has before been demonstrated to be 
expressed by white matter microglia in both normal and Alzheimer' s disease brain 
tissues (247). We have not in this study examined MMP-14 expression by other 
CNS resident cells, but such cells might contribute to the overall level of MMP-
14. MMP-14 has for example been shown to be expressed in reactive astrocytes 
(248). We found that MMP-14 was upregulated in unmanipulated CCL2 Tg mice 
(Fig. 5), which probably reflects expression in accumulated leukocytes. MMP-14 
correlates positively with IFNy expression in EAE spinal cord samples (Fig. 4). 
However, MMP-14 was downregulated in two cases where IFNy was present: In 
early EAE (Fig. 1) and in IFNy Tg mice (Fig. 9); and it was not altered in 
microglia from mice with severe EAE (Fig. 3). A possible explanation could be, 
that IFNy downregulates MMP-14 expression by CNS resident cells other than 
microglia, but the expression level increases on the whole tissue level in 
neuroinflammation due to the influx of cells expressing MMP-14. 
MMP-15 is known to be associated with tumor progression, possibly 
through anti-apoptotic activity (249), and has also been reported to activate MMP-
2 without the involvement of TIMP-2 (250). In general, MMP-15 is considered to 
be very similar to MMP-14 in structure and action, but it has not been studied to 
the same degree. We find that MMP-15 is regulated differently than MMP-14 in a 
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Figure 5. Gene expression ofIFNy and MT-MMPs in brain, 
WT or CCL2 Tg mice received PTx by iv. injection and were sacrificed 5 days 
later. Gene expression in brain samples was analyzed using real-time PCR. Values 
on the Y-axis are relative to expression of 18S rRNA, and normalized to the 
expression level of the control WT group (except for IFNy). The values are 
arbitrary and cannot be compared between panels, N = 5 for each group, 
Significance of comparisons between control and PTX-injected mice was 
determined using a two-tailed t-test. *:P < 0,05; ND: not detected; C: control; NS: 
not significant. Error bars represent SEM. 
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number of cases. We and others (214) have noted that MMP-15 is downregulated 
in EAE. This probably reflects downregulation by microglia and a relatively low 
level of MMP-15 expression by infiltrating cells (Fig. 3), as stated previously 
(199). In contrast to MMP-14, MMP-15 is negatively correlated with IFNy 
expression in EAE (Fig. 4). It is also downregulated in IFNy Tg mi ce (Fig. 9) and 
after stab lesion in the EC (Fig. 7). In accordance with a putative negative 
regulatory effect by IFNy on MMP-15, there was no downregulation ofMMP-15 
in IFNy-/- mice with EAE (Fig. 9). However, IFNy is not the only factor involved 
in MMP-15 regulation, as we also noted downregulation after stab lesion, where 
IFNy is not present. We were not able to demonstrate changes in expression of 
MMP-15 or other MT-MMPs in vitro (Fig. 8), perhaps due to the inherent 
activation involved with culturing cells, and/or lack of three dimensional matrix 
structure in culture (237, 251, 252). 
MMP-16 has been shown to be expressed by microglia in human brain 
tissue (253). We also find MMP-16 expressed by mouse microglia (Fig. 3). MMP-
16 was not downregulated by microglia in EAE. This and the fact that MMP-16 
was not downregulated after stab lesion are the only two major differences from 
the regulation of MMP-15 expression. Both CNS injury and EAE induce 
microglial activation (38, 254, 255). Taken together with the observation that 
MMP-16 is downregulated in many cases with IFNy present, it could mean that 
MMP-16 is downregulated by IFNy, but not by activated microglia. 
Expression of MMP-17 follows the pattern for MMP-15 with one 
exception, which is the significantly increased expression in brains of CCL2 Tg 
mice. MMP-17 is one of the two GPI-anchored MT-MMPs, the other being 
MMP-25. MMP-17 is expressed by monocytes (136), analogously to MMP-25 
which was found to be expressed by leukocytes (hence the original name for 
MMP-25: leukolycin), in particular by neutrophils (256, 257). Despite the 
analogies between MMP-17 and 25, we find them quite differently regulated. The 
pattern of MMP-17 expression and regulation is more like the pattern of MMP-15 
and 16, rather than MMP-25. 
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MMP-25 was upregulated in EAE at peak disease, like MMP-14 (Fig. 1 
and 2). In other aspects, however, MMP-25 was regulated differently from MMP-
14. Expression ofMMP-25 was not correlated with IFNy expression (Fig. 4), and 
not significantly altered in IFNy Tg mice (Fig. 9). MMP-25 was downregulated by 
microglia in EAE (Fig. 3), and in EC after stab injury (Fig. 7). It is possible that 
MMP-25 is downregulated by activated microglia in an IFNy-independent 
manner. MMP-25 has been proposed to be especially suited to facilitate leukocyte 
crossing of basement membranes (258), and we also noted expression by 
infiltrating leukocytes (Fig. 3). In IFNy-l- mice with EAE there was a trend 
toward upregulation ofMMP-25, although not statistically significant (Fig. 9). 
We observed MMP-24 expression in whole spinal cord and brai n, but not 
by microglia or infiltrating cells. This corresponds with previous findings that 
MMP-24 is CNS specific and expressed by neurons (259, 260). MMP-24 
expression might be regulated by IFNy, since it is downregulated in IFNy Tg mice 
(Fig. 9) and in WT EAE (Fig. 1 and 2), whereas it is not affected in IFNy-l- mice 
with EAE (Fig. 9). However, the negative correlation with IFNy expression in 
EAE was not sufficiently strong to be statistically significant (Fig. 4). The small 
upregulation by PTx in CCL2 Tg mi ce (Fig. 5) cannot be explained at this point. 
Sorne caution must be exerted in interpreting a result that shows a sm aIl 
downregulation of a molecule on the whole tissue level in an organ that is 
undergoing infiltration. We have previously determined the proportion of 
CD45high infiltrating cells at peak AT-EAE in SJL mice to be 34% in the CNS 
preparation for flow cytometry (199). If these infiltrating cells do not express a 
particular gene, which is expressed by endogenous cells in the unmanipulated 
CNS, then the influx of cells alone will lead to an overall downregulation at the 
whole tissue level, even if the expression level in individual resident cells did not 
change. We analyzed microglia from both unmanipulated mice and mi ce with 
EAE for direct comparison of this cell type in a disease state with the normal state 
(Fig. 3). 
MMP-15, 17 and 25 were downregulated in EAE microglia, and this 
corresponds with the change in whole spinal cord for MMP-15 and 17 (Fig. 1 and 
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Figure 7. Gene expression of cytokines and MT -MMPs after brain stab lesion. 
Real-time PCR analysis of cytokine and MT-MMP expression. Panels A-C show 
cytokine expression in EC (left hand side of graphs), and in spinal cord (right 
hand side). Panels D-I show MT-MMP expression in EC. Spinal cord samples 
were from B6 mi ce with grade 4 AT-EAE induced by MOG35-55 specific T cells, 
or from unmanipulated controls. EC samples were from B6 mice 24 after stab 
lesion, or from control EC. IFNy was only detected in one of the stab samples 
(Panel C). Values on the Y-axis are relative to expression of 18S rRNA, and 
normalized ta the expression level of the control WT group (except for IFNy). The 
values are arbitrary and cannot be compared between panels. Significance of 
comparisons between groups was determined using a two-tailed t-test. N = 4-6. 
*:P < 0.05; ND: not detected; Unm.: unmanipulated; C: control; NS: not 
significant. Error bars represent SEM. 
105 
2). For MMP-25, the change on the whole spinal cord level was in the opposite 
direction, which illustrates the point that changes in individual cell types can be 
masked by changes in cellular composition of the tissue. The same pattern of MT-
MMP regulation was apparent in stab injured EC as in EAE microglia. Possibly, 
this illustrates the same fundamental regulation of MT-MMP expression on 
microglia in both EAE and after stab lesion, but with a difference in the 
composition of the infiltrating cells. MMP-25 is expressed by neutrophils, and we 
determined the proportion of granulocytes in AT-EAE in SJL mice to be 9%, 
slightly higher than macrophages (7%) (199). We have not investigated the 
proportion of infiltrating granulocytes relative to macrophages after stab lesion. 
The functional consequence of upregulation of MMP-14, MMP-25 or any 
secreted MMP, in neuroinflammation is straight-forward to explain: expression of 
proteinases by infiltrating cells enables them to infiltrate the CNS by cleaving 
extracellular matrix proteins. This is most likely not the complete explanation, 
since MMPs have many other substrates than matrix proteins, and MMPs are 
likely also involved in regulation of the inflammatory process by cleaving 
bioactive molecules (124). The downregulation of certain MMPs in 
neuroinflammation does not correspond well with the simple notion of MMPs as 
only matrix degrading proteins. However, at this time, when the specific 
substrates of individual MT -MMPs are yet ill-defined, it is not possible to clearly 
explain the consequence of the down-regulation. One can speculate that microglia 
downregulate certain MT-MMPs in the process of activation, such as is the case 
for the innate immune receptor TREM-2 (261, 262). Further studies need to be 
carried out in order to determine whether it would be beneficial for patients with 
diseases involving neuroinflammation to inhibit or enhance the action of MT-
MMPs. 
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Figure 8. Gene expression by microglia stimulated in vitro. 
A: Microglia were isolated from whole CNS and determined by flow cytometry to 
be 95% pure. B, C: TNFa and MMP-15 expression by cultured microglia 
stimulated with IFNy at varying concentrations, or LPS at 100 ng/ml. Microglia 
from several WT or IFNyR-/- mice were pooled separately and dispersed in 
culture wells. Each bar graph represents average expression in three identically 
treated wells. Panels Band C show values on the Y -axis are relative to expression 
of 18S rRNA, and normalized to the expression level of the control WT group. 
The values are arbitrary and cannot be compared between panels. Significance of 
comparisons to the media-treated controls was determined using a two-tailed t-
test. *:P < 0.05; NS: not significant. Error bars represent SEM. 
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Figure 9. Gene expression ofMT-MMPs in IFNy Tg mice, and IFNy-/- mice with 
EAE. 
Gene expression was analyzed in spinal cord samples using real-time PCR. 
IFNy-/- mice were immunized with PLpI39.151 to induce EAE. Values on the Y-
axis are relative to expression of 18S rRNA, and normalized to the expression 
level of the control WT group (except for IFNy). The values are arbitrary and 
cannot be compared between panels. Significance of comparisons to controls was 
determined using a two-tailed t-test. N = 6 for WT and IFNy Tg groups, and 3 for 
IFNy-/- groups. *:P < 0.05; ND: not detected; C: control; NS: not significant; gr.: 
grade. Error bars represent SEM. 
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Table I. Changes in gene expression ofIFNy and MT-MMPs in in vivo models of 
neuroinflammationa 
MMP- MMP- MMP- MMP- MMP- MMP- Parenchymal 
IFNy 14 15 16 17 24 25 infiltration 
SJL AT-EAE Yes Up Down down down down Up Yes 
B6 active EAE Yes Up Down down down down Up Yes 
B6 AT-EAE Yes Up Down down down down Up Yes 
IFNy Tg Yes Down Down down down down No 
CCL2 Tg Yes Up up No 
CCL2 Tg 
+PTx Yes Yes 
IFNy -/-
active EAE No Yes 
Brain stab lesion No Down down Down Yes 
a Only statistically significant (P<0.05) changes in gene expression compared to 
the appropriate control group are reported as up or down-regulation. EAE results 
listed are for peak disease. IFNy is either present or not. 
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CHAPTERV 
Discussion 
5.1. Regulation of MPs in Neuroinflammation 
5.1.1. Gene transcription 
This study provides details about gene transcription of individual MPs in 
neuroinflammation. Protein expression was confirmed for MMP-15 and ADAM-
12 in Chapter 2. Gene transcription studies are instructive with regards to the 
response to inflammatory stimuli. However, it is important to consider that MP 
gene transcription need not always correlate exactly with enzyme activity. The 
fact that MPs are synthesized as zymogens adds a level of regulation by 
proteolytic or chemical activation. Furthermore, MPs need not necessarily be 
synthesized de nova in an inflammatory setting. In studies of cancer and spinal 
cord injury, it was demonstrated that inflammatory cells, especially neutrophils, 
can carry preformed MMPs to a site of inflammation and release them there from 
granules rather than producing them in situ (263, 264). The analysis of MMP 
message in a tissue undergoing inflammation might therefore underestimate the 
actual proteinase activity. In this light it is interesting to note, that we did not see a 
statistically significant upregulation of MMP-9 message in EAE (Chapter 2), 
which seems at odds with reports of increased levels of MMP-9 protein in CSF 
and serum in MS patients (110, 265). However, as described in Chapter 2, a large 
proportion of infiltrating cells were granulocytes. The granulocytes, including 
neutrophils, could increase the MMP-9 proteolysis level by degranulation. Indeed, 
increased MMP-9 enzyme activity in spinal cord of rats with EAE has been 
demonstrated with gel zymography (186). 
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5.1.2. Regulatory cytokines 
Cytokines are known to be potent inducers of MPs (242, 266). In 
neuroinflammation, a plethora of cytokines are expressed by a variety of both 
endogenous and infiltrating cells (267, 268), which likely leads to the regulation 
of several MP genes, as seen in Chapter 2. It seems probable that mechanisms are 
in place to counteract this great increase of proteolytic activity. Among those 
counteracting mechanisms is the upregulation of TIMP-l, which became the most 
highly expressed among the genes analyzed. Both infiltrating macrophages 
(Chapter 2) and resident astrocytes (183) contribute to the upregulated TIMP-l 
expression in EAE. IL-l P was strongly upregulated in EAE (Chapter 4), and this 
cytokine has the capacity to induce expression of MMPs, ADAMs and TIMPs 
(91, 269-271). As is the case for MPs, TIMP expression can be regulated by a 
number ofproinflammatory cytokines, including IL-lp, TNFa IFNy and 11-6 (91, 
272). Interestingly, Bugno and colleagues found that TNFa and IFNy upregulated 
TIMP-l, but downregulated TIMP-3 in cultured murine brain endothelial cells 
and astrocytes. In accordance with this, TIMP-l was upregulated and TIMP-3 
downregulated in spinal cord of mi ce with EAE (Chapter 2). Generally, it seems 
plausible that cytokines regulate both proteinases and their inhibitors 
concomitantly in neuroinflammation. 
5.1.3. Astrocytes 
In the present study, the potential for MP production by astrocytes was not 
studied. The role of astrocytes in neuroinflammation needs to be investigated 
further, specifically their potential role in regulating cell entry to the CNS 
parenchyma across the glia limitans, of which astrocyte endfeet make up a 
substantial part. Astrocytes have been shown to produce MPs both in vitro and in 
vivo (248, 270, 273, 274), but there is stilliittie known about the contribution of 
MPs by astrocytes in vivo. Activation of astrocytes occurs in EAE and MS. It is 
thought that astrocytes contribute to pathogenesis by producing proinflammatory 
cytokines and chemokines, and potentially by activating T cells (275). Astrocytes 
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form networks in CNS with both neurons and glial cells, and are increasingly 
recognized to have a regulatory role, e.g. by regulating blood flow (276). 
5.2. Regulation of MT -MMPs 
5.2.1. MT-MMPs in IFNy-/- mice 
Sorne MT-MMPs were downregulated III spinal cord in EAE, specifically in 
microglia from WT mice (Chapter 2). No statistically significant alteration of 
MT-MMP expression was observed in spinal cord of IFNy-/- mi ce with EAE, 
albeit with low n-values (Chapter 4). IFNy-/- mice develop a more severe and 
often lethal disease course when challenged with EAE (277-279). This is 
associated with striking infiltration of neutrophils (280, 281). An interesting 
hypothesis emerging from these findings could be that the downregulation of 
certain MT-MMPs in WT mice is protective against the lethal EAE phenotype 
seen in the IFNy-/- mice. In contrast to WT mice, IFNy-/- mice with EAE do not 
have F4/80 immunoreactive microglia in spinal cord parenchyma (280). Also in 
contrast with WT mice, IFNy-/- mice with EAE show no MHC II 
immunoreactivity in spinal co rd (280). These observations suggest that microglia 
in IFNy-/- mice with EAE are not activated in the same way as microglia in WT 
mice are. Perhaps this is the reason no downregulation of MT-MMPs is noted in 
INFy-/- mice with EAE (Chapter 4), although it remains to be verified directly 
that microglia from IFNy-/- mice with EAE do not downregulate MT-MMPs. 
Further studies should elucidate whether downregulation of particular MT -MMPs 
is a cause or effect of micro glial activation. 
5.2.2. MT-MMPs in 1FNr Tg mice 
Overexpression of IFNy specifically in the CNS did not lead to parenchymal 
infiltration or activation of glial cells in the IFNy Tg mice used in Chapter 4 (234), 
yet the present study shows significant downregu1ation of five of the six MT-
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MMPs. AIso, MT-MMPs were downregulated in EAE (Chapter 2). Both these in 
vivo modeis share the fact that IFNy was present in the spinal cord, where it is 
normally absent, and can lead to the straight forward conclusion that IFNy causes 
downregulation of certain MT-MMPs. However, MT-MMPs were aiso 
downregulated after ECL, where IFNy was not present, so other factors must be 
involved. CNS injury in generai Ieads to activation of microglia (38, 282-284), 
and this is also the case in the EC after Iesion (285). 
5.2.3. MT-MMPs in CCL2 Tg mice 
In the CCL2 Tg mice, no significant change in MT-MMP expression was detected 
after injection of PTx (Chapter 3). IFNy is present in the CNS of unmanipulated 
CCL2 Tg mice, but they do not show downregulation of any MT-MMPs 
compared to WT. At this point, it has not been established if the IFNy in 
unmanipulated CCL2 Tg mi ce is localized in the perivascular space or aiso in the 
parenchyma. AIso, it is not established whether microglia are activated in this 
model. It seems most likely that IFNy is expressed by the accumulated leukocytes, 
of which about 7% are T cells (Chapter 3). If this is the case, perivascular 
microglia might be activated due to influence by IFNy and maybe other cytokines 
produced by the accumulated leukocytes. Parenchymal microglia, on the other 
hand, are less likely to be affected by cytokines in the perivascular space, and 
therefore not likely to be activated. 
5.2.4. MT-MMPs in cultured microglia 
In vitro stimulation of microglia with IFNy did not lead to downregulation of any 
MT-MMPs. It is not clear yet if this lack of effect in vitro is due to an artifact of 
isolating and culturing microglia, or actuallY represents the situation in vivo. IFNy 
has been reported to inhibit MMP expression in vitro (270). In that study, the 
cytokines IL-l~ and TNFa, and the bacterial product LPS were shown to induce 
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expression of MMP-2, 3 and 9 by astrocytes and microglia in culture, but IFNy 
inhibited the response to LPS. 
5.2.5. Downregulation of MT-MMPs and the activation of microglia 
Downregulation of certain MT-MMPs might be involved in activation of 
microglia and a switch from antigen uptake to antigen presentation. This perhaps 
parallels the situation for the innate immune receptor TREM-2. TREM-2 mediates 
clearance of apoptotic neurons and downregulation of TREM-2 leads to increased 
production of inflammatory mediators (262). Dendritic cells also downregulate 
TREM-2 upon activation (286). TREM-2 is downregulated on microglia as part of 
activation, e.g. by IFNy (261). Analogously, IFNy-mediated activation of 
microglia could also cause downregulation of certain MMPs. 
5.3. Stages of Neuroinflammation 
5.3.1. The endothelium vs. the glia limitans 
Leukocyte migration across the glia limitans likely has different requirements 
than migration across the endothelial basement membrane. A role for cytokine-
induced chemokines in CNS infiltration has been proposed based on studies in 
cytokine-deficient mice. If EAE is induced in TNFa-/- mice, there is an initial 
asymptomatic period, in which leukocytes accumulate in the perivascular space 
(35), showing that TNF is not required for trans-endothelial migration, but 
facilitates parenchymal infiltration. The TNFa no'rmally produced in WT mice by 
infiltrating leukocytes was shown to stimulate production of chemokines by CNS 
resident cells, thereby facilitating leukocyte infiltration (190). The TNFa-/- mi ce 
do eventually develop EAE symptoms, which coincides with a transition from 
perivascular accumulation to parenchymal infiltration, i.e. crossing the glia 
limitans, showing that the TNFa-induced chemokine production is facilitatory, 
but not essential for parenchymal infiltration. 
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As further support for distinct mechanisms involved in migration across 
the two barriers, the endothelial basement membrane and the glia limitans contain 
different ECM proteins (29). MPs are potential candidates to be among the 
required factors needed by leukocytes to traverse the individual barriers. It is a 
possibility that particular MPs needed. for a cell to infiltrate the parenchyma are 
not actually expressed by that cell type. For example macrophages could aid the 
infiltration of T cells by expressing MPs that clear the way for T cells by 
degrading ECM proteins in the barriers the T cells need to cross to enter the 
parenchyma (discussed in section 5.3.2.). Macrophages are important in the 
development of EAE, as macrophage-depletion leads to perivascular 
accumulation, but not parenchymal infiltration, when mice are challenged with 
EAE (36). 
5.3.2. Macrophage MPs could aid T cell infiltration 
Depletion of macrophages markedly decreases the disease severity of EAE (36, 
287, 288). From these observations, it appears that macrophages control 
infiltration of myelin-specific T cells into the CNS. As discussed previously, 
macrophages may clear the way for T cells by expressing proteinases that are 
required for parenchymal infiltration. It is evident from Chapter 2, and from a 
study using human cells (189) that macrophages are the dominant pro duc ers of 
MMPs compared to T cells. Strongly upregulated MMPs in EAE would be logical 
candidates for a "macrophage-factor", that is required to aid CNS infiltration. A 
prime candidate is MMP-12 which is expressed by macrophages in MS lesions 
(289), and is the most upregulated MMP in spinal cord of mi ce with EAE (199, 
214). AIso, MMP-12 mediated macrophage infiltration of lung tissue in a model 
of smoke-induced emphysema (290). However, the role of MMP-12 in EAE turns 
out to be controversial, as MMP-12 null mice were recently shown to develop 
more severe EAE than WT mi ce (214). MMP-12 null mi ce showed a Th1 
cytokine shift and this may be the reason for the more severe EAE. It would be 
interesting to test if MMP-12 influences cellular infiltration in a non-immune 
mediated model of neuroinflammation. 
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5.3.3. Migration of transferred T cells in AT-EAE 
Two phases of infiltration follow AT-EAE (291). Initially, the cells enter 
peripherallymphoid organs, where they are shown to develop a more migratory 
phenotype, e.g. by upregulating chemokine receptors. After about 60 hours, the 
cells enter the spinal cord, get reactivated, and upregulate pro-infiltrating 
molecules further. The activation state of T cells determines their infiltration of 
the CNS parenchyma, and CNS antigen specificity is required for persisting 
parenchymal infiltration. Upregulated MMPs could be part of the activated 
phenotype that determines infiltration. MMPs have not been investigated in this 
context yet. It could be that transferred cells upregulate their MP expression 
profile in peripheral organs, which enables them to traverse the endothelial 
barrier, and again after reactivation in perivascular space, which enables the cells 
to enter the CNS parenchyma. 
5.3.4. CCL2 Tg mice 
Fuentes and colleagues showed that leukocytes accumulate spontaneously in the 
perivascular space in mice expressing the chemokine CCL2 in the CNS (34). The 
accumulation was potentiated by LPS challenge, although no overt pathology was 
observed. In Tg mice which overexpress CCL2 in alveolar epithelial cells, an 
equivalent phenomenon was observed (292). Transgenic CCL2 expression in the 
lungs leads to increased numbers of monocytes and lymphocytes recovered by 
bronchoalveolar lavage. CCL2 expression alone was not sufficient to cause 
activation of the accumulated leukocytes or inflammation in the lungs. However, 
when stimulated with LPS, the transgenic mice developed pulmonary infiltrates as 
opposed to WT mice. Mice expressing CCL2 under control of the glial fibrillary 
acidic protein (OF AP) promoter, which is specific for astrocytes, also develop 
neuroinflammation following LPS challenge (293). These OF AP/CCL2 Tg mice 
are more susceptible to Theiler's murine encephalomyelitis virus-induced 
demyelination. Bennett and colleagues reported diffuse infiltration of 
mononuclear cells throughout the CNS tissue in unmanipulated OF AP/CCL2 Tg 
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mlce, whereas leukocyte infiltration is restricted to the perivascular space in 
unmanipulated MBP/CCL2 Tg mice (34) used in the present study. In both 
OF AP/CCL2 and MBP/CCL2 Tg mice, LPS potentiates accumulation of 
leukocytes in the CNS, and in both types of Tg mice, PTx induces encephalopathy 
(Chapter 3 and (206). 
PTx increases the incidence of EAE in B6 mice immunized with MOG35-55 
in CF A (294). In that study, it was shown that TLR9 activating CpG 
oligonucleotides injected directly into the brain could substitute for PTx, in 
inducing encephalopathy although the symptoms were different from EAE, 
probably due to different localization of the lesions. Other studies have also 
identified TLR9 as important in EAE (295, 296). These studies support the theory 
that P AMP stimulation of APCs can lead to relapse of organ-specific autoimmune 
diseases, such as MS. Both PTX and LPS are pathogen-derived molecules, and in 
these studies cause pathology in synergy with chemokine overexpression. 
Likewise, in patients with chronic inflammatory disease, infection might augment 
the disease. 
5.4. Environmental Influence on CNS Infiltration 
5.4.1. The role of PTx in EAE 
PTx has been proposed to act through TLR4 (165). Clearly, PTx must also have 
other effects, as it promotes disease in C3H/HeJ mice (297), which are TLR4-
defective because of a point mutation that renders TLR4 nonfunctional (298). 
10/1 0 C3H/HeJ mi ce got EAE, when they were given PTx as adjuvant, whereas it 
was only 4/1 0 without PTx. Another important point is that TLR4 signaling can 
be bypassed entirely, given that EAE can be induced in C3H/HeJ mice. PTx was 
originally proposed to open the BBB and facilitate transmigration of pathogenic 
cells in EAE (162). Recent results go against this dogma by reporting that PTx 
does not enhance BBB permeability (218, 297). It seems likely that PTx promotes 
EAE through other mechanisms. PTx may enhance EAE susceptibility by 
overriding genetic checkpoints in the disease pathogenesis, rather than increasing 
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BBB permeability (299). Results from the present study show that PTx promotes 
parenchymal infiltration, but not necessarily through a direct effect on the BBB. 
PTx was shown to cause upregulation of MPs by leukocytes, thereby promoting 
their transmigratory capability (Chapter 3). This can subsequently lead to 
breakdown of ECM barriers of the neurovascular unit, and indirectly to increased 
permeability. 
5.4.2. Innate immune receptors in neuroinflammation 
Given the need for adjuvants in EAE and the correlation between infections and 
relapse in MS patients, it is reasonable to assume that innate immune receptors are 
involved in MS pathogenesis. As mentioned in section 5.3.4., TLRs have emerged 
as an important family of innate immune receptors which are proposed to link 
innate and adaptive immunity (300). TLR signaling leads to activation of 
transcription factors, particularly NFKB, most often through the common adaptor 
molecule MyD88, which is also used by IL-l and IL-18 signaling pathways. Most 
TLRs are expressed in human CNS, and upregulation of several of them was 
shown in the CNS of MS patients (301). It was recently shown that many TLRs as 
weIl as MyD88 are upregulated in EAE, and that MyD88-1- mice were resistant to 
EAE (295). 
It would be interesting to study at which level in neuroinflammation PTx, 
TLRs and other PRRs exert their disease-promoting effect. In actively induced 
EAE, they would be expected to participate in the generation of the autoimmune 
response by activating APCs. However, PTx also promotes EAE after adoptive 
transfer (302). One hypothesis could be that perivascular APCs are actively 
involved in MS pathogenesis by regulating CNS infiltration. As discussed in 
section 1.3.3., recognition of myelin antigen presented on perivascular APCs by 
infiltrating T cells promotes CNS infiltration, in which MPs are likely involved. 
This process could be enhanced by activation of perivascular APCs through 
binding of microbial products to innate immune receptors. 
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5.5. Therapy of Neuroinflammation 
5.5.1. Are MPs good or bad? 
It is not rneaningful to sirnply de scribe MP activity, or even activity of a single 
MMP, as either good or bad during disease. A particular MP expressed by a 
certain cell type under inflarnrnatory circurnstances can do tissue damage, 
whereas the sarne MP expressed in a different location in the sarne organ at the 
sarne tirne, rnight be involved in repair. Sorne generalizations can be made, 
though. In the early stages of inflammation, MP expression seems overall to be 
detrimental, whereas in later phases of chronic disease, MPs perforrn beneficial 
functions inc1uding repair, making overall MP activity beneficial (65). From this 
follows that inhibition of MPs would be beneficial in treatment of patients with 
acute inflammation as in spinal cord injury, stroke, or during an MS attack, 
whereas patients in the chronic stage of MS would not bene fit from MP 
inhibition. In a rat model of stroke, it was shown that treatment with MMP 
inhibitors in the acute phase was beneficial, whereas continued treatment in the 
delayed response phase inhibited beneficial effects of MP action and thereby 
impaired neurovascular remodeling and functional recovery (303). 
In the present study four of the six MT-MMPs were downregulated in 
EAE (Chapter 4). It seems unlikely that these four MT-MMPs are promoting 
transmigration. The other two (MMP-14 and 25) might promote migration, as 
they are upregulated in situations with parenchymal infiltration, and they could 
potentially be targets to inhibit in neuroinflammation. This should be tested in 
knock-out mice. 
The TIMPs are likely upregulated in a specific spatial and temporal 
manner to prevent excessive proteolysis by aIl the upregulated MPs. More insight 
into the sources and pattern of expression of both TIMPs and MPs is needed to 
understand the interplay between the proteinases and their inhibitors, with the aim 
oftherapeutically manipulate this. 
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5.5.2. Inhibition of MPs 
The antibiotic minocycline attenuated EAE symptoms in mice, and decreased 
leukocyte traffic across an in vitro fibronectin barrier (104). Minocycline 
decreased both expression and activity of MMPs in that study. Minocycline has 
also proven to be protective against EAE in rats, where it decreased inflammation, 
demyelination, micro glial activation as weIl as MMP-2 expression (304). 
Treatment of mi ce with minocycline improved the clinical outcome following 
spinal cord injury (305), where MMPs appears to have a detrimental role, as 
demonstrated for MMP-12 (175). In addition to inhibiting MPs, minocycline is 
also an inhibitor of microglial activation (306). Preliminary results from a clinical 
trial of minocycline in MS patients show encouraging results (307). 
In terms of MS therapy, it is not known exactly which proteases are most 
cri tic al to inhibit. In order to optimize treatment and prevent side effects in 
patients, it is necessary to use selective MP inhibitors. However, developing such 
selective MMP inhibitors has proven difficult, possibly because of an inherent 
conformational flexibility in the structure of MPs (308). However, sorne recent 
attempts at developing specific MMP inhibitors show encouraging results in 
cancer research. The MMP inhibitor Ro-28-2653, with high selectivity for MMP-
2, 9 and 14 was a more potent antitumor and antiangiogenic agent than the broad-
spectrum inhibitor BB-94 (309). The crystal structures of sorne MT -MMPs have 
been determined, and it might be possible to design specific inhibitors against 
those based on unique features (310). The crystal structure of secreted MPs 
binding substrates or inhibitors have been elucidated, including the structure of 
MMPs binding to BB-94 (311, 312). 
5.5.3. Alternative therapeutic strategies 
Perhaps a more strategic therapeutic approach would be to target the stimulus 
leading to excessive MP action, rather than the MPs themselves. For example 
could cytokines that cause upregulation of detrimental MPs be inhibited, or the 
action of cytokines leading to upregulation of beneficial MPs could be augmented 
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Signaling molecules or transcription factors leading to MP expression could also 
be targeted. Finally, the substrates c1eaved by MPs could be targeted for 
therapeutic purposes, i.e. if a particular product of MP c1eavage is detrimental, 
then the substrate could be sequestered; and if the product is beneficial, the 
substrate could be supplemented. 
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CONCLUSION AND PERSPECTIVES 
The results described in this thesis provide novel information about the regulation 
of MPs in neuroinflammation, and how MPs are involved indiscrete stages of 
CNS infiltration. Numerous MPs take part in the very complex process of 
neuroinflammation, where the y interact with other large families of inflammatory 
mediators: cytokines and chemokines. In this study, correlations between certain 
MPs and IFNy are described, as weIl as the interaction between MPs, the 
microbial product PTx, and the CCL2 chemokine. Furthermore, the distinction 
between endothelial transmigration and parenchymal infiltration has been more 
clearly illustrated. Obtaining more detailed knowledge about the interplay 
between these large families of inflammatory mediators and how they affect CNS 
infiltration would be of great bene fit in relation to therapeutic management of 
diseases involving neuroinflammation. 
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Canadlan Nuolear 
satety Commission 
CNSC/CCSN 
~ommisslon canadienne 
de sOre1é nucléaire 
NUC~EAFI SuaSTANCES AOO peRMIS PORTANT SUR LES 
RADIATION oevlCES SUBSTANCES N~ReS ET 
LICENCE r..es APPAREILS À R.b.YOONSI!NT 
613 99S 5086 P.02/13 
01187 w2-0e.! 
UOIflt'e rwmbe r 
IUndlo Of pem1is 
1) UGENSEE 
P\I.suant to jOQatien 24 of the 'Nuclear Safety and Co~trol Act, 
this licence i~ issued te: 
Mont.ea~ Neurologiesl InStitute ~ Hospital/Institut et Hôpital 
neurolo;i~ee da Montrêal 
3601 Univer;ity Street 
;Montreal, QC 
H3A 254 
Canada 
he.e1~afte~ «the 1icenaee~. 
This licence replaces lieence 01187-2-08.4 
If) UCE#Cë PIORIOO 
This licenoe i5 vaUd frcm: November 30, 2005 to "prit 30, 2008 
unless otherwise &uspended, amended, ravoked or rapl~ced. 
III) LlCEHSI!D A CT1VTTIES 
NJ 
This licence authorizes the licensee to possees, transf.r, import, 
export, use .snd 'tore the nucles~ ~.tance5 and the pr.sc~ibed 
equip~nt liBted in ~eetion IV) of ~is lie~a. 
This licence is iSBUed for: ccnsolidat.d uses of nuclea: substan~e; 
(915) 
NUCLEAR SUBSTANCES AND PffftSCR/BfD I!~ 
.I~ 
1 
2 
3 
4 
5 
6 
'7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
2S 
~ ~ l/OIiRa .u:,u.IIi:IlI soaRc.I ~ 
.~ NoU%JII11I lWCDIl1II JDJ!lI: ..um .III'I:).OZl, 
Ql7A.!Wr.I'!" QœII'l'n"l' 
CArbon 11 2 GBq nIa fila 
Carbon 14 U GBq ula nia 
caleiUlll 45 800 HBq nIa nia 
Chrcm.i.ùlI\ S 1 2 GB(,[ nia nia 
Cop~~ 64 925 HBq ilia nia 
Fl.uorine 18 2 Gaq nia nIa 
Iron liS 100 NBq nIa nIa 
Gallium 68 400 MBq nia nIa 
Hy<h'ogen 3 33 GB<;i nIa r./a 
Iodine 124 leS !œQ: n/la. nia 
Iodine 125 
" Cilq nia. nia Iodine 131 2 G!lq nia nia 
Krypton 9S 74. C;Bq '(J./,. nia 
Qx.ygen 15 2 GBq nia nIa 
Pllosphorus 32 11 G!lq nia n/~ 
Phosphorus 33 2 GSq nia nia 
Sulfut 35 22 GBq nia. nia 
'rechnetiUln 99m 11 GBq nIa nia 
Coj;)alt 57 nia 370 IGBq nIa 
cesium 137 nia 1 GBq nIa 
Germani"W1l 681 nia. l OSq nIa. 
Gall i UlII 68 
Sodium 22 nia. 4 Jœq nia. 
Ce"ium 137 nia 1480 Jc.Bq B~ekman LS series 
RadiUlll 226 n/~ 370 kBq Wa11ac 1200 Series 
E1,IropiUll\ 152 nla 740 kBq Wallac 1'00 series 
The total quantity of an unsea1ed nuolear substance in possession 
shall not exceed the corresponding listed unse<r.led source lI\aXilllUID 
quantity. The total quantity of nuclear substance per aealeQ 50urce 
ahall not exceed its corresponding li!ted sealed lource maximum 
quantity. Sealed sources shall only be used in· the corresyonding 
listed equip!l\lWt. 
ColftM.ia"ion COj;lY ... / 2 
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1+1 canadîan Nuclear Safl!'ly CommISsion IJommisslor1 canadienne de silreté nudéaire 
NUClEAR $UBST.t.NCeS AND Pau.tS PORTANT S\,IA WOS 
f1AOIAnON OEVICeS 81.JSsrANCES N~lfIIES ET 
UCE~ LES APPAREILS ~ AAYO~eNT 
VJ LOCA TlON(S) OF UCENSED AC'TMTIES 
VI) CONPmONS 
3801 University Street 
Montré"l, OC 
1. Intern~l AuthorizAtion 
The licensee sha1l ensure that 
~1117-2-08, 5 
Ul:enOl NOOlber 
NuiMfo <H permis 
Page 2 
Ca) internal authorizations are issued in aceordance with the 
lieens.e's internal authorizat1on policies and proeedures approvwd by 
the Commission or a person autborized by the Commission; and 
(bl internal authorization forœs are posted in a readily visible 
location in or near each room, are a or enclosure where nuclear 
substances and radiation devioes are used or stored. (c) the liceneed act1vity la conducted in aocordance with the terms 
and conditions of the internal authorization. 
(2215-2) 
2. Location NotificAtion 
The 1ie8ns •• shall, for any site where liceneed aotivities are to be 
conducted foi more than 90 consecutive daya, notify the Commission in 
writing of the site within 7 daye of st~ting to conduct the 
aotiviti.~ at the ,its. The licensee sha11 notify" the Commission ~n 
writing within 7 days of the disoontinuance of lic&nsed activlties at 
any site. The oontinuity of consecutive gays iB not broken durinq off 
site use or off site teatpOrary storag-e. 
(2300-2) 
3 . Froj ect Approval . 
'l'he licenS8e shall ohtain writ"ten Clpproval from the Coll'llllission or a 
person: authorized Dy the Conuui"ssion hetore starting any work 
requiring the use of more than 10,000 ex~tion quantities of a 
nuclear $ubstance At a single "time. 
(2214-0) 
,. Prohibition of Human Use 
Tnis licence does not authorize the use of nuclear substances in or 
on hUl114n beings. 
(2696-0) 
5. Emergency Contact - Radiation Deviee 
The lic~nsee shall poet and keep posted, in readily visible loca~ion 
at the place where any radiation device liste~ in section IV) of this 
11cense ie used, a durable and legihle sign that 1ndicates the name 
or job title and the telepnons numbQr of a person who can initiate 
the aceident procedure that pertains to the radiation device and who 
can he contacted 24 hours a day. 
(25S9-2) 
6. Area Classification 
The licensee shall classify each room, area or enclo.ure where more" 
than one eXeMption quantity of an unsealed nucl.ar substance i5 used 
at a single time aSI 
(a) baGic-level if the quantity doeg not exeeed 5 ALI, 
lb) intermediate-level if the quantity used does notexceed 50 ALI, 
(c) high-level if the quantity does not exceed 500 ALI, 
(dl containment-level if the quantity exceeds 500 ALI, or 
le) s~ecial purpOSQ if approved in writing hy the Commission o~ a 
person authorized by the Commission. 
Except for the basic-level classification, the licê."lsee shallnot. use 
linse.\I.led nuclear substances in tbese rooms, areae or enclosures 
without written approval of the Co~ssion or a person authorized by 
the Commission. 
.../ 3 
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Î. Laboratory Lists 
The licensee shall ~intain ~ List of aIL Areas, rooms and enclosure. 
in which I1IOre thAll one e>e4llllPtiotl. quantity of a nu<:!lsar 5~$tance il> 
used or IiItored. 
(2569-1) 
a. LaborAtory procedures 
'l'he lioenaee shall post iUlCl k .. ep po;t.ad. in .. readilY visib.lli! 
location in e.réU, rCXX1l.S or enclosures .... h.ra nuclear .sub"tancee ;tré 
hanQled, a radioisotope saf.t~ poster approved by the commission or a 
person authorized by the commission, Which eorresponds to the 
claeBifioa~ion of the Area, room cr enclo$ure. 
(2570-1) 
9. Thyroid Monitoring 
Every p~rBon who 
(a) UséS at a Bingle rime a quantitl' of volatile iodine-125 or 
iOdine-131 exceed1ng; 
( 1) S Jœq: in an open reCilll\; 
(iil 50 K8q in a fume hood; 
(ii1) 500 MBq in a glove b~1 
(iv) an)' oth~ quantity in ether contaiIll\1ent approve(l. in writing :oy 
the Cammi~8ion or a pers on author~zed ~ thR Commi.lion, or 
(hl is involved in a spill ot greater ~ 5 M5q of volatile 
iodine-125 or iodine-131; (c) or on ~ iodine-125 or iodine-131 èXternal contamination ia 
det.ated: and shaH. undargo thyroid screening within !ive day' 
followin9 the ~aurQ, to iedine-12S or iodine-l~l. 
(2046-7) , 
10. Thyreid s~eQning 
Screening for internal iodine-125 ând iodine-131 .hall ha perfornQd 
using: . 
(Il) .. direct me.surement of the tb.vroid with an instrument tha.t can 
detect 1 k~ of iod1ne-125 or iodine-131/ or 
(hl Il bio •• ;~y procedure approved by the Commission or a persan 
author1zed by the Commission. 
(2600-1) 
11. Tr~oid Bioassay 
if tbyroid sereening a.t.cta mor~ thao 10 kBq of iodine-125 or 
iodine-131 in the thyroid, the li~ensee ehall immediately mak. Il 
preliminary report to the CQtIIIIIiBsion Ol'" a peraon authorized Dy the 
Commission and bave bio&BBay pertormed within 24 houre ~ Il persan 
1icensed by the Commission to provide int~l dosimetry. 
(260l-4) 
12. Xxtremity OOsimetry 
'l'he lieenstH! I!hall Ql:I.Sure tbat any person who handles a eon.tainer 
whieh eontains more than 50 KBq of phosphorus 32, etrontium 89, 
yttrium 90, ~rium 153 or rhl!Ilium 185 wears il dng o:l.oaimoter. 'l'h. .. 
~o8imeter8 must be supplied and read oY il doairr~try service licensed 
by the cov.=ission. 
(2578-0l 
13. survey Mater ~iremènts 
The licen.ee .shall provide 'at aIl times where nuele~ substances, 
excap~ for hydrogen-3 and nickel·63, are handled or stored il 
raOlation survOl' meter. 
(2058-0l 
14. Cont~ination Meter Requirementè 
The U.cênSee ",hall I!\!I.ke availal:>le te workers at all times at the site 
of the licensed aotivity a properly funetioning portable 
contamination meter. 
(2572-1) 
15. Contamination Criteria . 
The licensee shall OQAvre that for nuclear substances listed in ~e 
licence application guide table title~ 'classification of 
CClll1ll.ission COpy 
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l' .. g~ 4 
~dioc.ucliQeli· ; (a) non-fixe<!. contamilUltion in ",11 arMS, rooms, Ol" melo.ures where 
1.l1'\.Sealed nuclear "ubllt~O~1l are US@Q 01: IItored does Dot e.xceed: 
(i) 3 bec~erels par 8quan centimetre for a11 Cl"ss A 
radionuclides 1 (ii) 30 becquerels per square centime cre far a1l ClaBs e 
r~onuclide.; or (iii) 3QO bec~~er@16 per square csntimetre for al1 Claes C 
radionucl ide", 
averaged over an usa not exclHlding 100 sq..\are centilnatree: and 
(~) non-fixed cOtltll.minat1on in a11 other I.relUi does not el(ceed, 
(i) 0.3 bgcquerels per ,quare centimetre for all Cl.~s A' 
radionuclides: 
(ii) 3 bacquerel~ per square ~entimetre tor ali'Clal' B 
radionuclides: or (iii) 30 beoquerels par s~. canti~trQ for .11 elaee C 
radionuclides: 
averaged over an area not e.xc .. ding 100 $quare coentimetres. 
(2642-2) 
16. b&commi.,ioning 
The licansee &hall ensure that prior to decommissioninq any are&, 
room or encloaure where the lic~.d aetlvity ha. baRn coDductedl 
(a) the non-fixed contamination for nuclear substanceS li~ted in the 
licence application guida table 'titlad 'classification of 
Radio~UQlide8' do.s net axceed: 
(i) 0.3 beCquerels pe~ square centime~re fo~ all Olas. A 
radiQl1UQUdu: 
(H 1 3 becq\lQ%elB p~ llquare c:entimetre for all Clu8 B 
radionuclidss: 4U1d 
(iii) 30 becquerels per square c~timetre for al1 Class C 
r&dionuc11des; 
aver.~ed over an ~ea not exceeding 100 square cantimetresl 
(bl tbe release of Any ~e., room or encloe~re oontain~ng fixeQ 
conteminat1cn, i8 approvad in ~iting by tbe commiaaion or person 
author.h;.cI by the COII\IIIisaionl " 
(a) all nuclear sUbstance. and radiation dev!ca. have been 
tranaferred in accordance with the conOitions of thi. licence, and (d) ~ll' radiation warning signa have been removed or det.ced. (2571-2) 
17. Stcrage 
The lie.neee ahall: 
(a) ensure that When in storage radioactive nuelear sub.t~oQS or 
radiation devices are accessible only to per.ong authorized by 'the 
licensee; 
(hl ensure that the dose rata at ~ oceupied location outside the 
sto~age area, rOQm or enclosure re~ltinq trom the substances or 
devices in storAga dce. not exceed 2.5 microSv/h, and 
(c) have 1118 •• ures in plAoe te enaure tbat the dose limita in the 
Radiation Protection Requlations are not exc •• ded a. a result of the 
substancea or devices in ster.ga.' 
(2575-0) 
lB. Disposal (Consa1idate4) 
When diepo.ing of ~ealed nuelear substances to ~cipal garbage or 
sewer syQtems or to atrncspnerR, the iicensa8 shall ensure that the 
following limits ara net ~oee~ed: 
COLUMN 1 
Carbon 14 
Chrornium 51 
COL~ 2(a) 
LIMITS 
BoUds to 
mm! oipal 
garbage 
IIystBll\ 
(quantity 
per xHogrèUJ\) 
3.7 MlIt< 
3.7 MlIq 
COLUHN 3 (1:» 
LIMITS 
liquida (wate~ 
soluble)to 
lZJ'.l.lij,c!pal 
lIeIo'Gr system 
(qwmtity per 
l'ear) 
10 000 !>!Bq 
100 KSq 
Cormission Copy 
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__ w. ____ ~ __ ~-__________________________________ w ______ ~---~------
Cobalt 57 0.37 MBC! 1000 MI!Iq 
_____ ~ _________________ r ____ • _____________ ~ _______ • __ ~ ---._-.---. 
Cobalt 58 0.37 )$q 100 KBq 
0.031 Iœq 100 1'[6(;[ 
37 MBq l 000 000 KBq 37 kBq 
Indil.Ul\ 111 0.037 z.mq 10'0 KBq 
Iodil1l! 123 3.7 HBq loba M1!q 
lodine 125 0.037 MBq 100 MEIq 
lodine 131 0,037 Mac; 10 KBq 0.175 kllq 
Krypton 79 0.37 ~ 
Xrypt.on 85 
PhosphOr\L4 32 0.37 MBq 1 KBq 
i~Qllphoxv.s 33 l KB<:I: 10 Hat;[ _______________ M _______________________________ ~ ______ __ • _____ ••• 
S\llfl,lr 35 0.37 Haq 1000 MBq 
--"-----------------------------------------------------.---.---. 
'l'eclmet;i.\IDI 99m 3,7 lŒq 1000 )!Bq 
'1'hallium 201 0.037 MBq 100 Jœq 
Xemm 133 3.7 lQiq 
(a) The li~ie& in eclumn 2 apply ta quantities of eolid wa.t. ct 1ess 
than three tonne8 'per year per tacili~y, Nuolear suPstanoes re1easeà 
to th. m1!Ilicipal garbage 'YIII:.am III\Il!It he in 80Ud to= ~CI w'lito:ml.y 
di.~ributed in the w..ta with'a CQncentrat10n that :Le les& than the 
lilDits in oolumn 2. Wh." more than one' nuc:lear substance iB dhpelilad 
of at one> t.ùne, the quo,t:ienta 'O:btained by <iivic1iDg the quantit.y Of 
eac..~ sUbstance by iu correspondinll l,imit in cl;>l= 2 sMll l''IOt 
ex~ one. 
(b) The l~ts in Col~ 3 app1~ to the wat.r soluble liquid fo~ of 
... cil nuclear substanc. which lliay he diepo&ed of per year per 
buildiDg. 
Col The l~ts in Co1umn ,~ may be av.ra~~ over a one-week period. 
Thase limits Ilpply to release& of'les8 tAAn 3 million oubie matres 
:per year. Where IIIOre th.an on. nuclear 8\lbstanoe ;i.s dispcuea of a.t one 
time. the quotients obt.inQd hy diViding the quantity of eaah 
.ubstance by its ccrresponding limit in column 4 ehall not ~cee~ 
one. 
(2160-3) 
19. Export Restrictions 
ThiB licence doe. not authori~e the lieensee te ~rt fer the v&lid 
period Qf ~B lie~oe: 
(a) UJ..y quantity in Im"j' forne of. 
(i' O.ut:erium1 
(:Li) Plutonium; 
(iii l 'l'horiUlllI 
liv) TritiUlll; 
(v) Uran1uml or 
(h) any quantity of the ell!!!llental tOrIn, or any quantity ot a. compound 
or lIIixture greater than or eqv..t.l to 37 GBq/kg, or any "ealed 
IIOUX08 or 11 .. vi.OQ greater thAn or eq..lal to 3.7 GBq of: 
(i) ACtinium 22S, 227; 
(ii) çaliforni~ 248, 250, 252, 253. 2541 
(iii) CUrium 240, 241, 24~. 24~, 244; 
(iv) Einsteinium 252, '~53. ~5', 255: (vI Fermium 257; , 
(vi) Gadolinium 148; 
<.vii) Mendelevium 258; 
camUs"ion copy 
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(c) any quan~ity of ~ricium 2(1 or 243, except in a co~~ound or 
mixture, or Any uealed 80urce or device; 
(d) any quantity of Neptunium 237, except il). a compo'.,md or .,uxtu:e, 
or any sealed aource o~ devicel 
Ce) Any quantity of Radilllll 226, or any qullntity of SI compounc:\ or 
mixture of Radium 226: 
(f) Any $e~led Bource or ~Qvic. (GXcept for rnedical applicatorel of 
mo~Q thàn 0.37 cmq of Radium 226; and 
(go) any neutron 51.l1erator syst8ll\ (inoludinl7 tube5) Cllasigne(! tor 
operation without an ~t.rnAl vacuum system ~ utilizing 
el.ctro.catie acoeleration to indueè a tritium-deuterium nucle.r 
reactiotl. 
(2403-2) 
20. Annual Compliance Report 
The licensee shall, by Fehru~ 29 of each y.ar, ~it to the 
C~ssion a writteu aonual eompliance repgrt in a form accePtable te 
the Commission. . 
(:2916-6) 
oesignated Officer pursuant to 
8Ubsaction 37(2)(c) of the NUolear 
Safety and Cont~ol Aot 
Commission Copy 
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1) 7T7l.IL4/RE OE PERMIS 
ConfO~~QOt à l'article 24 de la Loi ~ur la sÛreté et la réglementation 
nucléaires, le présent pe~s est délivré i, . 
Montreal Neuroloqieal Instieute and Hospital/Institut et HÔpital 
ne~oloqique, de Nontréal 
3801, rue On!versiey 
Montreal (Québec) 
H3A 2M 
CIUla.~ 
Ci-apres désigné ~ou, le n~ de «titulaire de permis~ 
Le présent ~s r~lace le permis 01187-2-08.4. 
U) DURS; OU PéRftlIS 
Ca permis est valide du 30 no~r. 2005 au 30 avril 2009, ga~f ai le 
pe~s est 8U~U, ~fié, révo~é o~ remplacé. 
IN) ACTlvrTÉS A~ 
IV} 
. Le prssent permis autorisa 1$ titulaire a avoir en sa ~osse'8ion( 
transférer, importer, exporter, utiliser et IItocker 'les sul:I.taocElS 
nuclaaires et les é~ipementB autorisé. qui sont énuméré. danll la 
section IV) du préaQot pe~ig. 
Le présent 
qlob.ale de 
permis est ~'livré pour le type d'ut~lisation: utilisation 
aubstaneQQ nucléaires (B15) 
SlJBSTANCES~ ETt.QUlPEMEM' ~ 
AA!'l'C'L!: ~ 1I0t1JlCJ: lION ~ .&.U.ENI.LIOI .DE .LA ~rpl:lll:1R -
1 
2 
3 
4. 
5 
li 
7 
8 
9 
10 
11 
la 
13 
14 
lS 
16 
17 
lB 
19 
20 
21 
22 
23 
24 
OIS 
Mr1C.LIi.\.:.U QtWft'%~ .acm~ r.I.BJUC.&Jn' rtl' IGZrJIP,.("K QI1JUII'r MU%JQr.l!! JIODhlt 
Car:&>ne 11 2 GlSq ./0 ./0 
Carbone 14 11 GBq s/o .. /0 
Calc;l.wn 45 800 Jœq s/o slo 
Chr(l!rul 51 2'GlSq ,/0 a/o 
CUivre 64 . 925 MBq 8/0 1/0 
l!'luor 18 . 2GBq s/o slo 
Fer 5S 100 !œq s/o s/c 
G&lUum 68 400 lIIBq ./0 slo 
Rydrogène 3 33 GBq s/o "0 Iode 124 185 Mllq _/0 slo 
Iode 125 4 GIIq s/o s/o 
:rode 131 2 GBq S/O 8(-0 
KrY.Pton 85 74 QBq '/0 alo 
Oxygène lS ;! GBq $/0 .1/0 
i'hosphore 32 11 GBq s/o .. /0 
Phosp~ore 33 2 GBq a/o slo 
Soufre 35 22 Cl!q a/o ./0 
'l'eehnétium 99m 11 GBc;! s/o ./0 
cob.alt 57 s/o 370 MBq 11/0 
CQsi\.à\ 137 a/o 1 Gaq s/o 
Ge.rme.nium 5al slo l GBq 'fl/o 
GAllium 69 
sodium 2;1. s/o 4 MBq r:.fo 
césium 137 s/o 1460 kBq Beekmàn LS series 
Radium 226 s/o 310 Ji:Sq Wal1ae Série 1200 
Europium 152 s/o 740 JtBq Wa11ee série 1400 
La quantité. tot~l., d'un .... uh!leanoe nuoiéaire non Ilo.llée possédé'é ne 
doit pa~ excéder la qu~ntité maximale qui est indiquéé pour une 
source non $cellée correapo~dante. La quantité de substance nucléaire 
par source scellée ne doit pas excéder la ~,tité maximale indiquée 
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par ~ource b~ellée correspondante. Lee sources ~cel1ées doivent être 
ut.ilisées seulement: dans l'équipement indiqué correspondant. 
3801, rue University 
Montréal (Québec) 
1. Exigencea d'autorisation interne 
La titulaire veille à oe que : 
a) de~ autorisations interne~ soient dèli~éel confor.mément aux 
politiques et prooédur8& d'autorisation interne du titulaire de 
permiS, . qui doivent être approuvées par la Commission ou une personne 
autorisée par la Co~i.sionl . 
hl les formulaires d'autorisation interne soient affichés bien en 
évidence dans chaque sall., zone ou enceinte où des substances 
nucléaires et de. appareils à rayonnement ~ont utilisés ou stockés, 
ou à proximité de ces salles. zones ou enceintes. 
c) l'aotivité autorisée est exercée conformément aux conditions de 
l'autorisation interne. 
(2215-2) 
2 • Avis cS' empiacellient 
Pour tout endroit où 8. dérouleront d.s activitée autorisées pendant 
plus de 90 jours consécutifs - sans égard à tout autre li~u 
d'utilisation ou· à toute période 6_ .tockaq~ temporaire, le titulaire 
de pe~is Signale l'endroit par écrit à la Commi.sion dan. les sept jours après le dêbut. des activités. Il l'avise par écrit dans les 
sept jours de la cessation des activit'. autorisées à cet endroit. 
(2300-2) 
3. Approbation du projet 
Le titulaire de permis obtiént l'autorisation écrite de la Comnûssion 
ou d'une per&onne autorisée par celle-ci av~~t d'entreprendre tout 
projet exigeant plus de 10 OOOquantitéi d'exemption d'une substance 
nc.cléaire à un 1Il0IDent donné. 
(2214-0) 
4. Interdiction visant l'utilisation chez les humains 
Le pGrltIis n'a.utorise pa!! l'utilisat.ion dessubstanees nueléairelil d<Ul11 
ou sur le corps d'une personne. 
(2696-0) 
5. Contact en cas d'urgence - appareil 
Le titulaire affich~ en pe~enC8 et bien ~ évidence,. sur les lieu~ 
où un appareil à r~yonnement figurant à la section IV) du permis est 
utili~é, un p~nneau durable et ~iaible indiquant le nOID ou le titre 
a~nsi que le numéro de té~éphone de la personne qui peut être 
contactée jour et nuit pour lancer la procédure A suivre en ca5 
d'accident pour cet appareil. 
(2559-2) 
6. ClaQsification des 2ones. pièces et enceintes 
Le titulaire de pertnis désigne chaque zone, pièce ou enceinte où on 
utilise plus d'une quantité d'exemption d'une substance nucléaire non 
scellée à un moment donné selon la Cls$.ificat1oo su1v~te : 
(al de nivea.u élément.aire :;Ji la. quantit.é ne dépal!s.e pas 5 !.AI, 
(bl de niveau intermédiaire si la quantité utilisée ne dépasse pas 50 
LAI, 
(c) de niveau sup~rieur ai la quantité ne dépasse pas 500 LAI, (d) de o'cnfinE!lllent ai la quantité dépasse 500 LAI; 
(e) à vocation ~péciale, avec l'autorisation écrite· de la commission 
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tra.'lailleurs sur les lieux. de l' ac:t:ivité 8.utoris~e un cont;unic.M\ètre 
portatif en bon état de fonctionnement. 
(2572-1' 
15. Critères de oont~nation 
En ce qui e. trait aux sllbstanceoS llUcl$airel!l figurant au tB.bleau 
~lQllification des radionuc19idss» 6u guide sur les demandes de 
pet'lllis r 10 titubire Qe permi. veille à ce que: 
(Il) la contamination non fixée dlul& toutes les :tamlll, pièces ou 
enoeintes où on utilite ou stocke de.s ~stance8 nucléatres non 
scel16es ne d~passe PAS : (i) 3 Bq/~ pour toua leg radionucléides de catégorie A, 
Cii) 30 Bq/0m2 pour tous las radionucléides de caté~orie S, (11i) 300 ~/cm2 pour tous les radionucléides de c:~t'gorie C, 
selon 1Jne moyenna ét~lie pour une surface ne. dépll&&ant pa.Il 100 cm2; 
(hl la cont~n~tiQn non fixée PQ~r toutes le8 Autrea zones ne 
c3épassu p.8.11 1 
(i) 0,3 Bq/cm2 pour tous les radi~uoléi~e~ de e.~égor~e ~, 
(iil 3 aq/em2 pour tous 1ea radio~ucl6ide8 de cat~gori. a, 
(ii!) 30 aq/cm2 pour tous las raaionue16ides de CAtégorie C, 
selon une ~yenne établie pour ~e surface ne ~pa&.ant pa.s 100 cm2. 
(2642-2) 
16. Déel.sse~ent 
Av.nt le aéclaslement ~'una zone/'d'une pièce ou d'une enceinte où 
a'est déroulée l'activité a~torisée, le titulAire de permis vQille • 
ce q\1C1 1 (al la contamination non fixée pour leB .uhstances nuoléaires 
figurant au tableAU «ClAssifieation des radion~cléide8. du gYide sur 
les demandes ~e permis ne dt.passe pas 1 
(il 0.3 I3q/cm4 pour tO"'1I les re.dionucléi"es ~ catégorie A, (ii) 3 Rqlcm2 pour tous 1 •• radionucléides de cat6g~iaB, 
(iii) 30 Bq/cm2 pour tous lei radio~~cléidel de catégorie C, 
selon une ~yenne établie' pour une s~~face nedép&ss.nt pal 100 cm2; (b) la mie. ~ disponibi11t4 ~. toute zone. pi.ce ou anceinte 
r:ontanant une contamination fiJœe 80i t approuvée plU' 1& Com:nission ou 
une perlonne autorisee ~cell.-ei, (a) toutes les substanc~.s nuc16air •• et tous les appareilS à 
rayonn~.ntont été tronaféré. conformément aux condit1ons du permis; 
Cd) tous 1 •• panne~~ de mis. en ga~de contre les rayonnements ont 
ét~ retirés ou ont été r~dus il1iiih1 •. (2571-2) . 
17. StOCkas. 
Le titulaire : . 
al veille A ce ~9 ~eules l.~ pers~as autorisaes ~r lui aient 
accès a~ Sub8~anCQ.s tiuc:l~Airas radioactives ou aux appareils l 
rayonn~nt stockésl 
b) veille à ce qu'à tout endroit oocupé à l'~térl.~ de la zone. de 
la salle ou de l'enceinte de etQekage le 4ébit de dosa provenant de* 
suostancea ou appare!ls stockés nedéP ••• 8 pas ~.5 microSv/h; , 
el a des mesures en place pour assurer que ,les limites de doe. 
indiquées dans le Règlement sur la radioprotection ne sont pas 
dépassé., an re.ison ~ stOckage de 'oes substances OQ appareilS. 
(2575-0' -
19. tvacuation (permi. global) 
Lo~.qu'il évacue des .~stances.n~cléaires non scell'es dans une 
6QC!hargé municipa..le, un ré.u,\l. . 
d'éqo~t; ou l'atmosphère. le titulaire de permie veille A ce qu~ les 
lim~tes suivantes ne soient pas 
ëlapassEÏès 1 
COLONNE 1 
SUbstance 
nucléaire 
Argon 41 
Carboné 14 
COLONNE' 2 (~) 
L IM:t:'I'ES 
solioes à. la 
daebarge 
municipale 
(quantit~ .u kg) 
3,7 HBq 
COLONNE 3 (b) 
LIMI'l.'ES 
l:iquit;l.es 
(hydrosolul:11es) 
à l'égout munioipal 
(~antité par anl 
10 000 MBq 
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COLONNE 4 (c) 
LIKIr;r;&S 
gu: c:\re.ns 
l'atmosphère 
qu«ntité au 
lMl:re cubé) 
0,037 kBq 
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À l'exoeption du niveau élWnent·,.~rti, le titulaire ~ permi.; n'utHise 
pas ~ substances nucl~ires non scellées ~ c~s zone., pièces ou 
enceintes 5ADS l'auto.~'Ation écrite de la Ccmmissicn o~ d'une 
personne autorisée par ~elle-~i, 
(2106-2) 
7. Liste de~ laboratoires 
Le titulaire de'permi8 tiQnt à jour une liste de toute. le; zones, 
salles et enceintes dans le.que1les plus d'une quantité Q'ex~tion 
d'une substance nucléaire est utiliaae ou stockée. 
(2569-1) 
8. Procédures ~ laborAtoire 
Le ti~u1aire affiche en tout temp. et bien en 'vidence ~ le.; 
zones,' les salles ou lee enceUl.t:es où des substancel nucléaires sont 
manipul~s une Affiche sur la radioprotect~on qui ... été approuvée par 
la C~isi~ QU une perlonne auto~1$ée par la C~sBion et qui 
corre.pond à lA c1A5eifioation de la zone, de la •• 11e ou de 
l'enceinte. 
(2570-11 
9. Surveillance thyrc~dienne 
La perlloMe 
Al qui util:l. •• à un ilIomcmt ë.onn' une quantité d'io~e :1-25 ou d'iode 
131 Volatil., dépassant : 
(il ! KBq dans une pi.oe ouverte, (ii) 50 HBq dans une hotta, . 
(iii) 500 KBq dans une bolte à gante, 
(iv) toute Autre ~tit' é1ana un. enceinte de continKment approùvée 
par 4crit por 1. C~.lIion ou ~ personne autorisée par oa11e-ci; 
(h) qui est impliqué dAIUI un déversEIINIIlt mettant en cause plus de 5 
MBq d'iode 125 ou d'iode 131 VQlatiles; 
Cc) che% la~.11Q on déteote une contamination externe. l'iode 125 
ou l'iode 1311 
doit 8e prête~ il un dépistage thy~o~dien dàn. 18. cinq jours suivant 
l'exposition. 
(2046-7) 
10. ~iatagè thyro~~ien 
Le ~iatage de l'iode 125 et de l'iodé 131 inte~es se f.i~ 1 
(a) par mesure directe il l'aide d'un instMenr. capaJ)le de détec:ter 1 
kSq d'iode 125·ou d'iode 131; 
[bl par essai biologi9Ue approuvé par la CommisBion ou une personne 
autoris@e par c.lle~cl, 
(2600-1) 
11. tssai biologique thyro~4ien 
Si la _c~ge t~oïdienne dans une personne depas8e 10 kBq ~'iode 125 
ou d'iode 131. le titulaira de pe~s doit préBente~ immédiatamant ~ 
rappo~t préltmillaire ~ la Comil\~saicn Ou 4 une p.~.onne autorisée par 
celle-ci. [)&nS un (141ai ~ 24 heures, la pe:t'Sonne ~ quution doit 
subir des essaiee biologi~es par une personna autorisé. par la 
C~ •• ion à offrir un service de dosi~t~ie interne. (2601-4) 
12. Dositllét.rie du extrémité .. 
Le titulaire de peraci.; veille 4 ce que toute personne qui ~ipule un 
cont.enant renfe~t. plus de 50 l!IBq de phosphore 32. ~e strontiUIII 89, 
d' yttrium 90. ele sama.ri\l.ll\ 153 01.1 cl.e rhmiUIII lB6 po~te une ba9\l& 
do&~tre. Lo dOGimèt~& est iourni et lu par un lervioe de dosimétrie 
autorisé par la commission. 
(2578-0) 
13. Radiamètres 
Le titulaire de pe~s fo~it en tout temps un radi~tre là où des 
substances nucléaires là l'.xclusion de l'hydrogène 3 et du nickel 
63) Bon~ manipulée$ ou stoçkéea. (2058-0) 
14. EXigences concernant les contaminamètree 
Le titulaire de permis Net en-tout t~s à la disposition des 
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Chrome 51 3,7 )Wq 100 Mbq 
:~~:~:_~~-~~-~--~:~~-~~---------~-~~~~-~~ .. ~---_._----~-----------
Cobalt 58 0,37 MBq 100 MBq 
G&llium 67 0,037 MBq 100 MBq 
Hydrogène 3 37 MIl.; l 000 000 MIlq' 37 ksq 
Indiwn 111 0,037 MBq 100 t(8q 
Iode 123 3,7 )!Bq 1000 lœq 
Iode 125 0,037 MBq 100 Jœq 
Iode 131 0,037 lœCt 101'lbq 0,175 kEIQ: 
0,37 kliq 
-~----~---------~--~-----._-------~-----_.----._.-------~-----------~ 3,7 lilIq _____ •• ______ • _____ u _____________ ~ __ ~ ___________ ~ _____ ~ __ ~ _________ ~_ 
Phospho:re 32 0,37 KJiIq 1 HBq 
Phosphore 33 1. MBq la Mbq __ M __ ~ ______ ~ ____ ~ _______ ~ __________________________________________ _ 
, ' 
soutre 35 0.31 Kaq 1000 lGq 
'rechnétium 9!i111\ 3,7 Mtlq lOOO Iœq 
Thallium 201 0,037 MBq 100 Jœq __ R _____________ W __ ~ _____ ._~ ____ • _________ • ___________ • _____________ _ 
xénon 133 3,7 kSq 
(al Les; limites indiqu4i88 à la. colol1lle 2 s'appliquent aux quantité5 
d. dâchet' solides de mgi~ de 
trois tOMIôII1 par 1I.!l. Le. l!Iub8tances nl.\c16aixe.8 évacuées dans 1. 
d4charge municipale do1v~t être 
sou. forme *olide et dist~lbu~as uni~orm8ment dans 1.; déchets; la 
concentration do!t .tre 
intéri.~r. al.\X limites indiquée, à la colonne 2. Lorsqu'on évacue 
plue d'une e~tance nucléaire à 
la fois, le quotient obtenu en divisaJ\1: la quantité Ol! chaque 
substance par sa 11=11:e corresponc!&ntll! 
d. la colonne 2 ne doit pas dépasser un. 
(bl Les l~it.s indiquées à la co~onne 3 S'appliquent à la forme 
liquide (hydroBo1ul;>le~ de ohaqu$ 
subBt;l.P.oe nucluire qui paut être éve.c::uée par an et par b$timent. 
(cl On peut faire la moyenne sur une semaine des limites indiquées .' 
la colo~e 4. Ces limites 
s'ill)pliquent aux rejets de n\(/ins; de 3 milliOllS de mètres; cube. par 
8,1.'1, Lo~squ' on éVacue plu. d'une 
aubstance nucléaire À lA ~oi., le quotient obtenu en divisant 1& 
quanti t4 de cMque ~stance par /la 
limite corre,pondante qe la colOlllle 4 ne doit pas, dépasser un. 
12160-3 ) 
19. Rescrictions à l'expoxtation 
AU cours de sa p4riode de validité, le pe~s n'a~torise ~ag le 
titul~ire de parmis • axporter , 
(a) toute ~antité, SC\U!l toute forme, 1 
(i) de deut'rium; 
(Hl ~ I:Ilutoni1.Ul\11 
(iii) de thorium; 
(!vl de ~~~~ium: 
(v) d' ura.nium; 
Ip) toute ~tité, sous fo~ jlém~taira, ou toute' quantité d'un 
composé oU d'u.~ mélange contenant l'un ou plusieurs des radio 
nucléides suivant,;, avec une activit:,é ég-ale 'ou S"Up~rieure « 37 
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GBqlkg, ou toute source 8cellée ou disposit1t do~t l'activité est 
égda ou supérieure .. 3,7 GBq : 
(il d'&otinium225, 227; (ii) da calito~1um 248, 250, 252, 253, 254; 
(iii) de curium 2'0, 241, 242, 243, 244; 
(iv) c:S.'einneniUll\ 25:1,253, 254, 255; 
(vl de feraUUlI\ 257; 
(v~) de gadolinium l~BI (vii) de mendé1évi~ 258, (i!x) de neptunium 235; 
(ix) de polcm1.um 208, 209, 210'; 
(xl de •• dium 223, (cl touts ~ti~' d'~rioium 241 ou 243, •• uf sous fo~ de composé 
ou de mQlange, ou toute source .c~llée ou di.positif; (d) toute quantita de neptunium 237, sauf sous forme 4. composé ou 
de mélange, ou toute eou~ce scellée ou diepoaitif; 
(e) toute quantité de radium 226, ou tout.e q.antité d'un composé eu 
d'un mélange èleradiuin 226: 
(f) toute SO\1rce scellée ou dillpositU~ (à l'exception delS 
a.pplicat:4!ura Il'Midic:auxl coneanant plu. de 0,31 G$q de "'adium 226; 
(g) tout Syst~ ~'nér.teur de neutrone, y compri' 1 •• tubes, conQU 
pour fonctionner .~s installation de vide extérieu~e et 
~tili.ant l'accél~ration élec~ostatique pour déclencher une 
rkction nucléaire I;ritium-deu.téril.llll. 
(2403-2) 
20. Ra~port annuel ~a·confo~té 
Le eitul.ire de parmi, soumet par éc~it à laCcmmission. &u plus tard 
le 2B févrie~ de chaqueannë., un .apport .. ~uel de oonformité BOUS 
une forme aoceptable à 14 Commis.~on. 
(2916-6) 
Fonctionn.ira d6signé en vertu ~ 
·paragra.phe 3H2)(-o) deI. Loi eur la 
.nraté et lB réglementation nucléaires 
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